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Abstract 
 
Having a robust and reliable assay that can be used by clinician inside or outside the 
hospital laboratory is vital for diagnosing and monitoring the health of a population. 
The aim of this PhD was to build a foundation of knowledge that could be used to 
utilise resistive pulse sensing (RPS) coupled with nanoparticles as a platform for 
biomarker detection. The target of interest, and the overall goal of this thesis, was 
the prion protein in human blood, which is used for the detection of variant 
Creutzfeldt–Jakob disease (vCJD). There is no standard detection method for this 
disease, instead doctors rely on a series of post-mortem tests to determine a 
diagnosis of an individual. A few assays have been developed, but due to their 
selectivity issues, and the fact they can take many hours, or days, they are not 
currently used.  
This PhD combines the use of RPS with deoxyribonucleic acid (DNA) modified 
particles as a label free sensor that allows the characterisation of an analyte bound 
to DNA modified particles. Namely, it is the ‘surface charge’ of the particle that is 
monitored using RPS, which could be a useful clinical tool for the detection of other 
biomarkers and not just vCJD described here. Altering and optimising the bound 
ligand to the particle’s surface would make this possible. Here, only DNA, either as a 
capture probe or aptamer is used, but the ligand could be inorganic or organic 
molecules, peptides or RNA. Monitoring of a particle’s relative velocity as it 
translocates through a pore gives information about its surface charge, which can be 
used to determine its zeta potential.  
The literature review in chapter 1 concentrates on highlighting the range of diseases 
caused by the conformational change of the human cellular prion protein (PrPc) to 
the infectious ‘scrapie’ form (PrPsc), known collectively as prion diseases. The chapter 
moves on to the cause of the outbreak of vCJD in the United Kingdom (UK) in the 
1990s and the extrapolated prevalence in the population. Finally, some of the most 
recent developments in the detection of Creutzfeldt–Jakob diseases (CJD) is given.  
 xviii 
 
The thesis moves to the theory of RPS, introducing the operation of the RPS platform 
called tunable resistive pulse sensing (TRPS), theory of transport in the system, 
particle velocities and zeta potential. Theory of aptamers and magnetic particles are 
also discussed.  
Before development of an assay for vCJD, the use of nanoparticles in biological media 
needed to be investigated, and work at characterising the formation of the protein 
corona is demonstrated in chapter 4. This study used blood proteins, as well as 
human plasma and serum. Understanding how the formation of a protein corona 
around a particle is essential to understand its new biological identity. Carboxylated 
polystyrene nanoparticles were incubated as a function of protein, blood fraction 
and temperature; offering an insight into the effects. The subsequent zeta potential 
values could be used in later work in the assay’s development.  
The surface of nanoparticles can be easily modified with a ligand(s), and in chapter 
5 a complementary DNA sequence of the Rassf1a promoter region is immobilised 
onto the surface. Since the charge of a particle is related to its translocation velocity 
through a pore, the varying concentration of bound DNA could be detected. Being 
confident in RPS’s ability to monitor this change, a site assessment study was 
conducted to determine hyper methylation of the Rassf1a sequence. Here, it was 
possible to assess if the sequence was single or double methylated, also the site of 
the methylation was obtained. The dose response of the method was investigated 
and determined to be more sensitive when half the binding capacity is used.  
The final assay for vCJD aims to use a DNA aptamer, so with the knowledge from 
previous chapters the foundations for an assay for the always fatal prion disease 
could be developed. The methods here determined the protocol’s limit of detection 
without pre-concentration, the selectiveness of the aptamer in 3 abundant blood 
proteins and the first stages of optimising the assay through a pre-concentration 
magnetic separation. 
To summarise, the work from this thesis has delivered three published journal 
papers, as well as being presented at numerous conferences, including the 22nd 
 xix 
 
Congress of the European Hematology Association in Madrid, Biosensors 2018 in 
Miami and the House of Common’s STEM for Britain event.  
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Chapter 1 
Introduction 
  
 2 
 
1 Introduction 
 
 Prion Diseases 
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are 
a group of rapidly progressing fatal neurological disorders in humans and other 
animals, which includes Creutzfeldt-Jakob disease (CJD). They are characterised by 
the presence of an abnormal protein isoform of a surface glycoprotein - prion 
protein, often denoted as PrPsc (SC refers to scrapie, the prion disease of sheep and 
goats) which accumulates in the brain.1 Research in the early 1990s supported the 
idea that the prion protein is the ‘infectious’ agent responsible for TSEs in humans 
and animals.1–3 Previously, it was thought that prion diseases, since they show 
transmissible properties and long incubation periods, were caused by typical 
infectious agents.4 Scrapie, a prion disease in sheep, was originally thought to be 
caused by a parasite.5 However, the general concept and the acceptance that a 
protein had the capacity to act as an infectious agent in a range of diseases was an 
extended and challenging process. As findings from prion research were released, 
numerous hypotheses emerged including the idea that a self-replicating protein was 
the cause.6 Unlike other diseases caused by other infectious agents, prions diseases 
differ from them with respect to the structure and the diseases they cause. These 
diseases may present with similar morphological and pathophysiological 
characteristics that resemble other progressive encephalopathies, such as 
Alzheimer's and Parkinson's disease.7 However, they are unique since the origin of 
these diseases can be transmitted, as well as being sporadic and inherited. Recently, 
evidence has emerged suggesting that Alzheimer’s can be transmitted.8 
The sporadic form of the disease, sporadic Creutzfeldt-Jakob disease (sCJD),  forms 
the majority of cases in humans - currently 85%.9 Current estimates concluded 
approximately 1 ½ per million will be affected by this form of the disease. The genetic 
forms of CJD are Familial (fCJD) and Gerstmann-Sträussler-Scheinker syndromes 
(GSS) and caused by a mutation in the gene, PRNP on chromosome 20, which codes 
 3 
 
for the normal cellular prion protein (PrPc). To date, studies suggest this mutation 
has been the cause of all cases of fCJD.10 Iatrogenic CJD (iCJD) is the accidental 
secondary transmission of other forms of CJD via medical treatments or surgical 
procedures such as blood donation. The first case of this form of CJD was identified 
in 1974 by Duffy et al and was cause by a corneal transplant contaminated with 
sCJD.11 Other possible routes for patient exposure to CJD include human growth 
hormone preparations, implantation of cadaveric dura and contaminated surgical 
instruments. The discovery of iCJD led to measures being implemented in the United 
Kingdom (UK) to reduce transmission risk. Although rare, iCJD can be clearly 
diagnosed from medical history records. In 1996 a new form of the disease emerged 
which was distinct in its clinical and pathological characteristics by Will et al and was 
termed variant CJD (vCJD).12 The discovery of this new variant of the disease was 
confined largely to the UK were differences in its clinical presentation were apparent 
compared to other forms of CJD. Generally younger people (median age ~ 28 years) 
would initially present with behaviour and psychiatric symptoms before neurological 
symptoms became evident.13 The distribution of PrPsc in the body was discovered to 
be strongly associated with the lymphoreticular system (e.g. spleen and tonsil), as 
higher concentrations of PrPsc were observed in these tissues compared to the 
central nervous system (CNS). This indicated accumulation of PrPsc in 
lymphoreticular tissue preceded the CNS invasion.14 vCJD was highlighted as being 
distinct from sCJD as a link was established that confirmed bovine spongiform 
encephalopathy (BSE), a zoonotic prion disease in cattle, had crossed the species 
barrier. Experiments carried out in the 1990s identified and confirmed this link, 
which showed BSE produced a distinct pattern of prion protein distribution and was 
consistent with being a human form of BSE; this was termed the BSE signature.12,15,16  
Further experiments conducted to establish the route of infection led to the 
recognition that consumption of infected BSE bovine products could lead to vCJD 
infection.17–19 After ingestion of the infected bovine product, PrPsc invades the 
lymphatic area surrounding the gut, before progressing through the autonomic 
nervous system (ANS) to the CNS. A large number of the population in the UK was 
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exposed to BSE infected food sources during the 1980s until 1995 when the link was 
identified. After this point, measures were implemented to reduce the transmission 
risk. To date, vCJD has killed 178 people in the UK, 27 in France and 25 elsewhere in 
the world.20  
Table 1.1: The common prion diseases of humans and animals, highlighting the postulated 
mechanisms of infection 
Disease Animal Postulated Mechanism of Pathogenesis 
Sporadic CJD 
(sCJD) 
Human Mutation or spontaneous conversion of PrPc to PrPsc 
Variant CJD (vCJD) Human Infection from bovine PrPsc source 
Iatrogenic (iCJD) Human 
Infection from PrPsc contaminated surgical 
instruments, dura grafts and hGH or surgical 
procedures 
Familial (fCJD) Human Mutation of PrP-Gene 
Gerstmann-
Sträussler-
Scheinker 
syndrome (GSS) 
Human Mutation of PrP-Gene 
Kuru Human Infection through cannibalistic rituals 
Bovine spongiform 
encathopathies 
(BSE) 
Cattle Infection with prions from sheep or cattle 
Scrapie Sheep Infection due to underlying genetic susceptibility 
 
 The Prion Protein 
The healthy, normal form of the endogenous cellular protein (PrPc) is ubiquitously 
expressed in a number of tissues in the body, which includes the CNS, lymphatic 
system and the blood.21 The role of  healthy PrPc in the body is largely unknown, with 
numerous functions proposed.22 PrPsc is formed from the healthy PrPc through a 
process of post-translational conformational change. PrPc undergoes this 
transformation to the proteinase resistant PrPsc in an autocatalytic manner.23 A 
number of theories to describe the mechanism have been proposed, but central to 
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them all is the idea the PrPsc isoform acts as a template for the conversion of the 
PrPc.23 The proteins are chemically identical but are distinguished by their secondary 
structure. PrPc has a structure rich in α-helices; while PrPsc is formed from mainly β-
sheets. It is this conformational change which forms the basis of the ‘protein-only’ 
hypothesis proposed by Prusiner et al; who won the Nobel Prize for his work in 
1997.6,24,25 PrPsc is highly resistant to proteinase digestion and is less water soluble 
than PrPc. These properties coupled with the autocatalytic nature of formation 
means PrPsc accumulates in the CNS causing neurological damage, and ultimately 
death of the patient. Once the process of conversion begins, the conformational 
change from PrPc to PrPsc is exponential, leading to this deadly accumulation.  
However, some research on CJD have postulated the prion protein is an effect rather 
than the cause of these diseases where the conformational conversion, or another 
intermediate, leads to neurological disease.23,26  
 The United Kingdom and vCJD 
Transmissible cases of CJD are rare but occur in the population since the prion 
protein is transmissible and infectious. The UK is the most affected country by vCJD 
with 178 reported cases since surveillance began.27 vCJD is often the form of prion 
disease widely known to the public. This is largely due to the mass media attention 
given to the outbreak of vCJD and the identification of the possible link to BSE in 
1996.12 The transmissible link was made as cattle affected by BSE had been fed using 
scrapie infected feed containing sheep carcasses.  
The median duration from symptoms appearing to death is typically longer than sCJD 
at 14 months. However, what has become apparent in studies is the extremely long 
incubation periods before a patient becomes symptomatic, which can be over a 
decade for vCJD and other prion diseases.13,28 This is especially the case when the 
prions have been transmitted from one species to another. vCJD is often given a 
possible or probable diagnosis based on differential diagnosis techniques. This often 
includes the use of magnetic resonance imaging (MRI), electroencephalogram (EEG), 
tonsil biopsy, as well as observing behaviour and psychiatric symptoms. Since the 
level of 14-3-3 and tau proteins is often raised in CJD patients, they can be used ante-
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mortem, however, the non-specific nature of these biomarkers mean their use is 
limited.29. To gain a definite diagnosis brain tissue must be subjected to 
histopathological assessment to identify PrPsc neuropathological contamination. 
Since the risk of infection to clinicians from this procedure is high, the World Health 
Organization (WHO) does not recommend the use of brain biopsy as a means to 
diagnose vCJD (and sCJD). Therefore, brain tissue is collected post-mortem at which 
point the definite diagnosis can be established. To address the threat and potential 
public health crisis, the UK government set up a surveillance centre called the 
National CJD Surveillance Unit, which is based at the University of Edinburgh. 
 Prevalence Studies 
Two epidemiological studies have been conducted to establish the prevalence of 
pre-clinical vCJD. The first of the two was carried out by Hilton et al in 2004 with the 
aim to provide an estimate, and therefore determine, the risk of iatrogenic spread 
of vCJD.30 They used immunohistochemistry on tissue taken from tonsillectomy and 
appendectomy samples collected from pathology departments around the UK. From 
the 12,674 specimens tested, 3 provided positive results for the presence of 
accumulated PrPsc. This gave an estimate of 237 per million, or 1/4000, of the UK 
population would be carrying the disease. The second study conducted by Gill et al 
in 2014 used archived appendix samples from the UK to understand the relevance of 
the 2004 study.31 They used 32,441 samples fixed in formalin and tested using 
immunohistochemistry. They reported 16 positive samples for PrPsc accumulation, 
which gave an overall prevalence of 493 per million or 1/2000. In this study they also 
estimated the prevalence in two birth cohorts; 1941 – 60 and 1961 – 85, however, 
they identified no significant difference between these cohorts. The 2014 study 
doubles the number of people likely to be infected, indicating broad agreement 
(same order of magnitude) with the 2004 study. It was noted, however, that it is 
possible not all carriers will go on to develop vCJD. A study in 2008 identified a 
genetic susceptibility to vCJD where all clinical cases of vCJD had methionine 
homozygosity (MM) at codon 129.32 Around 1/3 of the UK population is MM 
homozygous. Other genotypes may be susceptible to vCJD, but the incubation 
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periods observed could be much longer. Disease susceptibility and incubation 
periods could be affected by other genetic features. It should be noted much of the 
UK population has been exposed to BSE, especially those born pre-1995.  
 Current Risk Reduction Methods 
As PrPsc is found in the peripheral lymphoreticular system in vCJD patients, there is 
a risk the disease could be secondary transmitted through blood transfusion. Animal 
models were used to test this theory and the first convincing evidence of 
transmission of CJD through blood was reported in 2000.33 Four cases of 
transmission from transfusions have been identified to date, the first case in 2004, 
in an individual who received blood from a donor who went on to develop vCJD.34 
Since there is a lack of a reliable screening assay for pre-symptomatic vCJD the UK 
National Blood Service (NHSBT) has enacted a number of risk reduction measures. 
The first and the costliest was implemented in 1999, where leucodepletion filters 
were applied to remove white blood cells from blood donation since analysis of the 
risk of transmission indicated the source of PrPsc in blood was blood plasma.35,36 
However, this measure has indeterminable efficacy and is viewed as a uncertain 
necessity, for a step which has cost £530 million since implementation and a 
recurrent cost of £40 million per annum.37–39 The second measure was to remove the 
plasma fractions from UK blood sources and obtain plasma fractions from outside 
the UK. The final policy was to exclude donors who had previously been a recipient 
of blood and its products. Concerns still remain as to the effectiveness of these 
measures because components, other than white blood cells, have been shown to 
transmit the disease.40 Identifying carriers is, and will be, the most effective measure 
to reduce the risk of PrPsc transmission. In a number of hospitals in the UK, at the 
point of admission, surgical and other selected patients are asked a series of simple 
questions to identify their risk of transmitting vCJD to others.41,42  
 Assay Development in Prion Disease Detection 
Since the zoonotic ability of BSE and the link to vCJD was identified, there have been 
efforts by research institutions to develop a highly sensitive and selective assay. To 
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date, there is still no reliable assay that can be used in a clinical setting, either for 
screening or diagnosis. There are a number of reasons why developing an assay 
providing adequate sensitivity and selectivity has been challenging. What has 
puzzled researchers is the fact that PrPsc fragments isolated from organisms are 
identical but cause different strains of diseases with differing clinical 
manifestations.43 vCJD is not encoded by ribonucleic acid (RNA) and DNA, in contrast 
to other pathogenic agents, but still has the ability to transmit information.24 This 
lack of genetic material has negated the use of polymerase chain reaction (PCR) for 
nucleic acid detection methods. As the amino acid sequence is identical in both PrPsc 
and PrPc developing an antibody capable of differentiating between the isoforms has 
proven difficult. Often assays using antibodies have a denaturing step to open the 
secondary structure of PrPc to remove its binding ability. Lastly, the notion that a 
person could be asymptomatic and act as a carrier for vCJD may mean the levels of 
PrPsc are too low for traditional methods. There is an urgent need to develop an assay 
capable of confirming diagnosis for early clinical intervention, as well as used for 
screening. However, these challenges may not represent the only reason 
development has been slow, as commercial interest in researching prions diseases is 
lacking.38 European Union (EU) directive 98/79/EC, termed the in vitro-Diagnosis 
Medical Device, sets out strict requirements when testing for pathogenic agents.44 
In brief, the assay must be highly specific >99.5% and with sufficient sensitivity >90%. 
Since PrPsc is classified as a pathological classification agent 3, an amendment was 
made to the directive to include assays for the detection and diagnosis of vCJD.   
 Protein Misfolding Cyclic Amplification (PMCA) 
The first major assay to be developed was the Protein Misfolding Cyclic Amplification 
(PMCA) assay proposed by Saborio et al in 2001.45 The idea behind PMCA is to 
replicate the concept of PCR, however, no genetic material is amplified. This involves 
the in vitro conversion of PrPc to PrPsc in an accelerated manner. The idea of in vitro 
amplification has been studied previously in 1994, however, the experimental 
conditions used limited its yield and ultimately its use.46 The basic principle of PMCA 
is to amplify the low level of PrPsc that might be present in an asymptomatic patient’s 
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blood using a large excess PrPc.45 PrPsc acts as the template in which PrPc undergoes 
conversion to proteinase resistant PrPsc. Cycles of sonication and incubation phases 
are key to the nucleation dependant polymerisation model used in the process.47 
Under incubation phases the PrPsc converts the PrPc into further PrPsc units. Then the 
sample is subjected to sonication where the hydrodynamic forces shear the 
aggregates into small units, which promotes the further conversion of PrPc. These 
cycles of repeated sonication and incubation promotes the exponential growth in 
PrPsc to levels that can be easily detected by traditional methods such as 
immunoblotting. The original study used brain homogenates from scrapie infected 
hamsters and healthy hamster brain homogenates as a control. Serial dilution of the 
infected brain homogenates was used so that PrPsc was undetectable in the sample 
using immunoblotting. Subjecting the samples to cyclic sonication-incubation 
(sonicating the sample for 5 pulses, each for 1 second duration every hour), 
repeating the cycles for 5 – 40 times, the group noted an increase in PrPsc to 
detectable levels.  
After just five cycles of PMCA the group observed an average amplification rate of 
57.9 ± 19.9, which corresponds to a conversion rate of 97% of the total amount of 
PrPc present. Based on their experiments the group estimated the minimum PrPsc 
needed to be present in the infected samples for amplification would be 6 – 12 pg. 
Since the amplification of PrPsc is directly proportional to the number of cycles the 
sample is subjected to, the assay is limited to the number of these cycles applied. 
Under manual conditions the limiting factor is the number of cycles that could be 
applied in a working day. Using blood samples from mice and sheep it was possible 
to obtain 100% specifity.48,49 Later work utilised an automatic system, this not only 
increased the number of cycles that could be applied, but the number of samples 
which could be processed simultaneously increased to 96.50–54  
 Using PMCA to Detect Prions in Urine 
In 2014 Soto et al used PMCA to detect PrPsc in urine from patients infected with the 
three forms of CJD; variant, sporadic and genetic.55 Out of the 244 urine samples the 
samples from 13 (of the 14 positive patients’ samples) with vCJD had detectable 
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levels of PrPsc, confirmed against the typical electrophoretic profile observed in the 
disease. The group used healthy control samples and samples from patients suffering 
from other neurological diseases, none of which gave a positive result. They 
estimated sensitivity of 92.9% with specificity of 100%, with a lower limit of detection 
of 1 x 10-16 g mL-1. This minute quantity was estimated to be 40 – 100 oligomeric PrPsc 
units. The authors noted the number of amplification cycles used was extensive 
indicating the very low levels of PrPsc in urine.  
 PMCA and its Shortfalls 
Although PMCA based assays are proving to be highly sensitive and specific to vCJD, 
the technique is time consuming even with the automation and improvements made 
in recent studies. To obtain the level of sensitivity required for a diagnostic tool the 
method would take around 3 weeks.56 In this study 7 rounds of PMCA, each 
comprising of 100 cycles was used, obtaining a minimum detection limit of 1 ag.57 It 
was also discovered that small amounts of surfactant insoluble protease-resistant 
PrPsc  like molecules were present in the brain of uninfected patients.58 The findings 
from this study could impact on the diagnostic usefulness of this type of assay. 
However, further work is necessary to understand if these surfactant resistant units 
will become PrPsc units in vivo suggesting preclinical carrier state, or underlying 
dormancy.47 Either way, PMCA could be used to avoid iCJD transmission risks. Other 
drawbacks to PMCA include the generation of PrPsc of certain species through 
amplification, which may generate false positives and induce spontaneous 
generation of new strains.47,59,60  
 Quaking-Induced Conversion Assay (QuIC) 
In the Quaking-Induced Conversion Assay (QuIC), recombinant – protease sensitive 
PrPc (rPrP-sen) is used as a substrate to amplify very low levels of PrPsc in a sample. 
Unlike an amplification and seeding technique, such as PMCA, this method used 
quaking or shaking to induce the conversion of PrPc to PrPsc (here termed PrPres) 
fibrils and aggregates.56 The study used PrPc from hamster brains, which they 
remarked is easily concentrated, mutated and easily tagged with synthetic 
 11 
 
markers.61 The use of quaking was to improve the time and the practicality of the 
assay, which can be coupled to existing immunoblotting or enzyme-linked 
immunosorbent assay (ELISA) techniques. By subjecting the sample to shaking a 
uniform distribution of energy throughout the material can be achieved compared 
to the varying degree of vibrational energy placed on the material under sonication. 
One of the main advantages of this technique is the ability to process samples in a 
dedicated shaker, whilst returning a result within a day. The group reported from a 
single 8 hour reaction they were able to detect a seeded sample with as little as 10 
fg of PrPsc.62 Further work is needed to maximise its practicality and speed since the 
method still used a time-consuming western blot. One example of a refinement of 
this method is by Orrú et al in 2011.63 They integrated antibody 15B3 - basing their 
assay on immunoprecipitation, which yielded an increase in sensitivity of brain tissue 
diluted in human plasma. Many experiments were conducted using QuIC as a 
foundation combining with a thioflavin T (ThT) dye, as well as adding sodium dodecyl 
acetate (SDS) to stabilise the fibril stacks in a process called S-QuIC.64  
 Real Time QuIC 
The addition of ThT as a synthetic marker enables the monitoring in real time of the 
conversion of rPrPc to PrPsc; combining these technologies is termed Real Time QuIC 
(RT-QuIC).64,65 Many recent studies have used cerebral spinal fluid (CFS) as a biopsy 
specimen as CSF is more accessible than brain and lymphatic tissue. Since the use of 
blood has been limited its use as a screening measure for blood donations is lacking 
validity. CSF is routinely obtained from patients with neurological conditions and 
lacks the numbers of impurities blood has, which could make it useful in patients in 
a symptomatic state. RT-QuIC has not only been proven to detect PrPsc at levels as 
low as 1 fg, but it is also capable of detecting other forms of prion disease. It has also 
been reported that whilst the conversion of PrPc to PrPsc with identical sequences is 
efficient, the conversion of bovine rPrPc could be achieved using sCJD PrPsc. However, 
it was noted that there is a possibility that fibrils from other neurological disease 
could be amplified reducing the specificity of RT-QuIC. As of yet there is no evidence 
to support this claim.   
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 The World’s ‘First’ Blood Test for vCJD 
In 2011 a major breakthrough in the diagnosis of vCJD in symptomatic patients and 
preclinical asymptomatic individuals was made.66 Edgeworth et al at the Medical 
Research Council’s (MRC) Prion unit in London reported their findings on a prototype 
blood test. Notably this protocol exploited previous research that found PrPsc had an 
extremely high affinity to stainless steel.67 In this assay PrPsc in the blood sample is 
isolated on 45 µm stainless steel balls, and then detected by ELISA using ISCM18 
antibodies, before visualising using commercial chemiluminescence. The original 
work used a panel of whole blood samples; 190 in total spiked with brain 
homogenates, 21 from vCJD patients, 27 with sCJD, 40 from patients suffering other 
neurological disease and 100 control samples. They reported they were able to 
distinguish vCJD at a dilution of 10-10 when compared to a 10-6 dilution of brain 
homogenates. 15 of the 19 samples prepared from vCJD brain homogenates tested 
positive giving 74.7% sensitivity and delivered 97.8% specificity. Although the assay 
currently falls short of the European Commission’s Health and Consumer Directive, 
it does not rely on a lengthy amplification step (only requiring overnight incubation).  
To validate this assay further, work by Jackson et al employed the assay to screen a 
large sample population; this time using blood samples of 500 healthy United States 
(US) controls, 200 healthy UK controls, 325 from non-prion neurological disease, 105 
where a prion disease diagnosis is likely and finally 10 with confirmed vCJD to test 
the assays sensitivity.68 Blood samples from the US are considered to be free from 
vCJD due to its very low prevalence. The size of this sample set used in the study set 
a precedent for further work into vCJD detection. When tested, neither the 500 US 
nor the 200 UK healthy samples tested positive. This was also true for the non-prion 
neurological disease samples, which did not elicit any false positives. Therefore, the 
authors concluded the assay demonstrated 100% specificity. Of the 10 confirmed 
vCJD sample only 7 tested positive giving a sensitivity of 70%; lower than the original 
study. In addition to the 70% sensitivity to vCJD, 2 samples tested positive for sCJD. 
Although it has not been confirmed sCJD is present in blood of patients infected with 
vCJD, the test shows some sensitivity.69  
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Despite the assay’s insufficient sensitivity, the authors remarked that the high 
selectivity warranted a larger scale study. This time a population of 20,000 blood 
samples from US donors and the same number from UK donors would be used. The 
only other large scale study (20,000) using blood achieved 99.9% selectivity, but 
failed to deliver enough sensitivity to be useful for the detection of vCJD.70 During a 
recent House of Commons Select Committee hearing, Professor John Collinge noted 
there is a lack of funding for the study, largely due to the lack of commercial interest, 
holding back the £750,000 trial.38 What was remarkable from their finding was the 
fact they believed, despite the prototype assay limitations, it would be suitable for 
clinical diagnosis and screening, providing an initial estimate of the level of prion 
infection in the general UK population. At present, unless the group at the Prion Unit 
are able to refine the assay it is unlikely that the various blood authorities in the UK, 
and around the world, would be willing to implement the prototype. 
Being 100% selective is not the only metric that is unique to this prototype assay with 
numerous other assays having shown similar results. These include Ligand Based 
Immunoassay, immunocapillary Electrophoresis (ICE), Conformational Dependant 
Immunoassay (CDI), Misfolded Protein Assay (MPD) and Multimer Detection. For this 
reason relying on 100% specificity alone is not sufficient to make any prototype assay 
the choice.71–75 
 Assay Development 
The aim of this PhD is to develop the foundations for an assay for human prion 
diseases that can be used to screen blood. Having considered the diseases, their 
prevalence in the UK and the current assays that have shown promise in detecting 
these diseases the development process itself should be outlined. There are several 
prerequisites an assay used in biomedicine must have, as mentioned previously they 
must be robust, reliable and sensitive at their foundation. But it is not just these 
factors that must be considered; sample collection, workflow, time, sample 
preparation and data analysis must also be measured. Each developed assay, 
regardless of the detection method, will have its own eccentricities. There are 
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several fundamental questions researchers can ask to align the assay to its final 
application and usefulness in a clinician’s tool kit. These can be seen in Table 1.2. 
Table 1.2: Fundamentals that need to be considered by researchers when developing an assay 
Parameter Considerations 
Analytical Range 
• The assay’s dynamic range 
• Accuracy in determining concentration 
Performance 
• Assay workflow 
• Statistically appropriate 
• Signal to noise ratio 
Sensitivity 
• Limit of detection 
• Quantitative/Semi-quantitative 
• Sample volume 
Selectivity 
• Single analyte 
• Multiplexed 
Interference 
• Sample matrix 
• Assay reagent 
Robustness 
• Differences in sample handling 
• Variations in sample preparation 
• Analyst’s variations 
Reproducibility 
• Assay variability 
• Stability 
 
Over recent years there has been many advances in the drive to develop smaller, 
cost effective, point-of-care diagnostics, which are the spin-off from biosensors, 
microfluidic, bioanalytical platforms, lab-on-a-chip, and complementary 
technologies.76 The overall goal of these tests is to bring the assay closer to the end 
user, helping a person diagnose, monitor or manage a condition, but also allows the 
diagnosis of infectious diseases in low infrastructure settings.77 Currently, there are 
numerous issues that have to be overcome for an assay to move closer to the end 
user, either as a home test kit or used by a primary physician in a GP’s surgery. This 
shift is displayed in Figure 1.1, which shows how the complexity of the assay 
increases as the assay moves from the end user to the high technologies seen in 
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many biomedical research laboratories. These complexities include the use of 
specialist detection equipment, the workflow, or the reagents needed. But as 
knowledge of miniaturisation intensifies so does the desire for these to move closer 
to clinics, then to the home, resulting in more testing outside of hospital laboratories.  
 
 
Figure 1.1: The movement of the technologies and techniques used in biomedicine, highlighting 
the complexities of an assay as the distance from the end user increases  
 
Bioassays do offer a good commercial proposition for many companies, but not all, 
in fact a great many never make it outside the research laboratory. But not all assays 
developed are destined for the home or GP clinics. The work covered in this thesis is 
to work towards a whole blood assay that can detect the pre-symptomatic levels of 
PrPsc in human blood. Therefore, the assay will be placed at the hospital or specialist 
laboratory level – largely due to the ethical reasons around detecting CJD in 
humans.78  
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 Nanoparticles in Bioassays 
There has been an increase in the emergence of the use of nano- and microparticles 
in diagnostics.79 There are a number of factors that have facilitated this move. The 
fact particles can be easily manipulated by an external magnetic field, the ease of 
surface functionalisation and large surface to volume ratio have contributed to this 
rise. Magnetic particles can be extracted and undergo buffer replacement simply, 
also the fact they are commercially available in a variety of sizes makes them ideal 
for a bioassay. It has been reported magnetic particles not only have numerous 
advantages they are harmless to the human body.80 Having a high performance assay 
that can interface with a biological matrix, offering reliability and is also accurate, is 
highly desirable in the field of diagnostics. There is an array of nanoparticles that can 
be used in an assay and the one selected for an application depends on many things 
- being divided in to categories owing to their morphology, size and chemical 
properties.81 Some of the nanoparticle seen in the literature include gold 
nanoparticles,82 quantum dots,83 carbon nanotubes84 and magnetic nanoparticles.85 
Some examples of nanoparticles used in biomedical applications are detailed in 
Table 1.3. This thesis is largely based upon the use of magnetic particles and will be 
detailed further. 
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Table 1.3: Characteristics of several nanoparticles and their biomedical applications. 
Reproduced from Liu et al86 
Type of 
Nanoparticle 
Synthetic Protocol Size Range 
Possible Surface 
Modifications 
Quantum dot 
Colloidal synthesis, self-
assembly, viral assembly 
Several to tens of 
nm 
Lipids, polymer, 
targeting ligands or 
biomolecules 
Dendrimer 
Organic chemistry 
techniques 
Several nm varies 
from different 
‘generation’ 
Charge, polymer, 
targeting ligands or 
biomolecules 
Liposome Emulsion, polymerization 
Tens to hundreds 
of nm 
Charge, polymer, 
targeting ligands or 
biomolecules, viral 
protein coating, 
Gold 
nanoparticle 
Biological reduction, 
colloidal synthesis, vapor 
precipitation 
Several to 
100 nm 
Lipids, polymeric shell, 
targeting ligands or 
biomolecules 
Carbon 
nanotube 
Arc discharge, laser 
ablation, vapor 
precipitation 
Tens of nm 
Polymeric shell, 
targeting ligands or 
biomolecules 
Microbubble 
Emulsion, layer-by-layer 
fabrication, polymerization 
Tens to 1000 nm 
Polymeric shell, 
targeting ligands or 
biomolecules 
Iron Oxide 
Coprecipitation, 
decomposition, 
microemulsion, sol-gel, 
thermal 
Several to tens of 
nm 
Charge, dextran, lipids, 
polymer, targeting 
ligands or 
biomolecules 
Micelle Microemulsion Tens of nm 
Charge, polymer, 
targeting ligands or 
biomolecules 
Adenovirus Replication in host nucleus 
Tens of to 
100 nm 
Charge, polymer, 
targeting ligands or 
biomolecules 
Silica 
nanoparticle 
Chemical polymerization, 
microemulsion, sol-gel 
Tens of to 
100 nm 
Charge, polymer, 
targeting ligands or 
biomolecules 
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 Magnetic Nanoparticles  
Magnetic nanoparticles have been used extensively in a number of fields including 
drug delivery,81 metal ion detection,87 protein detection81 and DNA methylation 
analysis.88 The use of these particles has one major advantage, and that is the large 
surface-to-volume ratio of nano-scale particles (which can be relatively easily 
modified) resulting in a high extraction efficiency. Another advantage magnetic 
particles have over their non-magnetic counterparts is they can be isolated from a 
sample with the application of a hand-held magnet.81 The first reported use of 
magnetic separation occurred in 1973 with the advent of magnetic solid phase 
extraction by Robinson et al.89 Being easily separated is useful if the matrix of the 
sample is biological, highly contaminated or has a greater matrix effect that is likely 
to cause a higher degree of interference. Having a simplified workflow is preferential 
(without the need for sample preparation or pre-concentrating of the analyte) but 
as stated previously biological media is highly complex, made up from a mixture of 
complex components. When placed into the protein rich matrix that is blood the 
surface of the magnetic nanoparticle can become fouled with the formation of a 
protein corona.90 Many studies have been carried out to understand the formation 
and the structure of the corona, as well as the impact it has on the biological identity 
of the particle in vitro, and the likelihood this will impact on any in vivo uses.91–94 
Understanding this phenomena in the development of a blood assay is key to a 
useable test.  
 Surface Modifications of Nanoparticles 
The surface of nanoparticles can be easily modified to induce an interaction between 
the bound ligand and an analyte. The modified surface will also affect the surface 
chemistry and as such will alter the particle’s surface charge and mobility. There are 
many reported ligands that have been used for surface modification, such biological 
examples include DNA and RNA,95 proteins and antigens.86 But they can also be 
modified with inorganic and organic ligands such as polymers96 and APTES97.  
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Binding the ligand to the surface will depend on the ligand and particle selected. One 
of the simplest, quickest, is coupling via the non-covalent interaction between biotin 
and streptavidin. The tetrameric mechanism is used extensively to bind DNA, RNA or 
peptides to a streptavidin coated surface forming one of the strongest non-covalent 
interaction.88 A covalent method also used is EDC (N-(3-Dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride) crosslinking chemistry.86  
 Summary 
Detecting prion disease at the pre-symptomatic stage is an aim of the public health 
organisation in the UK. The availability of a robust, rapid and accurate assay to 
reduce the transmission risk for many individuals who undergo the many medical 
procedures every year has eluded researchers for two decades. Studies have 
indicated there may be 35,000 people carrying vCJD in the UK and have a strong 
theoretical possibility they will pass this disease to others via medical treatments. 
The work presented in this thesis attempts to build and design the foundations for 
an assay for these fatal diseases using surface modified nanoparticles and resistive 
pulse sensing (RPS).  
The use of nanoparticles in biomedicine has grown to become a powerful tool for 
many applications. Their recent expansion into many uses have been driven by their 
ease of modification, size and morphologies, as well as their commercial availability. 
Refining the detection and characterisation of nanoparticles, as well as their change 
in biological identity, is still needed. Here they will be used to capture and facilitate 
sensing using RPS.  
The first stage of this research challenge is to understand and characterise the 
formation of the protein corona around nanoparticles when they are placed in 
biological media. Using RPS, changes in size, surface charge and concentration could 
be monitored. Next nanoparticles will have ligands attached to their surfaces. The 
use of DNA modified nanoparticles will be studied using the epigenetic marker of 
DNA methylation to explore DNA particle immobilisation and target capture. Finally, 
a DNA aptamer (short stranded oligonucleotide sequences, which bind to a target 
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with high affinity and selectivity) will be immobilised to form DNA aptamer modified 
particles and subsequently studied to detect cellular prion protein using RPS.  
Although a useable clinic ready assay will not be unveiled here, the proof of concept 
work will, which will highlight the advantages of using nanoparticles and selective 
ligands in an assay, as well as the particle-by-particle nature of RPS. 
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2 Theory 
 
 Introduction 
Here, we focus on the development of the concepts - theoretical and physical - that 
underpin the technique of resistive pulse sensing (RPS). These include the behaviour 
of the fluid in the system, chemical and electrical properties, as well as the surfaces 
of the translocating particle and electrolyte solution. The theory discussed in this 
section outlines the transport mechanism of an analyte through a conical nanopore 
and is applicable to all chapters in this thesis. Whenever needed, additional theory 
will be included in each chapter.  
 Resistive Pulse Sensing (RPS) 
Resistive pulse sensing (RPS) is a technique based on the Coulter counter principle, 
which uses concepts identified by Maxwell and remains the cornerstone for many 
RPS sensors.1 The signal generated during a RPS experiment can be used to gain 
several properties of an analyte passing through a nanopore, which will be described 
in detail later. RPS utilises a non-conducting pore membrane to separate two fluid 
reservoirs containing electrolyte solution. Each fluid cell contains an Ag/AgCl 
electrode and when a potential difference is applied a steady state current is 
observed as a baseline.  
Figure 2.1: Schematic of a particle translocating through a conical nanopore with two fluid 
reservoirs with Ag/AgCl electrodes 
 34 
 
RPS can be used to determine the size and concentration of an analyte of interest 
when suspended in an electrolyte solution, but it can also identify its charge 
characteristics.2,3 Briefly, this theory states that in the presence of a non-conducting 
particle in an ionic-conducting buffer it will give rise to an increase in resistance. The 
increase in resistance is proportional to the occluded volume of the particle as it 
passes through the pore’s sensing zone. This increase in resistance is observed as a 
resistive pulse, or blockade event - Δip, as the time taken for the particle to 
translocate the pore. The magnitude of the blockade - Δip, is the size (volume) of the 
analyte, FWHM (full width half maximum) is the particle translocation time through 
the nanopore, and the blockade frequency is relative to the particle concentration 
(particles mL-1). The blockade magnitude is relative to the electrolyte resistivity, ρ, 
particle diameter, d, and pore diameter, D. This is summarised in Equation 2.1.  
 
∆𝑖𝑝 =
4𝜌𝑑3
𝜋𝐷4
 
 
The profile of the pulse created is determined by the particle’s own characteristics 
and the properties of the pore.4 If the pore is cylindrical in shape than the typical 
profile observed will be square and flat-bottomed, whereas in an asymmetric conical 
pore the profile will be peaked in shape; due to the resistance gradient generated by 
this pore type, which can be seen in Figure 2.2. 
Equation 2.1 
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Figure 2.2: (A) Current versus time of  particles traversing the pore and the resulting blockade 
events (B) Schematic example of a typical blockade generated by RPS with a conical pore 
geometry. Δip shows the blockade magnitude and FWHM indicates the analyte translocating 
the pore 
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 Tunable Resistive Pulse Sensing (TRPS) 
RPS has seen something of a resurgence in research in the past 20 years since the 
technique’s ability to detect differences in single stranded DNA using a biological 
pore was demonstrated.5 Since then several pore materials have been developed to 
analyse size, concentration and charge of nano- and micro-particles. Pores can be 
generalised into three categories: synthetic, biological and microfluidic. However, 
these fixed aperture pores limit the size range of the analytes they are capable of 
measuring. Tunable Resistive Pulse Sensing (TRPS), previously called Scanning Ion 
Occlusion Spectroscopy, utilises a synthetic elastomeric pore membrane, in which 
the pore diameter can be reversibly stretched quickly to be optimised for a particular 
sample to overcome this size limiting factor.6,7 This tunable pore allows for a more 
versatile application since this can be varied in size and therefore analysis of a wider 
range of analytes is made possible, in particular if the size of the analyte is unknown.  
TRPS is a proprietary technology (qNano and qViro) developed by Izon Science, based 
in New Zealand, and allows the particle-by-particle analysis of biological, synthetic 
inorganic nanoparticles and microparticles. TRPS utilises a reusable elastomeric 
polyurethane (PU) pore, which allows the analysis of a range of particle geometries, 
being able to ‘tune’ the pore to the analyte of interest.8 These pores can be used 
several times before needing to be replaced, allowing for a cost effective platform 
for size, concentration and charge analysis.  
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Figure 2.3: Analyte size range of nanopores manufactured my Izon Science Ltd (data given by 
manufacturer) 
 
Each of the pores supplied by Izon Science have the ability to analyse a range of 
analyte sizes, Figure 2.3. By using this information, a user of the TRPS system can 
select the most appropriate pore for the analyte(s). Fabrication of the pore has been 
described as a relatively easy process in which a sharp tungsten probe is utilised to 
penetrate the PU material, resulting in the conical pore shape.9 By altering the probe 
size, a range of pore sizes can be produced, yielding the pore geometries suitable for 
the application of single particle analysis in complex mixtures and solutions.  
TRPS has a similar set up to traditional RPS and is relatively simple. The pores used 
on the Izon system are manufactured in a cruciform configuration, with each of the 
arms having holes that are used to mount the pore on to teeth of the instrument. 
The qNano consists of two electrodes and electrostatic noise is reduced by the 
placement of a Faraday cage over these. Two reservoirs (or fluid cells) are mounted 
horizontally in the instrument either side of the pore with the lower fluid cell, Figure 
2.4a, being filled with a ‘blank’ electrolyte solution the sample is suspended in, and 
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contains a volume of 80 µL. The pore membrane is then placed over the lower fluid 
cell, and the upper fluid cell twisted into place over the pore and filled with the same 
electrolyte solution as the lower, or a sample, – 40 µL, Figure 2.4b and c. Finally, the 
Faraday cage is placed over this, Figure 2.4d. The instrument becomes tunable by 
altering the applied stretch to the PU pore using the teeth, changing the stretch to 
match the analyte. 
 
 
Figure 2.4: Instrument setup of the Izon qNano showing the electrochemical cell. (A) The lower 
fluid cell, which holds the electrolyte solution - 80 µL. (B) A membrane pore stretched using the 
teeth on the instrument. (C) The upper fluid cell, which holds 40 µL, is placed on top of the 
membrane pore. (D) The Faraday cage placed over the upper cell, which reduces electrostatic 
noise  
 
Blockages of the pore’s aperture can occur, resulting largely from impurities, 
aggregation or pore surface adhesion. The tunable nature of the qNano system can 
be utilised to unblock the pore by applying an increased stretch allowing the 
 
 39 
 
blockage to pass. Sometimes the addition of an external pressure may be needed. 
Although there are some issues with blockages in the pore, TRPS is a technique that 
can offer some of the highest resolution in the detection of multiple particle sizes in 
a sample. There is very little bias towards any sized particles using TRPS, unlike in the 
ensemble technique - dynamic light scattering (DLS), which takes several 
measurements of particles in the sample. 
The qNano system has an external variable pressure module (VPM) that can apply a 
pressure difference across the pore with either a pressure or vacuum. Applying a 
pressure increases the fluid flow from the upper fluid cell, which causes an increase 
in the baseline current. A vacuum has the opposite effect acting to reduce the 
baseline current, the VPM can be seen in Figure 2.5.  
 
 
Figure 2.5: The qNano system with its variable pressure module (VPM) in situ in the laboratory 
 
The VPM can apply a pressure at either a scale defined by Izon as cm or mm, here 1 
cm of pressure is equivalent to 100 Pa. Applying a positive pressure acts to increase 
the rate of particle translocations, which also increases their observed relative 
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velocity. Applying a vacuum decreases the particle’s relative velocity and can induce 
a reversed translocation. If a particle passes through the pore in the opposite 
direction, a reversed blockade would be observed, Figure 2.6. 
 
 
Figure 2.6: Reversed blockade event caused by a particle/analyte translocating the nanopore in 
the opposite direction 
 
As previously stated, when a potential difference via an external electric field is 
applied to the system a baseline current is observed. This baseline current is 
dependent on several factors, namely the ionic strength of the electrolyte solution, 
the applied voltage and the size of the pore.8  Since TRPS uses pores with a varying 
radius as a function of Z (conical geometry), its resistive peak will have an asymmetric 
pulse shaped appearance, as seen in Figure 2.2. 
Ohm’s law can be used to describe the process happening in the TRPS system at an 
elementary level, Equation 2.2. 
 
𝐼 =
𝑉
𝑅
 Equation 2.2 
Time (s) 
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Here, I is the current, V is the potential difference and R the resistance. Since the 
pore in the TRPS system is conical, therefore, when there is no particle present the 
total resistance is given by Equation 2.3.4  
 
𝑅 =  
4𝐿𝜌
𝜋𝐷𝑠𝐷𝐿
 
 
In this instance DS and DL are the diameters of the smaller and larger opening of the 
pore respectively, L is the length of the pore (thickness of the membrane), and the 
specific resistivity of the electrolyte solution is denoted by ρ. By substituting in to the 
equation Dz and Z, the diameter of the pore at a distance Z from the pore opening, 
for Dz and L, the resistance gradient of the conical pore can be estimated.4 The 
assumption that the resistivity of the electrolyte solution is constant throughout the 
pore system holds true for TRPS experiments since they are typically carried out in 
high salt environments, and the Debye length at the pore wall is smaller than the 
pore’s overall dimention10.  
 
Figure 2.7: Schematic of a nanopore used in TRPS, stretching the pore changes the size of the 
pore. L denotes the length of the pore, Ds and DL are the diameters of the small and large 
openings respectively 
Equation 2.3 
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Due to the manufacturing process the geometry and size can vary from pore to pore 
and as such it is important to calibrate the qNano system with particles of a known 
size and charge. Applied voltage, stretch, pressure and baseline current are 
maintained during all experiments and performed under the same conditions as the 
analyte. 
 Concentration Analysis  
Since the frequency of the blockades, J, observed is proportional to concentration of 
the analyte, Cs, accounting for the velocity of the particle translocating the pore, 
Equation 2.4  results.11 
 
𝐽 =  𝐶𝑠 ×  𝑣𝑝 
 
Here Vp is the velocity of the particle traversing the pore, which is the sum of three 
component velocities: electrophoretic, VE, electroosmosis, VO, and fluidic, VF, giving 
Equation 2.5.12  
 
𝑣𝑃  =  𝑣𝐸 + 𝑣𝑂 +  𝑣𝐹 + 𝐷𝑓 
 
Although there is a presence of diffusion, Df, in the system it is not often included in 
the analysis since it has a minor contribution to the analyte’s translocation velocity. 
This has been estimated to be less than 5% of the electrophoretic velocity.13,14  
 
 
 
 
Equation 2.4 
 
Equation 2.5 
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𝑉𝑝, can be rewritten as:  
 
𝜈𝑃 =
𝑄
𝜋 (
𝐷𝑆
2 )
2 +
𝜀𝜁𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
𝜂
𝐸 −
𝜀𝜁𝑝𝑜𝑟𝑒
𝜂
𝐸 
 
Where 𝑄 =
3𝜋𝐷𝑆
3∆𝑃
128𝜂(
𝐿
𝐷𝐿−𝐷𝑆
)
 
 
In Equation 2.6 and 2.7, ε is the permittivity of the solution, η kinematic viscosity, Δp 
is the pressure across the pore, ζpore and ζparticle are the zeta potentials of the pore’s 
channel and particle respectively, E is the applied electric field. L denotes the length 
of the pore, Ds and DL are the diameters of the small and large openings respectively. 
The pressure applied to the system is also related to the pulse frequency observed. 
The inherent pressure head, due to gravity is ≈ 50 pa.15 Using the VPM, a greater 
external pressure or vacuum can be applied to the sample. It is useful to apply a 
higher pressure when analysing a sample low in concentration as the pulse 
frequency will increase as the applied pressure increases. 
 Size Analysis 
When a sample is present in the upper fluid cell, a particle can translocate to the 
lower cell via the pore. The particle excludes a volume of electrolyte solution 
proportional to its size. This creates an increase in resistance and observed as a 
blockade event or pulse. This pulse gives details of the size, Δip and the speed at 
which the particle translocated, given as FWHM. Unlike the square shaped pulse 
typical of cylindrical pores, conical pores give rise to an asymmetric pulse since there 
is a resistant gradient. The effects observed in conical pores affects the resistance 
across the pore and therefore the electric field, which is focused at the opening to 
the pore.4 As the resistance is higher at the opening of the pore, a large drop in 
Equation 2.6 
Equation 2.7 
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resistance tailing back to the baseline as the particle passes through the pore is 
observed. The change in resistance, ΔR, across the length is summarised in Equation 
2.8.16  
 
∆𝑅 = 𝜌 ∫
𝑑𝑧
𝐴(𝑧)
− 𝑅
𝐿
0
 
 
L is the length across the pore, ρ is the resistivity of the electrolyte, A(z) is the 
unobstructed cross-sectional area of the pore perpendicular to the pore axis Z and R 
is the resistance. Using calibration particles of a known size, charge and 
concentration the blockade magnitude of the pulse can be used to determine the 
size of a particle as a function of the change in resistance, ∆R, which is directly related 
to the analyte’s volume.  
 Theory of Transport  
The mechanics of a particle translocating through a nanopore are dependent on 
several factors. These include the external influences applied to the system such as 
electric field, pressure, geometry of the pore and the properties of the electrolyte 
solution. This concept is described by the Nernst-Planck equation, by combining 
Equation 2.4 and Equation 2.6, seen in Equation 2.9.17 
 
𝐽
𝐶𝑠
= 𝜀 
𝜁𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 −  𝜁𝑝𝑜𝑟𝑒
𝜂
 𝐸 +  
𝑄𝑝
𝐴
 
 
To recap, J is the total particle flux, CS is particle concentration, ε and η are the 
permittivity and kinematic viscosity of the solution respectively, ζparticle and ζpore are 
the ζ (zeta) potentials at the particle surface and the pore wall. Where 𝐴 is the cross-
Equation 2.8 
Equation 2.9 
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sectional area of the pore, E and Qp are the electric field and pressure-driven 
volumetric fluid rate.  The contribution of ζparticle and ζpore  are due to electrophoretic 
and electroosmotic transport, again diffusion has been omitted from the equation 
due to the negligible effect it has on the system.18  
When a pressure is applied, this force has the greatest effect on the movement of 
the particle through the pore. However, when no pressure (except inherent 
pressure) is applied the electrophoresis force dominates over electroosmosis19. The 
zeta potential of the particle can be calculated by measuring its velocity when the 
contributions from the conductive and electroosmotic forces are considered as well 
as the particle’s electrophoretic mobility.  
 
 
Figure 2.8: The three forces which act upon the particle as it translocates the pore to give the 
particle’s overall velocity, VP, of a truncated conical pore 
 
 Electroosmosis 
When a potential is applied across the pore, bulk movement of the electrolyte 
solution is observed as a baseline current. The counter ions in the electrolyte solution 
compensate for the particle’s surface-solution charge imbalance forming a mobile 
double layer on the pore’s surface. Electroosmosis originates from the electrical 
forces on the ions in this double layer and influenced by the net charge of the pore 
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membrane, applied potential and the ionic strength of the electrolyte solution. Ions 
in the double layer migrate to the oppositely charged electrode. The velocity of the 
electroosmotic velocity, VO, can be calculated by applying the 
Helmholtz−Smoluchowski equation, Equation 2.10: 
 
𝑣𝑜 =
𝜀𝜁𝑝𝑜𝑟𝑒
𝜂
𝐸 
 
 Electrophoretic Mobility 
Electrophoretic mobility is defined as the translocation of a charged particle through 
solution under the influence of an electric field. Electrophoretic retardation is 
observed as counterions, in the solution, moving in the opposite direction to the 
particle causing drag, which hinders the particle’s movement and reduces its 
mobility. Electrophoretic retardation has the following effect: a thin double layer 
surrounding the larger particle will have an lesser effect on the particle’s mobility; 
and a diffused double layer around a small particle will result in a larger effect on the 
particle’s movement.20 This is summarised in the Helmholtz-Smoluchowsk equation, 
Equation 2.11, which takes into account electrophoretic retardation. 
 
𝑈𝐸𝑃 =
𝜀𝜀0𝜁𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
𝜂
 
 
Here the electrophoretic mobility of the particle, UEP, is proportional to the 
translocation mobility, µtr.21 In TRPS the electrophoretic mobility is determined by 
the particle translocating through the pore; couple this with the translocation speed 
and applied voltage, the zeta potential and the translocation duration can be 
determined. 
Equation 2.10 
Equation 2.11 
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 Zeta Potential and Translocation Velocity 
The zeta potential of a particle in a colloidal system is defined as the electrostatic 
potential at the interface of the diffuse layer and the stern layer22. The stern inner 
layer is formed from strongly bound ions, the outer diffused layers are formed from 
ions which are less firmly bound. The surface potential cannot be measured directly 
as these are defined at different locations.23 Zeta potential is used as an alternative, 
which is close to the value of the stern layer, defined as the electrostatic potential at 
the shear plane.24 The value measured for zeta potential is altered by the surface 
charge of the particle and the environment the particle is in.  
 
Figure 2.9: Schematic showing the double layer surrounding a particle in electrolyte solution. 
The electrical potential at the slip plane is equivalent to the zeta potential 
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The Smoluchowski approximation summarised states the electrophoretic mobility of 
an analyte relates to its relative velocity, µ, under given conditions. After µ is 
determined the Smoluchowski approximation is used to relate µ to ζparticle to define 
zeta potential.14 The Smoluchowski approximation defines zeta potential as: 
 
𝜁 =
𝜂µ
є
 
 
Here, ζ is zeta potential of the particle, η is dynamic viscosity of the fluid, µ is particle 
mobility and ϵ  is the dielectric constant. The Smoluchowski approximation supports 
the notion that the zeta potential of a particle can be determined from its velocity, 
when taking in to account electrophoretic mobility and electroosmotic forces, as well 
as convection forces due to the inherent pressure head (or any applied pressure). 
Since electrophoretic mobility is proportional to translocation mobility of the 
particle, Equation 2.13 is related to its zeta potential.21 
 
 𝜇𝑡𝑟 =
𝜀𝑟𝜀0𝜁𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
𝜂
 
 
Here, εrε0 and η are the solution permittivity and viscosity inside the pore. When this 
equation is combined with the instrument parameters, the relationship between the 
translocation velocities, voltage applied, translocation mobility and duration (and 
the zeta potential) the following equation is obtained, Equation 2.14: 
 
?̅? = 𝑙 (
1
𝑡𝑡𝑟
),    𝜇𝑡𝑟 = 𝑙
2
𝛿(
1
𝑡𝑡𝑟
)
𝛿𝑉
,   𝑡𝑡𝑟 =
𝜂𝑙2
(𝑉+𝐶)𝜁𝜀𝑟𝜀0
 
 
Equation 2.13 
 
Equation 2.12 
Equation 
2.14 
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Therefore, the zeta potential of the particle is: 
 
𝜁𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 =
𝜂𝑙2
𝜀𝑟𝜀0
𝛿(
1
𝑡𝑡𝑟
)
𝛿𝑉
= 𝐴
𝛿(
1
𝑡𝑡𝑟
)
𝛿𝑉
 
 
L is the length, V is the applied voltage and C is an integration constant, which is the 
voltage offset (which is generally unknown) and changes between experiments. It is 
possible to measure
𝛿(
1
𝑡𝑡𝑟
)
𝛿𝑉
, since V and translocation is known, 𝐴
𝛿(
1
𝑡𝑡𝑟
)
𝛿𝑉
 is obtained 
through calibration with particles with a known zeta potential. In TRPS calibration 
particles are commonly used, allowing accurate measurements of zeta potentials.21 
Using the Izon Control Software the translocation velocity can be calculated and is 
related to the zeta potential of the particle – a highly charged particle will move 
faster to the opposing electrode when compared to a lesser charged particle. The 
software takes measurements at multiple points along the tail of the blockade pulse, 
these are recorded as T values i.e. T0.1, T0.2 and so on. Figure 2.10 shows how each of 
these relative velocity measurements are taken along the tail of the resistive peak, 
and how they relate to the position of the particle in the pore. Taking the reciprocal 
of these values gives the relative velocity of the particle.2 Since the qNano is a 
multiple particle analysis, often each measurement has a population greater than 
500, an average of the sample’s relative velocity is given during subsequent chapters.  
 
Equation 2.15 
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Figure 2.10: Schematic of the blockade times, T0.3, T0.5 and T0.7 as a particle translocates the 
pore. The T values indicate the relative position in the pore for example T0.3 equals 70% through 
(not to scale) 
 
The resistive pulse is used to calculate the relative velocity and identifies the point 
of greatest resistance in the signal trace (resistive blockade peak). The time at which 
the peak occurs is defined as T1.0 (time at 100% of peak magnitude) and the maximum 
magnitude of the pulse is recorded as dRmax.25 The blockade magnitude is 
proportional for any given particle. In most chapters to keep the method simple and 
applicable in further applications, the actual zeta potential of the particle is not 
calculated, and for further simplicity the only measurement used to represent the 
particle’s relative velocity is 1/T0.5.  
 Particle Stability  
In many industries, colloid stability is essential for the manufacture, storage and 
usage of many products. Being able to measure a particle’s zeta potential is key to 
understanding the stability of particles in solution. Particle stability is also a factor in 
its mobility through a pore, affected by its size and surface chemistry. To understand 
stability, four scientists, Derjagun, Landau, Verwey and Overbeek, developed the 
DLVO theory, describing the interactions that cause aggregation in a colloid. It 
combines the effects from van der Waals attraction forces and electrostatic 
repulsion to explain why some colloidal systems aggregate, while others do not. The 
theory states that if the potential energy barrier is larger than the average kinetic 
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energy of the particles, then the colloid is described as a stable system.26 However, 
if the particles have enough energy to overcome the potential energy barrier the 
particles in the system would become unstable, which leads to aggregation. They 
suggest the aggregation rate can be slowed by a stability ratio, VT, which is the total 
energy of interaction. This is the sum of the two factors: the total of van der Waals 
attractive forces, VA, and the total of the electrostatic repulsive forces in the double 
layer, VR. From this knowledge it is known smaller particles will aggregate more 
swiftly, meaning they have lower stability in a colloid system.  
Steric and electrostatic repulsion affects the stability of a colloid system. Steric 
repulsive forces arise from any polymers that adsorb to the particle’s surface. Here 
the larger the polymer, the more steric hindrance, which acts to inhibit van der Waals 
forces. Electrostatic forces acting on a particle is determined from the charge 
distribution of the particle. The greater the charge distribution found in the double 
layer, the stronger the electrostatic forces. 
Zeta potential can be used to describe the stability of a colloid system as it is linked 
to the repulsive forces, VR, highlighted in Equation 2.16.   
 
𝑉𝑅 = 2𝜋𝜀𝑎𝜁
2𝐼𝑛(1 + 𝑒−𝑘ℎ) 
 
Here VR is the repulsive forces in the double layer, ε is permittivity, a is the particle 
radius, ζ is zeta potential, κ is the Debye length, and h is the particle separation. 
 Calibrating the qNano for Zeta Potential Measurements 
The nanopore chosen for an experiment depends on the size of the analyte, as well 
as the size of the calibration particles that are used. As described before, Izon 
manufacture several pores capable of detecting an analyte as small as 40 nm and a 
pore able to detect up to 2000 nm in their nanopore range, Figure 2.3.  
Equation 2.16 
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Calibration particles are measured at 3 voltages and 2 pressures, which are input into 
the Izon Control Software. Typically, these are selected based on the applied stretch 
and resulting baseline current for a particular pore. When taking a measurement, a 
baseline current greater than 100 nA is used since this allows the data to be 
compared across several experiments. The stretch and voltage used in a study are 
adjusted to maintain a similar baseline current as each pore has its own baseline 
characteristic (due to the manufacturing process). In addition to matching the 
baseline current the blockade analyte signal should be greater than 0.05 nA, 
compared to a background noise of around 10 pA. Calibration particles of known size 
and zeta potential are used in experiments to determine the analytes properties.   
 
  
Figure 2.11 Calibration output spreadsheet generated from analysing calibration particles with 
the qNano using 3 applied voltages and 2 pressures  
 
When measuring zeta potential, it is essential that the stretch of the pore and the 
potential difference are not changed during a measurement. The sample 
measurements are then completed close to the highest voltage used in the 
calibration measurements. It is essential new calibration measurements are 
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completed prior to analysis or when a new nanopore is used. When analysing 
samples that are of a lower concentration it may be beneficial to apply an external 
pressure using the VPM so that the data collection is within the 10 minute window 
given by the software, ensuring a greater number of translocations occur.  
 Aptamers 
Aptamers are ligand binding short single strands of deoxyribonucleic acid (ssDNA) or 
ribonucleic acid (RNA) that are highly selective with high affinity to a particular 
target. They are molecules that can be artificially obtained from in vitro selection or 
in nature as genetic regulators called riboswitches.27 Their affinity’s and selectivity’s 
have been reported to rival those of antibodies without the need for biological 
expression.28 The affinity of an aptamer is largely target dependant, and as such 
ranges from the picomolar to the nanomolar scale for a number of protein targets.29 
Although they have been used for analytical applications, they have also been 
utilised as active compounds in medicines. One such example is the drug Pegaptanib, 
a RNA based drug for the treatment for ocular vascular disease.30 Users of aptamers 
report many advantages over antibodies, not only their ease of selection, but also 
their thermostability, cost and the fact they are chemically synthesized molecules 
free from cell-culture-derived contaminants. They are also essentially non-
immunogenic, hence their development into therapeutic agents. The specific base 
sequence used in an application is dependent upon a specific target analyte, this 
could be a protein, peptide, virus, bacteria, cells or even non-biological targets such 
as metal ions and small molecule structures.31 Aptamers can be readily modified, 
having the ability to be modified to incorporate linkers, chemical modifications, dyes 
or moieties, and modified with 2’-fluoro and 2’-O-methyl substitutions to reduce the 
degree of nuclease breakdown.32,33 Also, the secondary structure of the aptamer can 
be engineered further to create an analytical-dependant conformational change, 
that can be used in a variety of signal inducing methods – electrochemical, optical or 
mass based. Since they are nucleic acid derived, they can also be implemented into 
amplification techniques.   
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Aptamers are typically isolated from a library of a random pool of oligonucleotides 
(>1013 different sequences) in a process known as systematic evolution of ligands by 
exponential enrichment (SELEX) – this process was first described by two 
laboratories in 1990 and characterised by repetition of the five mentioned main 
steps - binding, partition, elution, amplification and conditioning, Figure 2.12.28,34–37  
 
 
Figure 2.12: In vitro selection of target-specific aptamers using SELEX. Starting point of each 
SELEX process is a synthetic random DNA oligonucleotide library consisting of a multitude of 
ssDNA fragments with different sequences (∼1015)36 
 
The in vitro process classically involves a purified target being incubated with an 
oligonucleotide library. Over multiple rounds of selection, the large populations of 
different sequences can be filtered, and the few fittest nucleic acid species can be 
isolated, akin to a Darwinian driven process. The weakly bound sequences are 
isolated from the binding sequences and removed. Target bound sequences are 
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eluted and amplified by polymerase chain reaction (PCR) and placed into a new 
oligonucleotide pool. The new (enriched) pool of oligonucleotides is used to bind to 
the target in the next SELEX round, this process repeats until a relatively few 
sequences remain, which have high affinity and selectivity to its target. The number 
of rounds depends on a number of factors, such as target features and 
concentration, design of the starting DNA oligonucleotide library, selection 
conditions, ratio of target molecules to oligonucleotides, or the efficiency of the 
partitioning method.36 The final stage of the SELEX process involves the cloning of 
the PCR products to isolate individual clones from the selection pool. The individual 
aptamers are sequenced to characterise their binding features in more detail. 
Experiments can be performed to narrow down the minimal binding region within 
the aptamer sequence by exploring mutation and truncation. It is common for most 
selected aptamers in the SELEX process to undergo a number of post-SELEX 
modifications in order to use the aptamers in analytical assays. The traditional in 
vitro selection process usually requires several weeks to months, but recent 
automation can reduce this to a few days. 
 Superparamagnetic Particles 
Having a rapid, low cost assay that offers a robust diagnostic tool is fundamental for 
medical assessment, in or outside a medical setting. Due to the highly complex 
nature of biological matrices, bioassays can be subjected to a low signal-to-noise 
ratio and subject to a significant amount of non-selective binding. In order to 
perform an assay on a biological sample it may be necessary to separate and isolate 
a target from the multiple components. Most traditional methods currently used 
either require the sample to be centrifuged and/or filtration, which are often long, 
involving numerous steps, and time-consuming for the analyst. One way to 
overcome these issues is to incorporate superparamagnetic particles (SPPs).38,39 
Functionalising the surface of SPPs allows for the attachment of ligands or receptors 
for the specific binding of a target.40 
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Previous studies have used magnetic separation in a number of industries from coal 
desulfurization to enzyme reaction engineering and bioengineering.39–41 More 
recently the use of magnetic particles and an external magnetic field for the 
separation of biological analytes from a bulk solution have become more 
mainstream. The process was first highlighted by Robinson et al who applied the 
theory to cellulose magnetic microspheres to immobilize enzymes.42 The process of 
magnetic separation is to capture and separate an analyte selectively with differing 
magnetic forces acting upon the magnetic particle and the media the particle is in. 
In the very basic sense of magnetism, it is the forces of attraction and repulsion 
between objects produced by electric charge and the magnetic moments of atoms.  
When a magnetic material is placed in a magnetic field of strength H, the individual 
moments of the atoms contribute to the overall response – the magnetic induction, 
Equation 2.17.  
 
𝐵 =  𝜇0(𝐻 + 𝑀) 
 
µ0 is the permeability of the free space and M is the magnetism; M is: 
 
𝑀 = 𝜒𝐻 
 
Here χ is the magnetic susceptibility; the physical quantity that characterizes the 
properties of the magnetic medium.  
SPPs used in this thesis act differently from ferro- and ferrimagnetic materials. The 
latter two form a permanent magnet in the presence of an external magnetic force.43 
Paramagnetic particles demonstration no hysteresis at room temperature and as 
such offer the potential to be used in separation of an analyte in a biological matrix.44 
Reducing the size of ferri- or ferromagnetic particle to the tens of nanometre range 
Equation 2.17 
Equation 2.18 
 57 
 
has the effect of embedding the material with a superparamagnetic state. This 
phenomenon is due to the confinement of the domains, and as such they can rotate 
freely as there are no domain walls to move. Here the magnetic moment of the SPPs 
as a whole is free to vary in response to thermal energy, while the individual atomic 
moments maintain their ordered state relative to each other. The theory that 
underpins the physics of superparamagnetism is examined by the activation law of 
the relaxation time, τ, of the magnetism of the particle when the magnetic field is 
removed, Equation 2.19  
 
𝜏 =  𝜏0exp (
Δ𝐸
𝑘𝐵𝑇
) 
 
Here E is the energy barrier to moment reversal, and kBT is the thermal energy. In 
the simplest form the energy barrier is given as,  
 
Δ𝐸 = 𝐾𝑉 
  
This direct proportionality between E and V is the reason that superparamagnetism 
- the thermally activated flipping of the net moment direction - is important for small 
particles since K is the anisotropy energy density and V is the volume of the particle. 
Therefore, reducing the volume of the particle reduces the energy barrier to moment 
reversal and for small particles ΔE is similar to KB at room temperature and the 
particles can separate. Since the SPPs used in the work outlined in this thesis are iron 
oxide nanoparticles, their presence in a magnetic field means they can be separated 
from the bulk and when the magnetic field is removed, they move back under 
Brownian motion, or with a mechanical vortex. 
Equation 2.19 
Equation 2.20 
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As larger SPPs have more domains, they move towards the magnet faster, this is 
expected from the magnetic force equation, Equation 2.21.  
 
𝐹 =  
𝑉. Δ𝜒
𝜇0
 (𝐵. 𝛻)𝐵 
 
This is due to the overall response of the particles plus the solution is approximated 
by B = µ0H. Here F is the force on the particle in the magnetic field, V is the particle’s 
volume, Δχ is the susceptibility differences between the particle and the solution, µ 
is the magnetic permeability and B, the magnetic field strength. Since the volume of 
the particle increases, so does the force acting upon it and therefore a larger particle 
will lead to faster separation.  
 
 
 Equation 2.21 
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Figure 2.13: Representation of the steps involved in a simple magnetic separation of a target 
using SPPs 
 
The intrinsic properties highlighted in this section gives an insight into the reason 
SPPs will be used in this thesis. A basic schematic shows how they can be used in the 
development of a blood-based assay, Figure 2.13.  
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3 Calibration for Zeta Potential Using Izon’s RPS 
Platform  
 
 Theory of Zeta Calibration  
The average velocity of each particle is calculated from applying several reference 
points to each blockade event. By averaging the velocity of each particle, the value 
of the zeta potential determined is more robust and reduces any errors in the 
calculation. Obtaining a calibration of the pore results in a linear relationship of 1/T 
and the voltage applied, V, at each of the reference points along the blockade event. 
This is demonstrated by Equation 3.1, where,  (𝑣𝑥)𝑒𝑙 𝐶𝑎𝑙 and (𝑣𝑥
𝑖 )𝑒𝑙 𝑆𝑎𝑚𝑝𝑙𝑒  are the 
particle velocities of calibration and sample particles respectively and 𝜉𝑛𝑒𝑡 𝐶𝑎𝑙 and 
𝜉𝑥 𝑛𝑒𝑡 𝑆𝑎𝑚𝑝𝑙𝑒
𝑖  are their zeta potential values 
 
(𝑣𝑥
𝑖 )𝑒𝑙 𝑆𝑎𝑚𝑝𝑙𝑒  
(𝑣𝑥)𝑒𝑙 𝐶𝑎𝑙
=  
𝜉𝑥 𝑛𝑒𝑡 𝑆𝑎𝑚𝑝𝑙𝑒
𝑖
𝜉𝑛𝑒𝑡 𝐶𝑎𝑙
 
 
Therefore, the zeta potentials calculated at each of the blockade events reference 
points can be used to determine the overall zeta potential of each particle that 
passed through the pore. This is done by using Equation 3.2, where, i, is each 
individual particle as it passes through the pore, 𝜉𝑆𝑎𝑚𝑝𝑙𝑒
𝑖 .  
 
                 ξSample
i =
∑ ξx Sample
i
x
Σx
=
∑ (vx Sample
i −vx Cal
P ×𝑃)/(vx Cal
V ×𝑉)x
Σx
× ξnet Cal + ξm                       
 
 
Equation 3.1 
Equation 3.2 
 67 
 
Herevx
V
Cal,vx
P
Cal, P, and V are electrokinetic velocity per unit voltage, convective 
velocity per unit pressure, applied pressure and voltage respectively. Ix is the position 
of the particle in the nanopore after time t=Tx, 𝑣𝑥
𝑖
𝑆𝑎𝑚𝑝𝑙𝑒  is the sum of the particle 
velocities at relative positions, lx.1 
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4 The Effects of Biological Matrices on 
Nanoparticles 
 
 Abstract 
Biological fluids are complex matrices made up of many components, such as 
proteins and peptides. Since the final assay will be performed using resistive pulse 
sensing (RPS) in biological matrices, specifically human blood, the behaviour of DNA 
aptamer modified particles within the biological sample matrix must be 
reproducible, and stable. The addition of nanomaterials into protein rich samples 
can lead to the protein’s coating the particles surface, drastically altering their 
properties and subsequent behaviours. This protein-nanomaterial interaction leads 
to the formation of a protein corona around the particle’s surface. The resulting 
protein/particle interface represents the ‘new’ biological identity of the particle, 
influencing or affecting its application. The knowledge of protein corona formation 
around a nanoparticle is important in the fields of diagnostics, drug delivery, 
biomedical imaging, toxicology and ecotoxicology. The work in this chapter sets out 
to understand the behaviour of the formation of a protein corona around a particle, 
the pore wall, as well as the influence it is likely to have on the analysis of particles 
using RPS and zeta potential as a measurement. Using tunable resistive pulse sensing 
(TRPS) to monitor protein/particle interactions has its advantages over existing 
technologies, one being the ability for fast measurements.  
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 Aim and Objectives 
The fundamental aim of this work is to gain an understanding of the formation of the 
protein corona and the kinetics of the protein binding interactions when 
nanoparticles are placed into biological matrices. An understanding of how RPS can 
be used to measure this will also be developed. It is vital to know this knowledge as 
any assay developed using nanoparticles, and blood as the sample matrix (described 
in further chapters), needs to have the robustness and reliability demanded from a 
diagnostic tool.    
 Introduction 
Recent developments in nanoparticle fabrication has allowed a particle’s surface 
chemistry to be easily modified for their subsequent applications.1 This has in-turn 
led to their use in diagnostics and drug delivery being explored.2,3 However, when 
placed into biological matrices, the in vitro properties are altered by the presence of 
the numerous proteins that make up biological fluids when in vivo, critically affecting 
the interaction of nanoparticles within living systems. The need to measure the 
properties of nanoparticles is as important as changing the pH, temperature, ionic 
strength or their purification since it can misrepresent their behaviour in their 
‘natural environment’. The introduction of nanoparticles into a biological medium 
causes immediate snarling of the particle’s surface as a protein corona forms in 
layers known as the hard and soft corona.4,5  
 
Figure 4.1: Representation of the soft and hard corona formed from proteins found in blood 
around a nanoparticle 
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This can lead to a distorting of the properties a particle will have – largely the change 
in surface chemistry. The proteins in the hard corona have a higher affinity that 
interact directly with the nanoparticle surfaces, whereas proteins forming the soft 
corona engage in a weaker protein-protein interaction with the hard corona.6 It has 
previously been found that a vast range of particles bind successfully to 
apolipoproteins in physiological fluids.7 Formation of a protein corona alters the size, 
aggregation properties and surface properties of nanoparticles, thus creating a new 
biological distinctiveness for further application.8 This new identity of the 
nanoparticle is a result of the composition of the corona, which has been reported 
to also change their pathophysiology.9 There are 5 main components that define the 
composition of a protein corona; thickness and density, identity and quantity, 
orientation, conformation and affinities. Protein adsorption kinetics are key to 
understanding the binding mechanisms that will occur in a biological environment. 
Although the process is time-dependent, the kinetics rely on the kon and koff rate 
constants for adsorption and desorption of proteins. kon is largely dependent on how 
often the protein contacts the nanoparticle’s surface, as well as the probability of 
successful binding between the two materials. The rate of absorption is dependent 
on the number of times the protein interacts with the nanoparticle’s surface 
together with the probability of a successful protein/particle binding.10 Desorption 
of bound proteins depends heavily upon the binding strength between the two 
materials.10 In a weak low energy interaction, the koff value will be high and 
conversely if the interaction is strong in nature with high energy, the resulting koff  
value will be low. Understanding this process gives an insight in to processes 
occurring when the nanoparticles are introduced in vivo.  
As physiological systems are highly dynamic and highly complex, the protein corona 
shares these properties. To fully understand the complexities, it is important to 
obtain information of protein corona formation quickly. Methods that have been 
used to understand the protein corona include dynamic light scattering (DLS), 
fluorescence quenching, differential centrifugal sedimentation, mass spectrometry 
and circular dichroism.6,7,11,12 Electron microscopy has also been utilised to 
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determine the thickness of the corona. Ensemble techniques used to characterise 
the protein corona have a few drawbacks, the most noticeable being the fact they 
take several measurements of particles in the sample. This has the effect of falsely 
estimating the sub-population of particles caused by the averaging of all particles 
present in multimodal samples.3,13  
When using RPS and DNA modified nanoparticles for disease detection it is 
important to have a foundation of knowledge and understanding around the protein 
corona formation phenomenon. This can be applied to future work likely to be 
undertaken using human plasma, serum or even whole blood.  As the majority of 
research into protein coronas has been performed using DLS, this work will also 
highlight RPS’s ability to monitor the changes in zeta potential of a sample at a single 
particle resolution. Ultimately, characterising nanoparticle/protein interactions and 
protein binding from each protein studied will develop a much needed further 
understanding on how nanoparticle exposure to a biological matrix can impact on 
the development of blood-based assays.  
Here work has been completed to observe the changes in the properties of 
calibration nanoparticles; using zeta potential as a function of biological matrix, 
temperature of the matrix and protein concentration. This includes the use of human 
plasma and serum, and isolated proteins found in human blood at their physiological 
concentrations – namely purified human albumin, fibrinogen and γ-globulin. By 
mimicking these physiological environments, the effects the particles will be 
subjected to in the high protein concentrations, and the high ionic strengths, found 
in human serum and plasma can be studied. RPS was also used to monitor the change 
in the protein corona as a function of time as serum samples containing 
nanoparticles are spiked with plasma. The change in the so called soft and hard 
corona layers illustrates the varying affinities different proteins have on the particle 
and gives an insight into the formation, kinetics and the mechanisms involved.  
The data presented in this chapter not only outlines the necessity to consider the 
biological matrices in assay development but also the use of nanoparticles in 
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medicine. Here RPS has been used successfully to observe the changes in a particle-
by-particle method, using zeta potential – a value that represents the electrostatic 
potential at the shear plane - as a mean to do this in a simple and rapid way.  
 Experimental and Materials 
 Chemicals and Reagents  
4.4.1.1 Buffers 
Phosphate buffered saline (1x PBS tablet (0.01 M phosphate buffer, 0.0027 M 
potassium chloride, 0.137 M sodium chloride) in 200 mL deionised water (18.2 MΩ 
cm, Smart4Pure, TKA)) was used for particle analysis. PBS tablets (P4417) were 
purchased from Sigma-Aldrich, UK. 
4.4.1.2 Carboxyl Polystyrene Standards 
For zeta calibrations, carboxylated polystyrene particles, denoted as CPC200, with a 
mean nominal diameter of 210 nm and a stock concentration of 1 X 1012 mL-1, were 
purchased from Bangs Laboratories, USA. and used as a calibrant. They were also 
used as the sample particles. The particles were vortexed for 30 seconds followed by 
a 2 minute sonication to ensure monodispersity prior to any RPS analysis. 
4.4.1.3 Isolated Proteins  
Isolated proteins used in experimentation were purchased from Sigma-Aldrich, UK, 
and used without modification or purification unless stated otherwise; fibrinogen 
from human plasma (F3879), albumin from human serum (A9511) and γ-globulin 
from human blood (G4386).  
4.4.1.4 Human Plasma and Serum Samples 
Blood samples were collected and prepared at Peterborough City Hospital Pathology 
Laboratory, UK. Plasma collection was completed using blood from a healthy 
volunteer donor, collected in citrate medium (Sarstedt, UK) and centrifuged at 3000 
rpm for 8 minutes. Serum was gathered using blood from a healthy volunteer donor 
that was collected into a Sarstedt monovette/collection tube and was centrifuged at 
3000 rpm for 6 minutes. The supernatants from each sample were transferred into 
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separate sample vials and stored at room temperature prior to use or for longer term 
storage - stored at -80°C. The samples were removed from the -80°C and left to 
equilibrate to room temperature prior to use. 
 Isolated Protein Studies 
Using PBS buffer, isolated albumin, fibrinogen and γ-globulin samples were prepared 
to give the following concentrations; 43 g L-1, 3.2 g L-1 and 20 g L-1 respectively as to 
mimic protein concentrations found in human plasma. The concentrations of 
proteins were measured from human plasma and serum samples. The samples used 
in this study were analysed by an Instrument Laboratory ACL TOP CTS500 
coagulation analyser (Werfen, Spain) to obtain the fibrinogen concentration. 
Albumin and γ-globulin levels were taken from test serum samples that were 
analysed by a Roche Cobas biochemistry analyser (Roche Diagnostics, Switzerland). 
CPC200s were added resulting in a final concentration of 1 X 1010 mL-1. Each sample 
was vortexed for 30 seconds and sonicated for 1 minute before incubation. Samples 
were then incubated at 25°C and 37°C in a mini dry bath (Benchmark Scientific, USA) 
for 10 minutes prior to TRPS analysis.  
 Serum and Plasma Studies  
Immediately before experimentation, human plasma and serum were prepared to 
minimise ex-vivo artifactual changes. The previously prepared plasma and serum 
samples were separately diluted 10x fold with PBS before the additions of CPC200s 
particles, resulting in a final particle concentration of 1 X 1010 mL-1. Samples were 
vortexed for 30 seconds and sonicated for 1 minute, followed by incubation in a mini 
dry bath (Benchmark Scientific, USA) at 25°C and 37°C for 10 minutes before TRPS 
analysis. It should be noted that it is possible for some proteins in human plasma and 
serum to interact and adsorb onto the pore walls, therefore, a control measurement 
of CPC200s (with a known zeta potential) in PBS was completed before and after 
each protein/plasma/serum sample to establish if any changes had occurred to the 
pore itself. 
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  Plasma Spiking Assay 
Human serum was diluted 10x fold in PBS before CPC200s were added to a final 
concentration of 1 x 1010 particles mL-1. Samples were vortexed for 30 seconds and 
sonicated for 1 minute before being incubated for 10 minutes at 25°C and 37°C in a 
mini dry bath (Benchmark Scientific, USA). After 10 minutes, 5% (v/v) human plasma 
was added to the serum samples and the samples were vortexed for 30 seconds. 
TRPS measurements were completed once the plasma had incubated with the serum 
sample for 5, 10, 15, 20, 30 and 60 minutes. Again, a control measurement of 
CPC200s (with a known zeta potential) in PBS was completed before and after each 
sample. 
  Tunable Resistive Pulse Sensing (TRPS)  
A qNano (Izon Science Ltd, NZ) was used to complete all measurements in this study. 
The nanopores used throughout all experiments were capable of detecting particles 
within the size range of 80 - 500 nm (as stated by the manufacturer, Izon Science 
Ltd), and denoted as an NP200. To account for the variation in the manufacturing of 
the nanopores, appropriate stretch (44 - 46 mm), voltage and pressure were applied 
in all experiments; the conditions were matched to the blockade magnitudes of 
CPC200s in PBS being of a similar size throughout all experiments. Izon’s propriety 
software (Izon Control Suite v3.1.2.53) was used for data capturing. In all 
experiments the lower fluid cell contained 80 µL of PBS buffer, ensuring no bubbles 
were present. When a sample measurement was being taken, the upper fluid cell 
contained 40 µL of the sample (suspended in PBS buffer). After each measurement 
was taken the nanopore was rinsed several times by removing and replacing 40 µL 
of buffer, each time applying varied pressures until no particles were observed. This 
process was performed several times to remove any residual particles in the system 
and thus ensure no cross contamination between samples.  
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 Results and Discussion  
To obtain the zeta potential of a particle, the theory of RPS utilises the duration of 
the particles translocation as a function of the applied voltage, using an average 
electric field and particle velocity as explained in chapter two.14,15 Briefly, these 
averages are taken from the whole of the sensing zone with the electrophoretic 
mobility of a particle derived from 1/T. Here T is the durations of the blockade along 
the blockade event, and voltage, which is squared by the length of the sensing zone 
of the pore. Each T is referred to as a blockade reference point and the average 
particle velocities are determined across several of these reference points to reduce 
any errors in the zeta potential calculation, Figure 4.2 shows this in schematic form.  
 
 
Figure 4.2:  I1.0, I0.8, I0.6, I0.4, I0.2 represent the position of the particle as it translocates the pore 
(where I1.0 is the narrow pore entrance) and are relative to T1.0, T0.8, T0.6, T0.4, T0.2, which 
represent the time taken (ms) for the particle to reach that position. T1.0, is equivalent to dRmax 
when the blockade event is at 100 % magnitude; T0.8, T0.6, T0.4, T0.2, correspond to when the 
blockade is 80, 60, 40, and 20 % of its dRmax and indicates the particle traversing the pore 
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 Isolated Protein Study 
As previously stated, the concentrations of the isolated proteins used in this study 
were chosen based on their relative abundances found in human blood.16,17 
However, it must also  be noted that the concentrations used were in large excess to 
coat each particle’s surface. It was expected that using such a large excess the 
proteins would adsorb onto the particle’s surface to form a corona, changing the 
surface charge density and measured by change in particle velocity.  
Albumin and γ-globulin are present in both plasma and serum samples at 
approximately 4 and 2 %, whereas fibrinogen (as well as other clotting factors) is only 
found in plasma at approximately 0.4 %. This translates to concentrations of 40 g L-1 
for albumin, in comparison to the fibrinogen and γ-globulin samples only having 
protein concentrations of 4 and 20 g L-1 respectively. After the particles were 
incubated at 25°C in the isolated protein, the zeta potential of the particles was 
determined, which can be seen in Figure 4.3. From the data obtained, it was shown 
that fibrinogen and γ-globulin elicited a smaller change in mean zeta potential 
compared to the control CPC200 carboxyl particles incubated solely in PBS; 3.2 and 
3.6 mV respectively. Albumin, the protein at the highest concentration, had a larger 
change of 9.2 mV from the control.  
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Figure 4.3: Mean zeta potential (mV) versus the protein the particles were incubated with. The 
blue bars show results for a 10 minute particle incubation at 25°C and the red bars show the 
mean zeta potential values for particles incubated with the proteins for 10 minutes at 37°C. The 
dashed line represents the measured mean zeta potential for particles in PBS that were run 
after each protein sample to show the protein samples were not having a direct effect on the 
pore walls themselves that may influence the recorded zeta potentials of future samples run on 
the same pore. Error bars are representative of the 1 x SD from the mean, where n=3 
 
To test the effect of temperature on protein corona, carboxyl CPC200 particles were 
incubated in each of the isolated protein for 10 minutes, at the higher temperature 
of 37°C. Again, since the concentrations of the proteins were in a large excess, there 
would be sufficient amount of proteins to cover the surface of each particle in the 
10 minute incubation time and therefore little effect on the results obtained was 
hypothesised. However, when the incubated particles were analysed, each protein 
produced varying shifts in the particle’s zeta potential. This time γ-globulin had the 
largest shift of 11.3 mV, from -20.3 to -9.0 mV, indicating a protein interaction with 
a particle’s surface is unique to that protein. γ-globulin also showed the largest 
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change in zeta potential as a function of incubation temperature at 5.0 mV, whereas 
albumin showed the smallest change at 1.3 mV, Figure 4.3.  
To investigate further, a constant concentration (5 g L-1) of each of the isolated 
proteins were incubated at 25°C and incubated for 10 minutes. This was done to 
determine the effect concentration had on the formation of protein corona on 
carboxylated particles, the result can be seen in Figure 4.4. 
 
Figure 4.4: Mean zeta potential (mV) versus protein particles incubated with fibrinogen, 
albumin and γ-globulin. The datasets show results for a 10 minute particle incubation at 25°C 
and for all the proteins at a concentration of 5 g L-1. The dashed lines represent the measured 
mean zeta potential for particles in PBS for comparison to protein incubated particles. Error 
bars are representative of the 1 x SD from the mean, where n=3     
 
It was observed that the relative change in zeta potential of a particle incubated in 
the constant protein concentration had a similar trend. Fibrinogen and γ-globulin 
had the smallest change in mean zeta potential values of 3.3 and 4.9 mV, 
respectively. Albumin had the largest change at 8.9 mV. These results indicate that 
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the changes in zeta potential are specific to the protein and are not concentration 
dependent. 
A possible reason for these changes in zeta potential is likely due to the isoelectric 
points (pI) of the proteins and their behaviour at the physiological pH of 7.4 used in 
these experiments. Albumin has a pI of 4.7 whereas fibrinogen and γ-globulin have 
isoelectric points of 5.8 and 6.6, respectively.18 Reports have suggested that as the 
pH of absorption moves from the proteins pI values, the adsorb molecules will 
occupy a larger area of the particle surface. This is due to internal electrostatic 
repulsions and therefore the lower structural stability.19 Since the PBS buffer used 
throughout this study had a pH of 7.4, albumin was expected to occupy a larger area 
of the surface of the particle, as adsorption was occurring furthest from its pI. This 
could be the reason albumin had the largest change, and smaller changes observed 
for fibrinogen and γ-globulin, where their pI values are closer to the pH of 7.4. To 
demonstrate the particle-by-particle analysis TRPS is capable of, a plot of zeta 
potential versus particle size was plotted, seen in Figure 4.5.  
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From the plot of zeta potential versus particle size at 25°C and 37°C, the spread of 
the data does not change as a function of temperature, but the mean zeta potential 
at each temperature had changed significantly. Previous work has suggested that the 
maximum adsorption of a protein is observed at 15°C, 25°C and 37°C.20 This could be 
used to explain why there is a larger change in zeta potential at 37°C, to a less 
negative value, when compared to incubation at 25°C. The hard corona layer will 
alter the particle surface chemistry and will result in a slower particle translocation 
velocity through the pore due to shielding of the negative particle surface, which 
consequently results in a smaller, less negative zeta potential. More interestingly, at 
the 25°C incubation, Figure 4.5a, the γ-globulin and particularly the fibrinogen 
sample showed a wider spread of data than those samples incubated at 37°C. It also 
shows that as temperature increased there was an increase in particle size, forming 
a thicker corona layer observed as an increase in particle size; this could be an 
entropy mechanism.21 This would suggest the binding kinetics of protein to 
nanoparticles is one that is a function of temperature. The population spread 
observed for the 25°C incubation may be down to the protein not reaching the 
maximum levels of adsorption to the surface of the particle, hence the lesser change 
in zeta potential from the control.20 
 Incubation of CPC200s in Human Plasma and Serum 
The next sets of experiments were used to monitor the change in zeta potential of 
carboxylated particles when incubated in a more complex medium; human plasma 
and serum. Plasma and serum are fractions collected from blood and both contain a 
complex composition of proteins. Relevant to this study, serum contains albumin, γ-
globulin, and apolipoproteins. Plasma has a similar protein composition to serum, 
but also contains the clotting factor, fibrinogen. Figure 4.6 shows the measured zeta 
potential values of carboxylated particles in PBS and the same particles when 
incubated for 10 minutes in plasma and serum. 
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From the previous experiments described earlier, fibrinogen and γ-globulin isolated 
proteins gave a small change in their zeta values when incubated at 25°C, compared 
to the control particles in PBS. This was also observed for the zeta values of the 
particles incubated in plasma and serum. However, at the increased temperature of 
37°C the plasma appeared not to give a significant change in zeta potential, whereas 
the serum incubated particles had a change of 5.9 mV. The most obvious difference 
between plasma and serum is the fact serum lacks the clotting factor fibrinogen. This 
difference in protein composition in the biological medium will have an effect on the 
structure of the protein corona formed around the particle and the interactions 
observed.8 The complex nature of physiological mediums such as blood fractions will 
have an inherent effect on the protein corona structure and resulting interactions 
with the particle surface. The formation of the corona is complex, consisting of the 
simultaneous binding of numerous proteins to the particle surface creating both 
protein-nanoparticle interactions as well as protein-protein interactions8.  
The proteins in the plasma and serum undergo competitive binding assay to the 
surface of the particles, and proteins of higher concentrations and/or affinity 
proteins bind more rapidly when first exposed. Protein-protein interactions are also 
common in plasma and serum samples and some proteins will have a higher affinity 
to a subsequent protein over the particle surface. The distribution of zeta potential 
as a function of incubation temperature for particles incubated in plasma and serum 
can be seen in Figure 4.7. 
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When the incubation temperature was increased the zeta potential for both particles 
in plasma and serum was smaller, as with the isolated proteins. The distribution plot, 
which can be obtained through the particle-by-particle analysis using RPS, allows the 
distinct differences between the populations to be observed which might not be 
identifiable from the mean zeta potential value alone. Using Figure 4.7 to highlight 
this element, the distribution of particle incubated in plasma at 25°C is nearly twice 
as wide as particles incubated at 37°C, yet the difference in mean zeta value was a 
mere 0.4 mV. This difference in distribution was also highlighted by establishing the 
median skewness values. Median skewness values for a sample population of 
particles incubated in plasma were 0.111 for 25°C and -0.065 for 37°C. Particles 
incubated in serum also showed the same effect; as the incubation temperature 
increased, the median skewness values decreased from -0.105 for 25°C to -0.343 for 
37°C.  
 Plasma Spiking 
Since the varied nature of protein corona formation was observed for plasma and 
serum, an experiment was conducted to investigate this through a process of plasma 
spiking. Its aim was to establish if there was a reordering of proteins in the soft 
corona in the presence of proteins found in plasma. It has been studied that over 
time proteins with higher affinities, but lower concentrations, replace proteins with 
lower affinities, but have higher concentrations.  
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Figure 4.8: The effect of spiking a sample of particles incubated in serum with plasma. Particles 
were initially incubated in serum for 10 minutes at 37°C before being spiked with 5% (v/v) 
plasma. Zeta potentials were measured at 5, 10, 15, 20, 30 and 60 minutes. The plot shows the 
mean zeta values versus time. Error bars represent 1 x SD from the mean, where n = 3 
 
The Vroman effect is used to explain plasma protein adsorption to a particle’s 
surface, which is defined as the constant change in protein composition based on 
continuous adsorption and desorption at a surface.22 Depending on the protein, this 
effect can have slower and faster stages. Albumin, γ-globulin and fibrinogen are 
examples of proteins that rapidly adsorb onto the surface of the particle since they 
are present in high abundance, but are later replaced by less abundant 
apolipoproteins, which can happen in a matter of seconds. This occurs due to their 
fast dissociation characteristics.23 Apolipoproteins, however, although of low 
abundance, have a much slower dissociation constant and will therefore remain on 
the potential surface for longer.24 
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As with a lot of nanoparticle-based assays, there may be an element of competition 
between proteins in binding to the nanoparticle surface that will affect the protein 
corona structure as displacement and exchange reactions take place over time. As 
the hard corona involves the higher affinity proteins, this should remain adsorbed 
onto the nanoparticle surface over time and during any biophysical event that may 
occur.8 The outer layer of the corona, the soft corona, is formed from proteins with 
weaker interactions and will be subjected to faster dissociations and protein 
exchange. This effect is largely dependent upon the relative concentrations of all the 
proteins present in the system; plasma and serum. The material the particles are 
manufactured from also has an effect on the formation and lifetime of the protein 
corona.25  
The measurements for this experiment were taken at 5, 10, 15, 20, 30 and 60 minute 
intervals. From 5 to 10 minutes, after the addition of plasma to the serum incubated 
particles, Figure 4.8, the zeta potential of the particles decreased. This is due to the 
addition of proteins into the sample and the interactions of proteins, at higher 
concentrations, with the particles resulting in a slower translocation velocity. After 
15 minutes the zeta potential was reduced to its lowest value. To explain this, a 
number of plasma proteins could have displaced those from serum having previously 
reversibly bound to the particle’s surface, forming the hard corona layer. The plasma 
proteins may have a higher affinity compared to those present in the serum sample, 
therefore forming the new hard corona layer.6,26 After 20 minutes and up to 60 
minutes, the zeta potential of the particles became more negative, indicating an 
increase in particle translocation velocity. The weak interactions of the soft corona 
could be used to explain this observation. For example, once the plasma proteins 
have displaced those in the original hard corona, the displaced proteins will form 
part of the soft corona and be part of weaker protein-protein interactions. Over time 
the soft corona proteins will dissociate more readily away from the particle due to 
their loose interactions, reducing the protein coverage around the particle and thus 
resulting in a larger zeta potential.25 The zeta potential becomes larger after this 
process as there are less bound proteins surrounding the particle to reduce the 
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particle’s translocation velocity. Since the particles translocate through the pore 
faster a larger zeta potential value is observed. 
 Conclusion 
This work has demonstrated that RPS can monitor the effects of more prominent 
proteins found in protein coronas individually (isolated in PBS) and within their 
natural environment (within plasma and serum samples) on carboxylated 
polystyrene nanoparticle surfaces. The effects on the nanoparticle varied depending 
on the matrix, and its complexity, the particles were immersed. Reported in this 
chapter is the foundation of knowledge needed for the development of a bio-assay 
using the components of blood as the biopsy tissue. This is fundamentally important 
as it is not solely down to the particle’s surface chemistry that determines its 
biological behaviour, but the complexity of the protein competition within human 
blood that interacts with it. 
Protein-nanoparticle interactions involved in the formation of a protein corona have 
been found to be protein dependent at 25°C, as well as temperature dependent for 
each studied protein. The isolated proteins used in this work (albumin, γ-globulin, 
and fibrinogen) and the serum sample showed a larger move to a less negative zeta 
potential when incubated with the nanoparticles at 37°C. However, the plasma 
sample showed little change. Significant changes in particle zeta potentials were 
observed when all the proteins interacted with the nanoparticles at 37°C, 
demonstrating the complex nature of particle/protein interactions when 
competition for binding is introduced. 
RPS technology has enabled single particle analysis, as well as information on the 
zeta potential distributions amongst a given sample population in all experiments 
carried out. This has proved invaluable by allowing a more detailed picture of binding 
kinetics and protein affinities. It was observed although a stable ‘hard’ and ‘soft’ 
corona can be formed around particles in serum, the various protein displacement 
and exchange processes occurring when plasma proteins are introduced to these 
samples can be tracked. This has provided more detailed information on the 
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affinities and reaction kinetics of protein coronas dependent on their biological 
medium and incubation conditions. Future work that would add to this study would 
be to investigate more of the proteins found in blood to further characterise the 
proteins likely to be displaced in the corona. This could include the mixing of isolated 
proteins to investigate their interactions. A further understanding of protein-
nanoparticle interactions in complex matrices and in physiological conditions is 
proving useful for advances for the development of an assay for prions.  
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5 Site-Specific Assessment of DNA Methylation  
 
 Abstract  
DNA methylation is a common feature to control gene expression of eukaryotic 
organisms - maintaining DNA stability and integrity. Given the number of cellular 
processes involving this mechanism, the focus of many researchers has been to 
understand the link between methylation and human disease. Many diseases are 
thought to be defined by patterns of DNA methylation, which result in aberrant gene 
expression. Despite recent advances in genomic DNA (gDNA) methylation research, 
not only does the exact role of methylation remain largely unknown but also how 
gDNA methylation patterns are regulated. The work presented in this chapter lays 
the basis of a rapid assay based upon resistive pulse sensing (RPS) to characterise 
sequence specific DNA methylation sites in gDMA. The process negates the need for 
complex and harsh organic reactions, and sequencing to determine gDNA 
methylation. More simply the surface of superparamagnetic particles (SPPs) are 
modified with DNA (capture probe, cpDNA). The particles are added to solution 
where they bind to and extract sequence specific DNA (target DNA, tDNA). The tDNA 
loaded SPPs are then incubated with antibodies which bind to the methylation sites, 
and the velocity of the SPPs through the nanopore reveals the number and location 
of the epigenetic markers within the target. The approach can distinguish between 
different methylation sites within a DNA promoter region. Crucially, the approach is 
not dependant on accurate sequencing of assayed DNA, with genomic regions 
targeted through complimentary probes. As such the number of stages and reagents 
costs are low, and the assay is complete in under 60 minutes including incubation 
and run times. The format also allows simultaneous quantification of the number of 
copies of methylated DNA and illustrated as a dose response curve.  
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 Aims and Objectives 
The work conducted in this chapter is to understand the feasibility of the RPS 
platform as a biosensor for the detection of methylated DNA. The fundamental aim 
is to develop an on-particle technique, which uses RPS, without the need for 
sequencing or bisulfite conversion. Establishing the limit of detection and 
quantification is essential for any novel assay that can be used clinically, however, 
these are not the only factors that should be considered. Reliability, robustness and 
the speed the assay can be conducted are also vital elements to consider. In this 
chapter these factors will be explored and reported. 
 Introduction 
One of the most challenging goals in modern bioscience remains: how can we 
understand disease through analysis of biological variation?  In the post genomic era, 
quantitative biological science has been dominated by seeking the answer through 
analysis of genomic and transcriptomic variation. This arises not from an ad-hoc 
understanding of the pre-eminence of these components, but rather the relative 
ease, scope and reliability of the underlying measurements. As the range of 
quantitative tools available to researchers expands, and improves, so does our 
understanding of the role of metabolomic, proteomics and epigenetic dysregulation 
in disease.1–3  
The role of DNA methylation has been shown to be fundamental to many processes 
including ageing, exercise and cancer.3,4 In fact cancer specific DNA methylation 
patterns have been observed across many tumours.5 Despite the potential utility of 
methylation assays their adoption in the clinic and the lab has been far from absolute 
due to intrinsic challenges. Methods for measuring DNA methylation often rely on 
chemical modification through bisulfite treatment.6 Treatment of cytosine with 
bisulfite leads to conversion to uracil, a reaction that is prevented in 5-
methylcytosine, Figure 5.1. The modified base (or lack thereof) can be identified 
through sequencing or hybridisation of sequence specific primers and subsequent 
PCR amplification. However, the process has many problems arising from bisulfite 
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conversion, which includes DNA degradation, reaction by-products leading to 
alternative modifications, and a need for large sample quantities, PCR bias, etc.7 
 
 
Figure 5.1: Bisulfite conversion treatment of cytosine to uracil 
 
Recent studies have demonstrated the potential of solid state nanopores in 
identifying DNA methylation sites.8 By binding MBD (methyl binding domain) 
proteins to 5-methylcytosine sites, they were able to observe a 3-fold increase in 
ionic blockage current relative to unmethylated DNA. The technique avoids the 
need for bisulfite conversion and its inherent problems yet requires detailed 
sequence analysis on the nanopore platform.  
As described before, tunable resistive pulse sensing (TRPS) is a solid state nanopore 
technique based upon the Coulter counter principle.9,10 Chapter 4 also demonstrate 
the use of TRPS technologies for the characterisation of nanomaterials, which has 
also been previously studied in the literature.9,11–15 Also, existing studies have shown 
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it is possible to quantify DNA protein interactions, in the form of a bound protein 
biomarker to a DNA aptamer.16–19 In this assay DNA was conjugated to 
superparamagnetic particles (SPPs) creating a negatively charged surface.  Protein 
binding to this DNA changes the charge density around the particles and 
subsequently reduced the relative velocity of the particle as it traversed the 
nanopore, which was shown to be relative to the concentration of protein in 
solution.   
Rassf1a is a tumour suppressor gene, repression of which has been associated with 
a range of cancers.20 Hypermethylation of CpG islands in the promoter of Rassf1a is 
prognostic of its dysregulation, with degree of methylation inversely correlated with 
gene expression.21 Here it is hypothesised that RPS can monitor and thus determine 
the level of methylation in a proportion (54 bases) of the promoter region of Rassf1a. 
Anti-5-methylcytosine antibody (an antibody that specifically binds methylation sites 
in single stranded DNA) is bound to the promoter (target), which is anchored to a 
nanoparticle through a complementary (capture) probe. Measuring the degree to 
which the DNA charge is shielded by the antibody will determine the level of 
methylation. Crucially the assay negates the requirement of the pore to sequence 
the DNA, with specific genomic regions targeted through hybridisation to 
complementary probes.  
The aim is to produce a rapid, reliable assay for methylation, with applications 
ranging from the clinic to the farming industry.22 It was found the assay is highly 
sensitive in discriminating between methylated and unmethylated sequences. In 
addition, methylation sites at different points in the sequence could be distinguished 
in the ion blockade profiles of the nanoparticles as they traversed the pore. The assay 
also correlates particle velocity with the number of methylations sites in the 
promoter region, whereby the presence of single or double epigenetic markers can 
be identified. The number of methylated target DNAs in solution allows a dose 
response curve for the quantification of methylated DNA in solution over two orders 
of magnitude. 
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 Experimental and Materials 
 Chemicals and Reagents 
5.4.1.1 DNA Sequences 
A 54 base region from the Rassf1a promoter sequence from chromosome III of the 
human genome was selected (5’-GG[met1-C]CCGCCCTGTGGCCCCG[met2-
C]CCGGCCCGCGCTTGCTAGCGCCCAAAGCCAGCGA-3’), this is to simulate the product 
of a restriction enzyme digest. A 30 base capture probe complementary to the 
Rassf1a promotor sequence was purchased from Sigma-Aldrich with a 5’ biotin tag 
and 5T linker (Biotin-TTTTTTCGCTGGCTTTGGGCGCTAGCAAGC). In addition, four 
variations of the Rassf1a promoter: unmethylated ControlDNA, 5’ single methylation 
(at site met1-C above EndDNA), 3’ single methylation (site met2-C MiddleDNA) and 
double methylation (sites met1-C and met2-C DoubleDNA), were also purchased in 
lyophilised powders with RP1 purification from Sigma-Aldrich, UK.  
5.4.1.2 Anti-5-Methylcytosine 
Anti-5-methylcytosine antibody at 1 mg mL-1 (ab73938) was purchased from Abcam, 
UK. The concentration of the antibody was verified using UV-Vis spectroscopy 
(Nanodrop 2000, Thermo Fisher Scientific). Using the average molecular mass of the 
antibody (970,000 g mol-1) the number of antibodies per unit volume could be 
established and used for ratio calculations.  
5.4.1.3 Buffers 
Water purified to a resistivity of 18.2 MΩcm (Smart4Pure, TKA) was used to make all 
solutions. Phosphate buffered saline (PBS, P4417 (1× PBS tablet (0.01 M phosphate 
buffer, 0.0027 M potassium chloride, 0.137 M sodium chloride) in 200 mL deionised 
water (18.2MΩcm)) was purchased from Sigma-Aldrich, UK and used unmodified 
through the experiments.  
5.4.1.4 Calibration Particles  
Carboxylated polystyrene particles, denoted as CPC200, with a mean nominal 
diameter of 210 nm and stock concentration of 1 × 1012 particles mL-1, were 
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purchased from Bangs Laboratories, USA and used as a concentration calibrant at 2 
x 109 mL-1. Prior to use, the particles were vortexed for 30 seconds and sonicated for 
1 minute to ensure monodispersity. 
 Preparation of SPP 
125 nm streptavidin coated particles (Ademtech, France (03211)) were used and 
functionalized with the biotin labelled capture probe with the Rassf1a promoter 
sequence as follows: Equal volumes of oligonucleotides, corresponding to 100% of 
the particle’s binding capacity (calculated using the manufacturer’s specification) of 
the streptavidin modified particles, were vortexed for 30 seconds prior to heating to 
95°C for 5 minutes in a mini dry bath (Benchmark Scientific, USA). The reaction 
mixture was vortexed again for 30 seconds and allowed to cool to room temperature 
for 30 minutes on a rotary wheel before the addition of particles.  The mixture was 
placed on a MagRack (GE Healthcare, UK) for 10 minutes until a cluster of particles 
was visible. The solution was carefully removed and replaced with an equal volume 
of PBS. The concentration of particles was kept constant throughout all experiments 
at 2 x 109 mL-1.   
 Concentration Analysis 
Anti-5-methylcytosine antibody (a pentameric IgM) was added to the DNA 
hybridised particles. The ratio of antibodies to particles varied from 0 up to three 
orders of magnitude of antibodies per particle. After the addition of the antibody the 
mixtures were vortexed for 30 seconds and placed on a rotary wheel for 8 minutes 
and prior to RPS analysis the mixture was vortexed for 15 seconds and sonicated for 
5 seconds.   
 Dose Response 
5.4.4.1 Full-Binding Capacity Experiment 
The concentration of Rassf1a was maintained at 100% relative to the binding 
capacity of the particles, to which varied amounts of complementary DNA equivalent 
to 0, 10, 20, 40, 60, 80, and 100% of the particle’s binding capacity were added. The 
bound DNA sequences were then hybridised to the particles as previously described. 
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The concentration of anti-5-methylcytosine antibody was maintained at three orders 
of magnitude relative to the particle concentration.  
5.4.4.2 Half-Binding Capacity Experiment 
Throughout this set of experiments the Rassf1a concentration was kept constant – 
50% of the particle’s binding capacity. The particle binding capacity is calculated to 
be half using the manufacturer’s specifications and assumed from previous 
studies.19,23 The amount of complementary DNA varied from 0, 10, 20, 30, and 40% 
of the particle’s binding capacity. As previously described the bound DNA was 
hybridised to the particles with the concentration of anti-5-methylcytosine antibody 
maintained at three orders of magnitude relative to the particle concentration.  
 RPS Analysis 
RPS was performed using the qNano system purchased from IZON Science (New 
Zealand). The technique uses elastomeric tunable nanopores with Izon’s own data 
capturing software, Izon Control Suite (v3.1.2.53). NP200 pores were used, suitable 
for analysing particles between 80 and 500 nm (stated by the manufacturer).  An 
appropriate stretch and voltage were applied throughout so that the blockades of 
CPC200s in PBS were at least 0.5 nA above the background noise; a measure to 
account for the variations in pore manufacturing. The operation of the qNano is 
described elsewhere but briefly: the lower fluid cell was filled with 80 µL of PBS, 
ensuring no air bubbles are present and the upper fluid cell contained 40 µL of the 
sample.10,16,23 After each measurement the sample was removed from the upper 
fluid cell and replaced with PBS. This was repeated several times, applying varying 
amounts of pressure and vacuum, until blockades were no longer observed. Samples 
were replicated in triplicate, unless stated H15 estimates of the mean are reported 
and used for normalisation.  
 Calculating the Particle Velocities  
The method used the resistive pulse to calculate the relative velocity and identifies 
the point of greatest resistance in the signal trace (the resistive blockade peak).  For 
each blockade, the time at which the peak occurs is defined as T1.0 (time at 100% of 
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peak magnitude) and the maximum magnitude of the pulse (relative to the local 
baseline resistance) is recorded as dRmax. Here the value at T0.5 (width of the pulse at 
50% of the peak magnitude is used).23,24 To keep the method simple and applicable 
in further applications the actual zeta potential of the particle is not calculated and 
for further simplicity in the subsequent figures only one measurement is used to 
represent the particle’s relative velocity, which is 1/T0.5.   
 Results and Discussion 
 DNA Hybridisation  
The outline for the assay is shown in Figure 5.2. Here a synthesised target is used, 
however, it should be noted the concept can be adapted to any working assay where 
the genomic DNA is first extracted and digested prior to analysis. A biotinylated 
capture probe is added to the DNA sample, Figure 5.2a. The capture probe was 
designed to be a perfect complement to a flanking region of the Rassf1a gene where 
the methylation is known to occur. The mixture was heated to 95°C for 5 minutes to 
denature the target DNA. The mixture was then allowed to cool to room 
temperature for 30 minutes allowing the biotinylated probe to hybridise to its target. 
Streptavidin coated SPPs were then added to the solution, mixed for 5 minutes, 
Figure 5.2b, and extracted with a magnetic rack before being placed into PBS buffer. 
During this extraction the aim was to allow the SPPs to bind the biotinylated capture 
DNA along with the hybridised target DNA Figure 5.2c. 
 
 
 103 
 
 
Figure 5.2  Schematic of the assay. (A) Biotinyated Capture probe is incubated with the target 
DNA. (B) Streptavidin coated SPPs capture the DNA. (C) Antibody is added to the solution. (D) 
Depending upon the target DNA present the SPPs have: i – unmethylated Target DNA, ii – 
single methylated site (EndDNA) iii – single methylation (MidDNA) or iv – two methylation sites 
(DoubleDNA). (E) The velocity of the particles through the RPS reveals which target is present 
 
The concentration of SPPs added to the solution was adjusted such that their total 
binding capacity was equal to the concentration of biotinylated DNA.  This results in 
the extracted SPPs always having a coating of DNA even in the absence of target 
DNA, Figure 5.2di. It has been shown that the length and concentration of single and 
double stranded DNA on SPPs can be monitored using TRPS.23 The same concept and 
signal transduction mechanism are utilised here. In summary the binding of DNA to 
the SPPs results in the zeta potential of the particles becoming more negative. The 
change in zeta potential is measured by monitoring the translocation velocity of the 
particles through the pore, and measured via the full width half maximum (FWHM), 
Figure 5.2e. Increasing the number of DNA molecules or the length of the sequence 
around each SPP results in an increase in zeta potential, inferred by an increase in 
1/T0.5 i.e. more negatively charged particles move through the pore quicker. An 
example of this is shown in Figure 5.3. The relative velocity of the particles is then 
plotted as the reciprocal of T0.5 and shown for streptavidin SPPs (blank), capture 
probe modified SPPs (ssDNA) and target probe modified SPPs (dsDNA). The relative 
order of the velocity of the three particles shows that the target DNA is faster than 
capture probe only, and the slowest particles are the blank SPPs.
i 
ii
 
iv
 
iii
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Here the translocation velocities are not converted into zeta potential values, as it’s 
not required and adds an extra stage within the calibration. Monitoring the relative 
change in velocities of the particles is enough to determine the presence of the DNA.  
 Assessment of DNA Methylation Markers 
Having captured the target DNA, the next stage was to assess if the methylated bases 
within the target DNA could be identified. Two samples were prepared, the first was 
a target DNA with no methylation markers, and the second with a single methylation 
point approximately halfway within the sequence (MidDNA) Figure 5.2i and Figure 
5.2iii, respectively. The anti-methyl antibody was incubated with the SPPs and if 
epigenetic markers are present, they should bind to the DNA. RPS has been recently 
demonstrated as a system that can monitor protein-DNA interactions and is the basis 
for many aptamer-based sensors. The binding of the antibody to the DNA changes 
the charge density around the particles and results in a change in particle relative 
velocities.16,18,19,25 A decrease in relative velocity (with respect to a positive bias 
below the pore) is thought to be due to several parameters. Changes to the DNA 
structure as it binds the protein may require an increased number of counter ions to 
stabilise any tertiary structure, secondly the protein’s pI is between 6-7.4, and 
therefore has a net (and slight) positive charge for the pH used in the experiment, 
which can counter the charge on the DNA backbone. In addition, the binding of the 
protein (even if in a net neutral charge state) to the DNA will disrupt the double layer 
structure and affect the electrophoretic mobility. 
To test this hypothesis, and to optimise the amount of antibody required, differing 
particle/antibody ratios shown in Figure 5.5, were titrated. For the methylated 
sample, as the number of antibodies per particle increases from 0 up to three orders 
of magnitude (≈ 1:1000), the particle velocity decreases as they bind to the DNA.  
Whilst there is a selective interaction between the antibody and methylation site, 
there will be some non-specific interactions between the antibody and DNA. Thus, 
at the larger concentrations of antibody the change is attributed to non-specific 
interactions between the IgM and the DNA/particle surface. It should also be noted 
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that whilst the binding of the antibody changes the relative velocity of the particle, 
it was not observed within the current setup, a change in particle volume.  
Table 5.1: Summary of the DNA used in this study. DNA hybridisations were completed in PBS 
(NaCl at 137 mM) 
Name Sequence 
MiddleDNA 
5’-GGCCGCCCTGTGGCCCCG[met2-
C]CCGGCCCGCGCTTGCTAGCGCCCAAAGCCAGCGA-3’ 
EndDNA 
5’-GG[met1-
C]CCGCCCTGTGGCCCCGCCGGCCCGCGCTTGCTAGCGCCCAAAGCCAGCGA-3’ 
DoubleDNA 
5’-GG[met1-C]CCGCCCTGTGGCCCCG[met2-
C]CCGGCCCGCGCTTGCTAGCGCCCAAAGCCAGCGA-3’ 
ControlDNA 
5’-GGCCGCCCTGTGGCCCCGCCGGCCCGCGCTTGCTAGCGCCCAAAGCCAGCGA-
3’ 
Capture 
Probe 
Biotin-TTTTTTCGCTGGCTTTGGGCGCTAGCAAGC 
 
The experiment was repeated using target DNA which contained a single 
methylation site at a different location further from the particle surface (EndDNA) 
Figure 5.2dii, and a target DNA which contained two methylation sites (DoubleDNA) 
Figure 5.2div. Similar trends were observed i.e. as the antibody number increased 
the particle’s relative velocity decreased at a rate much higher than the control. It 
should be noted there was no particle aggregation observed, and the particle size 
distribution plots are given in Figure 5.4.  
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In the presence of non-specific interactions taking place at higher antibody numbers 
it was concluded that a ratio of three orders of magnitude more antibodies to 
particle was a suitable ratio to proceed with further experiments. 
It was hypothesised that the location at which the antibody bound to the DNA, i.e. if 
the methylation site was in the Mid, End or Double, may result in different 
magnitudes of relative velocity change, helping identify the location of the 
methylation site. However, it can be seen in Figure 5.5b the mean velocity change 
and distribution of velocities for hundreds of particles are similar in this design of the 
experiment. 
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 Dose Response  
From the above experimental design, the presence of the epigenetic marker could 
be easily identified. To quantify the number of DNA copies in solution which 
contained these markers, a dose response curve was prepared. To demonstrate this 
the MidDNA was chosen. In this experiment the number of SPPs, the concentration 
of capture DNA and antibody ratio was kept constant. The concentration of target 
DNA was varied, and the results shown in Figure 5.6a. The dose response curve 
shows a change over 2 orders of magnitude. As the number of target DNA increases 
the velocity of the particles decrease. At lower concentrations of target DNA most of 
the SPPs surface is covered with biotinylated capture probe, and as it does not bind 
to the antibody, its negative charge dominates the particle’s relative velocity.  
To improve the sensitivity of the dose response curve at lower concentrations of 
target DNA, a lower number of capture probes were used - A 50% of the binding 
capacity of the particles, i.e. keeping every other parameter the same as Figure 5.6a 
but the concentration of the capture probe was halved. The ratio of the particle 
concentration, binding capacity, capture probe capacity and numbers of antibodies 
are given in Table 5.2.  
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Figure 5.6: Concentration of particles was kept constant at 2 x 109 mL-1. (A) Concentration of 
capture probe is 100% relative to the binding capacity of the particle. The concentration of 
target EndDNA was varied from 0 – 100%, relative to the binding capacity of the particle. (B) 
Concentration of capture probe is 50%, relative to the binding capacity of particle. Again, the 
concentration of target EndDNA was varied from 0 – 40% of the particle’s binding capacity. 
Events for each data point >500. Data was normalised against the velocities of capture probe 
modified particles with 1000 antibodies per particle present 
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Table 5.2: Concentration of SPP, capture probe and antibodies in assays. *the particle to 
antibody ratio is an approximation and is referred to as three orders of magnitude in the text 
Particle to 
Antibody 
Ratio* 
Capture Probe Concentration 
Relative to the Particle’s 
Binding Capacity (%) 
Target EndDNA 
Concentration Relative 
to the Particle’s 
Binding Capacity (%) 
1:1000 100 0 
1:1000 100 10 
1:1000 100 20 
1:1000 100 40 
1:1000 100 60 
1:1000 100 80 
1:1000 100 100 
   
1:1000 50 0 
1:1000 50 10 
1:1000 50 20 
1:1000 50 30 
1:1000 50 40 
 
As can be seen in Figure 5.6b, halving the capture probe concentration resulted in a 
sharp decrease in relative velocity of the SPPs as the concentration of target DNA 
was increased from 0 nM to 119 nM. The dynamic range of this assay is lower than 
that in Figure 5.6a as the particles can only capture half the concentration of target 
DNA, and at concentrations above 47.6 nM, there was no further decrease in 
velocity. Owing to the rapid change in relative velocity for the lower concentrations 
of capture probe, 1/T0.5 for the Mid, End and DoubleDNA targets were measured to 
see if their relative velocities differentiated. Table 5.3 shows the change in velocity 
for the same concentrations of SPP, antibody and target DNA for the different 
variations of epigenetic target DNA.  
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Table 5.3: Relative velocity for the SPP modify with unmethylated DNA (Blank), Mid, End and 
Double DNA. The concentration of DNA was 50% relative to the binding capacity of the 
particles, 30% target DNA, particles 2 x 109 mL-1 and antibody three orders of magnitude more 
antibody per particle. Events for each DNA type, and blank >600 (blank 2303; MidDNA 932; 
EndDNA 979; and DoubleDNA 686) 
DNA Type Mean Velocity, 1/T0.5 ms 
Standard 
Deviation 
Velocity Decrease, % 
Double 2.76 0.36 50.73 
Middle 3.39 0.31 39.48 
End 2.94 0.41 47.56 
Blank 5.60 0.22 - 
 
Table 5.3 shows that the largest change in velocity was observed for the double 
methyl target, followed by the end and middle. At the lower concentrations of 
capture probe the relative velocity of the particles allows differentiation of the 
location of the epigenetic marker. At these lower concentrations of capture probe 
the average distance between neighbouring DNA on the SPP’s surface increases, this 
may allow the antibody-DNA to adopt a different structure/bind easier than in the 
fully packed SPP experiment. Although it should be noted that the middle 
methylation target still shows a change in velocity and thus binding to the antibody 
must still take place.  
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  Conclusion 
It has been demonstrated here that the characterisation of methylated DNA 
sequences through RPS is possible. The process allows for the rapid quantification of 
epigenetic markers with insight into the location of the marker within the target. The 
capacity of the technique to quickly and reliably quantify nucleic acid-protein 
interactions presents a platform for the potential analysis of: polysome gradients 
(translation rate), RNA methylation (anti-5-methylcytosine also binds methylated 
RNA), protein phosphorylation and histone acetylation. This is in addition to previous 
studies that have demonstrated the ability of RPS to quantify single nucleotide 
polymorphisms, microvesicles, protein biomarkers etc. RPS is a burgeoning 
technology that lends itself to multiomic analysis, highlighting its application in the 
characterisation of methylation sites within DNA. Further optimisation of the 
approach may yield a multipurpose tool for the clinic capable of analysing biological 
variation beyond the scope of current technologies. 
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 Abstract 
In this chapter experiments were conducted to determine the ability of resistive 
pulse sensing (RPS), as a detection platform, to detect the low levels of cellular prion 
protein (PrPc) in a physiological buffer. A DNA aptamer was immobilised onto 
streptavidin modified superparamagnetic particles (SPPs) before incubation with 
PrPc. It has been previously hypothesized the polyanionic backbone of the DNA, or 
RNA, would be shielded by the bound protein causing a change in translocation 
velocity. Here, work has been conducted to establish if RPS has the sensitivity to 
detect this interaction using translocation velocity and/or zeta potential. 
The first stage optimises the grafting of an ssDNA aptamer onto SPPs. By varying the 
concentration of DNA aptamer relative to the binding capacity of the nanoparticles, 
a significant change (p<0.05) in zeta distributions was observed.  In proof of concept 
work, the functionalized SPPs were then used to detect the cellular prion protein in 
phosphate buffered saline (PBS) by monitoring the relative change in velocity 
through the nanopore, which can be converted to zeta potential. Increasing the 
concentration of the protein caused shielding of the polyanionic DNA by the slightly 
positive protein at pH 7.4, therefore the relative velocity of the protein/particle 
conjugate decreased. The DNA aptamer’s selectivity was studied by incubating the 
SPPs in three abundant blood proteins – fibrinogen, albumin and γ-globulin. The 
basis of an assay developed in this chapter was determined to have a detection limit 
without a pre-concentration step in the low nM range. With further optimisation, 
including the addition of the pre-concentration step prior to RPS analysis, the 
detection limit could theoretically be lowered further.  
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 Aims and Objectives 
Fundamental to this work conducted in this chapter is to understand the feasibility 
of the RPS platform as a biosensor for the detection of the minute levels of the 
infectious form of the human prion protein found in blood. Establishing the limit of 
detection and quantification is essential for any novel assay in development, 
however these are not the only factors that should be considered. Reliability, 
robustness and the speed the assay can be conducted are also vital elements to 
consider. In this chapter these factors will be explored and reported.  
 Introduction 
Prion diseases are a group of fatal transmissible neurological conditions whose 
disease etiology is characterised by the change in conformation of the normal 
intrinsic cellular prion protein (PrPc) into the highly ordered insoluble amyloid state 
conformer (PrPsc). The significant event fundamental to the progression of these 
diseases is the self-catalytic, and perpetuating, nature of the conversion of PrPc in 
the presence of PrPsc aggregates.  
The emergence of variant Creutzfeldt-Jakob disease (vCJD), the most predominant 
prion disease in humans in the United Kingdom (UK) during the 1990s, is thought to 
be an effect of dietary exposure to the bovine spongiform encephalopathy (BSE) 
agent through contaminated meat products. The link between BSE and vCJD was 
uncovered after lengthy surveillance, epidemiologic studies and experimental 
investigation. Unlike the sporadic form of the disease (sCJD), the infectious prion 
protein associated with vCJD is found outside the central nervous system (CNS), 
accumulating in peripheral lymphatic tissue, which increases the public health 
concern. The evidence around the transmission of sCJD is often thought as 
circumstantial due to its confinement to the CNS. A series of studies have been 
conducted using appendix and tonsil tissue to assess the possible occurrence of the 
disease in the general UK population. To date, the widely accepted estimate for the 
prevalence of vCJD in the UK puts the number of potential carriers at 1 in 2000.1 
Although most of the occurrences of vCJD have occurred in the UK, there has been a 
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number of individuals that have developed the disease overseas. It has been noted 
that some of these individuals have either spent an amount of time in the UK or 
exposed to the disease via meat products in their home country.  
Since the disease is known to be infectious and transmissible, the iatrogenic ability 
of this disease is a significant risk to public health through blood transfusion products 
and surgical procedures. This risk was realised when four individuals developed the 
disease after receiving blood products between 2004 and 2006. Several non-assay-
based reduction methods have been introduced by the UK’s Blood and Transfusion 
Service (NHSBT) – these include donor screening and leucodepletion. There is still a 
level of uncertainty around the efficacy of these measures so reservations 
surrounding the prevalence, distribution and level of infectivity of individuals.  
There have been efforts by researchers to develop an assay that can detect the low 
levels of the infectious protein in the peripheral blood of pre-symptomatic patients 
that has the selectivity and sensitivity the assay will need. However, to date there is 
still no routinely available assay that has been able to overcome this challenge. What 
has continued to cause issues for researchers is the fact that the disease PrPsc 
fragments isolated from organisms are identical but cause different strains of 
diseases with differing clinical manifestations.2 Also the amino acid sequence in both 
infectious and cellular form are identical meaning the isolation of specific antibodies 
to each form have been difficult. But one overriding reason for the absence of an 
assay some 20 years after vCJD’s discovery is due to the lack of commercial interest. 
Whilst the outbreak of vCJD has declined from the levels seen in the 1990s, there is 
mounting concern the long-term effects of the disease’s progression is unknown 
meaning a continued need for vigilance with respect to the use of matter from 
human origin in medicine.  
Although the peak of the vCJD outbreak is thought to be over, there remains 
underlying uncertainty if there will be a ‘second wave’ of patients. This could be due 
to person to person infection through medical procedures; if there are enough 
potential carriers in the UK then it might be possible that further cases appear in the 
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future. One possible cause for further outbreaks is the associated long incubation 
times of individuals who have a particular genotype, 129MV.3 Therefore, it cannot 
be discounted that a second outbreak of vCJD will occur, something that can only be 
determined through observation and time. Whilst the risk of food borne infection 
has been effectively eliminated in the UK, the risk of an individual having been 
infected through this route is thought to be possible if they consumed the product 
between 1980 and 1996. Nevertheless, the long incubation times (as seen with 
another prion disease – Kuru, which has been observed to be as long as 40 years) 
also causes concern.  
Two methods that have proven promising require an amplification step to increase 
the level of the infectious protein to a detectable level using the in vitro conversion 
of PrPc into PrPsc. These protocols, termed Protein Misfolding Cyclic Amplification 
(PMCA) and Quaking-Induced Conversion Assay (QuIC), work in similar ways.4,5 
Briefly, they use cycles of either shaking or sonication interspersed with incubation 
periods. If PrPsc is present in the sample the large excess of added PrPc undergoes 
conversion and amplifies the PrPSC into the detectable range of existing detection 
techniques. One major challenge researchers in this area have faced is the lack of an 
immune response and therefore there is a lack of specific antibodies. Many assays 
have been proposed (some outlined in chapter 1) and overcome this issue by 
detecting the infectious form of the protein directly. An assay that has been most 
promising, and used by medical professionals in an isolated manor, is one that was 
first revealed in 2011, which utilises stainless steel balls as a capture media. 
Developed at the Prion Unit based at University College London it exploits the 
protein’s extremely high affinity to stainless steel, and when coupled to an enzyme-
linked immunosorbent assay (ELISA) the protein can be visualised using a commercial 
chemiluminescence protocol. Although the process is quicker than the former 
mentioned amplification methods, the assay still falls short when it comes to 
sensitivity.   
Delivering a usable, reliable, and a relatively quick assay that can provide the 
necessary selectivity and sensitivity warranted by current legislation would 
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overcome some of the concern public health bodies in the UK have when considering 
the effects of vCJD on the general population.  
  Experimental and Materials  
 Chemicals and Reagents 
6.4.1.1 Buffers 
Phosphate buffered saline (1x PBS tablet (0.01 M phosphate buffer, 0.0027 M 
potassium chloride, 0.137 M sodium chloride) in 200 mL deionised water (18.2 MΩ 
cm, Smart4Pure, TKA)) was used for analysis, without further modification unless 
stated. PBS tablets (P4417) were purchased from Sigma-Aldrich, UK.  
6.4.1.2 Control Study Proteins 
The control study proteins used in the study were γ-globulin from human blood 
(G4386), albumin from human serum (A9511) and fibrinogen from human plasma 
(F3879), all sourced from Sigma-Aldrich, UK. 
6.4.1.3 Streptavidin Modified Particles  
Streptavidin surface modified SPPs were purchased from Ademtech, France (03211), 
with a known mean diameter of 125 nm and a measured concentration of 1 x 1012 
mL-1 and used in all experiments. The particles were vortexed for 30 seconds before 
a 2 minute sonication to ensure monodispersity before use and analysis.  
6.4.1.4 DNA Oligonucleotides 
A custom oligonucleotide used in the study was purchased from Sigma-Aldrich, UK 
in lyophilized form (0.2 µM). The oligonucleotide was purified using reverse-phase 
cartridge purification (RP1) by the manufacturer. The details and its modifications: 
5’ CTTACGGTGGGGCAATT[BtnTg] 3’. Here [BtnTg] is biotin TEG modification with five 
additional T bases. This was made up into a stock solution of 100 µM with deionized 
water. This aptamer was previously reported by another study.6 
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6.4.1.5 Human Cellular PrP 
Recombinant N-terminal His-tagged full-length prion protein (residues 23 – 231, PR-
902) was purchased from Jena Bioscience, Germany in lyophilized form. The protein 
was reconstituted in 1x PBS containing 0.5% Triton X-100 (Sigma-Aldrich, UK). 
Aliquots were prepared and stored at -80°C until required.  
 Aptamer Immobilisation  
Streptavidin modified SPPs were diluted to a concentration of 1 x 1010 mL-1, vortexed 
for 30 seconds and sonicated for 2 minutes to ensure monodispersity.  The aptamer 
was added at concentrations equal to 33% and 100% binding coverage; having 
determined this from the binding capacity given by the manufacturer’s 
specifications. Concentrations of 33% and 100% were selected as each RPS signal 
would be identifiable from each other. The samples were placed on a rotary wheel 
for 1 hour at room temperature. Any unbound oligonucleotides in solution were 
removed by placing the samples on a MagRack (GE Healthcare, UK) for 15 minutes 
until a cluster was visible adjacent to the magnet before removing and replacing the 
buffer. The resulting capture probe was stored at 4°C or used for further study the 
same day.   
 PrPc Binding 
DNA modified SPPs were vortexed for 30 seconds before being placed on a rotary 
wheel for 30 minutes prior to use. At varying concentration between 0 – 100 nm, 
PrPc was added to the particles, which had a final concentration of 2 x 109 mL-1, and 
vortexed for 30 seconds before incubation at room temperature on a rotary wheel 
for 10 minutes. The sample was then vortexed for 15 seconds and then analysed.   
 Varying Temperature DNA Aptamer Binding  
Prior to DNA aptamer immobilisation the concentration equivalent to 100% binding 
capacity (determined from the manufacturer’s information) of the streptavidin 
modified SPPs, in PBS, were vortexed for 15 seconds before heating to either 21°C 
or 90°C in a mini dry bath (Benchmark Scientific, USA) for 5 minutes. The mixture 
was allowed to cool to room temperature for 30 minutes on a rotary wheel before 
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the addition of particles. The mixture was placed on a MagRack (GE Healthcare, UK) 
for 10 minutes until a cluster of particles was visible adjacent to the magnet. The 
solution was carefully removed and replaced with an equal volume of PBS. The 
concentration of particles was kept constant throughout all experiments at 2 x 109 
mL-1.   
 Control Protein Binding 
After modifying streptavidin SPPs with DNA aptamer, albumin, fibrinogen or γ-
globulin was added at a concentration of 200 nM and incubated for 20 minutes on a 
rotary wheel. The particle concentration was kept constant at 2 x 109 mL-1. The 
samples were vortexed for 30 seconds before analysis. This would test the aptamers 
selectiveness to the prion protein. 200 nM was selected as this concentration is 2x 
higher than the highest concentration used in the calibration curve.  
 PrPc Preconcentration 
DNA aptamer modified SPPs were vortexed for 30 seconds before being placed on a 
rotary wheel for 30 minutes prior to use. To a concentration of 2 x 109 mL-1 DNA 
modified SPPs PrPc was added to give a final concentration of 50 nM – the sample 
volume here was 1 mL. The sample was then vortexed for 30 seconds and incubated 
for 10 minutes on a rotary wheel, after which the relative velocity of the particles 
was then measured using RPS. The SPPs were then magnetically separated by placing 
the samples on a MagRack (GE Healthcare, UK) for 15 minutes until a cluster was 
visible adjacent to the magnet before removing and replacing the buffer with 100 µL 
10x PBS solution. The sample was sonicated for 30 seconds then vortexed for 30 
seconds before being placed on a rotary wheel for 20 minutes. After, the SPPs were 
magnetically separated for 15 minutes (as before) and the supernatant removed. To 
the supernatant DI water was added to dilute the 10x PBS to a 1x PBS solution, and 
an aliquot of SPPs modified with DNA aptamer were added to give a concentration 
of 2 x 109 mL-1; these were then incubated for 10 minutes on a rotary wheel. After 
sonicating for 30 seconds then vortexing for 30 seconds, the sample was then 
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analysed. The separated SPPs were analysed using RPS to determine their relative 
velocity after removal of the PrPc.  
 Resistive Pulse Sensing (RPS)  
A qNano (Izon Science Ltd, NZ) was used to complete all measurements in this study, 
with the theoretical details explained in chapter 2. Briefly, in all experiments the 
lower fluid cell contained 80 µL of PBS buffer, ensuring no bubbles were present. 
When a sample measurement was being taken, the upper fluid cell contained 40 µL 
of the sample (suspended in PBS buffer). After each measurement was taken the 
nanopore was rinsed several times by removing and replacing 40 µL of buffer, each 
time applying varied pressures until no particles were observed. This was performed 
several times to remove any residual particles in the system and thus ensure no cross 
contamination between samples. The nanopores used throughout all experiments 
were capable of detecting particles within the size range of 85 - 500 nm (as stated by 
the manufacturer, Izon Science Ltd), and denoted as an NP200. To account for the 
variation in the manufacturing of the nanopores, an appropriate stretch (44-49 mm) 
was used; the conditions were matched to the blockade magnitudes of CPC200s in 
PBS.  
 Zeta Potential Measurements Using RPS 
When carrying out zeta potential measurements the nanopore stretch was kept 
constant for calibration and sample measurements. To calibrate a nanopore for zeta 
potential analysis the calibration particles, of known size and zeta potential, were 
measured in PBS at 3 applied voltages; the particles measured at the highest voltage 
were measured at 2 external pressures (in addition to the inherent 50 Pa pressure 
head on the system). When running samples, the blockade magnitudes were 
ensured to be at least 100x larger than the respective background noise of circa. 10 
pA. In accordance with the calibration runs, the samples were run at the highest 
calibration voltage. Calibration measurements were completed when a new 
nanopore (NP200) was introduced or the start of the day.  
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 Calculating the Particle Velocities  
The method used the resistive pulse to calculate the relative velocity and identifies 
the point of greatest resistance in the signal trace (the resistive blockade peak).  For 
each blockade, the time at which the peak occurs is defined as T1.0 (time at 100% of 
peak magnitude) and the maximum magnitude of the pulse (relative to the local 
baseline resistance) is recorded as dRmax. Here the value at T0.5 (width of the pulse at 
50% of the peak magnitude is used).7,8 To keep the method simple and applicable in 
further applications the actual zeta potential of the particle is not calculated and for 
further simplicity in the subsequent figures only one measurement to represent the 
particle speed which is 1/T0.5. 
 Results and Discussion 
As previously stated, the detection of the infectious prion protein has proven 
challenging using the typical assay techniques found in a biomedical laboratory. 
There are two reasons that this is the case. Firstly, the concentration of infectious 
protein in the circulating blood is at a level assays are unable to detect; and secondly, 
the configuration between the protein types does not differ - but their conformation 
does. This means raising antibodies to the infectious protein is difficult, if not 
impossible, so the use of antibodies to distinguish the protein is often ruled out. An 
example of a proposed ‘blood test’ uses a denaturation step of the protein so that 
an antibody can be used.9 
The work outlined in this chapter sets out to overcome the two challenges associated 
with detecting prion diseases in blood by utilising RPS and DNA aptamers coupled 
with SPPs. There has been numerous studies that have highlighted the use of 
aptamers in sensing technologies and their possible use as an alternative to 
antibodies.10–12 A DNA aptamer was used in this work largely due to their stability at 
a range of temperatures, and shelf life; their ability to be modified; their relative 
lower cost when compared to monoclonal and polyclonal antibodies; and their high 
selectivity and sensitivity to a range of targets. An RNA aptamer was considered, 
however, their susceptibility to nucleases breakdown without further modification 
 128 
 
meant they were ruled out.13 Biotinylated DNA and streptavidin coated SPPs were 
utilised in all experiments as immobilisation of a DNA aptamer to them would involve 
fewer stages. Although not a covalent bond, the interaction between the two 
proteins forms one of the strongest non-covalent bonds known. 
 DNA Aptamer Immobilisation 
The first step to developing an assay to prion diseases using a DNA aptamer and RPS 
was to conjugate the aptamer to the SPPs, and then be able to observe a change in 
signal to confirm this. Particles were incubated with concentrations of DNA 
equivalent to 33% and 100% from their manufacturer’s specified binding capacity at 
room temperature for 1 hour, whilst maintaining a constant particle concentration 
of 2 x 109 mL-1. At 33% it was calculated there would be in the order of ≈ 4173 strands 
of DNA aptamer on each particle and ≈ 12,646 strands at 100%. At 22 bases the DNA 
aptamer used in this study would have an approximate length of 13.86 nm, assuming 
the DNA is linear and perpendicular to the SPP’s surface.14 However, the DNA will 
have a secondary structure so its length from the surface is likely to be less than this. 
Using RPS it would be possible to capture a particle-by-particle analysis, however, at 
13.86 nm this length would not elicit an observable change significant enough to 
enable a robust assay (P>0.05), Figure 6.1. 
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Figure 6.1: Box plot of blockade magnitude of SPPs with concentration of DNA aptamer 
equivalent to the 33%, 100% and without DNA aptamer. Experiments were conducted in 1x PBS 
at 0.4 V and 48.9 mm stretch. n = 3 and events for each data set >500 
 
For this reason, the instrument’s ability to detect a change in relative velocity of 
translocating analytes, and as velocity is linked to the zeta potential this too can be 
calculated. The particles were then analysed using RPS to determine their zeta 
potential. The change in zeta potential is measured by monitoring the translocation 
velocity of the particles through the pore. Increasing the number of DNA aptamer 
molecules around each SPP results in a decrease in zeta potential, inferred by an 
increase in translocation velocity i.e. more negatively charged particles move 
through the pore quicker. Here, the concentration of DNA aptamer equivalent to 
100% of the SPP’s binding capacity is hypothesised to have the fastest relative 
velocity due to the highest negative charge around the particle, and this was 
observed.  
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From the data it can be seen that there is a change in zeta potential for both 33% 
and 100% binding capacity when compared to the ‘blank’ particles where there is no 
conjugated DNA aptamer present. To summarise this effect the binding of DNA to 
the SPPs results in the zeta potential of the particles becoming more negative.  
The measured zeta potential values obtained decreased as the concentration of DNA 
added to the SPPs increased. For the blank control bead set a slight negative mean 
value of -1.16 ± 1.31 mV was observed. As the concentration of DNA increased a 
decrease in zeta potential was observed; 33% a mean value of -4.43 ± 0.78 mV and 
100% -7.75 ± 0.94 mV. Median skewness values -0.878, -0.935 and -1.341 for blank, 
33% and 100% respectively. This can be seen in Figure 6.2.  
The addition of DNA aptamer to the SPPs was not expected to give maximum 
coverage since there will be an inherent difference between each SPP’s streptavidin 
coating.8 A decrease in zeta potential (to more negative) can be accounted for by the 
addition of the high poly-anionic phosphate backbone of DNA molecules, therefore 
increasing the charge density around the particle. As a positive bias was applied to 
the electrode below the lower fluid cell the increase in negative charge density 
would result in a faster translocation velocity, due to electrophoretic mobility this 
would translate to a decrease in zeta potential. At this point in the assay’s 
development, the immobilisation of biotin-TEG modified DNA to streptavidin beads 
has proven to be successful and is observable with RPS and the Izon instrument. The 
slowest was the blank SPPs as there is no DNA conjugated to its surface and hence a 
more positive zeta potential.  
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 Varying Temperature DNA Aptamer Immobilisation  
ssDNA can interconvert conformation under changes in environments, even under 
mild changes in conditions. Next, the immobilisation ability of the DNA aptamer and 
any changes in temperature will have on the zeta potential of DNA modified particles 
will be studied. The tendency to fold into discreet structures is often due to 
associated π-π stacking and intermolecular hydrogen bonding. The structure of DNA 
lends itself well to this as it contains six rotatable, highly flexible phosphodiester 
backbone, as well as an array of sugars and a rotatable glycosidic bond, allowing a 
wide range of conformations. The melting temperature of the DNA aptamer used in 
this study can be seen in Table 6.1.  
In this study the DNA aptamer was heated to two temperatures: 21°C and 90°C to 
‘unfold’ the DNA and allowing it to cool forming its preferred folded conformation.15 
The manner in which the DNA is folded, and thus its secondary structure, can affect 
the charge density around the SPPs, which in turn will affect their zeta potential. 
However, it became apparent that any change in charge density of a temperature 
effect, if there was a resulting change, was not measurable, Figure 6.3. The only 
measurable change was that of the addition of the DNA aptamer to the SPPs as a 
decrease in zeta potential to more negative. At this stage of the assay’s development 
it was decided to perform the DNA aptamer immobilisation to the SPPs at room 
temperature. This would simplify the assay, and ultimately reduce the time taken to 
run each test. 
Table 6.1: Summary of the melting temperature (Tm) of the DNA aptamer used in this study. 
DNA hybridisation were completed in PBS (NaCl at 137 mM) 
Aptamer Sequence GC Content 
Melting 
Temperature, Tm (°C) 
CTTACGGTGGGGCAATTTTTTT[BioTEG] 41% 65.7 
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 PrPc Concentration Analysis 
At this stage of the assay’s development zeta potential has been used to measure 
changes in the SPPs translocating the pore. However, it became apparent that the 
additional stage of calibrating a pore for zeta potential measurement added an extra 
step to an assay that is not needed. Also, the reporting of zeta potential values for 
DNA and DNA–protein covered nanomaterials can be misleading, as there is no 
consistent location of the plane of shear and no assumption is made about the 
structure. Therefore, having studied the use of relative translocation velocity as a 
measure in chapter 5, it was decided from this point relative velocity would be 
utilised.   
Having determined RPS’s ability to detect the presence of varying concentrations of 
DNA conjugated to a SPP’s surface, the next step of development is to determine the 
techniques limit of detection (LoD) in PBS. To SPPs with a DNA aptamer 
concentration of 100% relative to their binding capacity, a range of PrPc 
concentrations were used to establish the proposed assay’s LoD – the range used in 
this section was 0 to 100 nM of PrPc. The DNA aptamer used in this study has been 
used previously and has shown to be able to detect the protein with a linear range 
of 0.4 to 1.6 nM.6 Here the protein was incubated for 10 minutes at room 
temperature and if present in the sample the relative velocity of the SPP should 
decrease as there is a protein/DNA interaction.  
It has been recently demonstrated how the RPS system can monitor protein/DNA 
interactions and is the basis for many aptamer-based sensors.16 The binding of the 
protein to the DNA changes the charge density around the particles and results in a 
change in particle velocities.17–20 A decrease in relative velocity (with respect to a 
positive bias below the pore) is thought to be due to several parameters. Changes to 
the DNA structure as it binds to the protein may require an increased number of 
counter ions to stabilise any tertiary structure; secondly the protein’s isoelectric 
point (pI) is 9.4, and therefore has a net positive charge at the pH used in the 
experiment, which can counter the charge on the DNA backbone.21,22 In addition, the 
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binding of the protein (even if in a net neutral charge state) to the DNA will disrupt 
the double layer structure and affect the electrophoretic velocity. 
 
 
Figure 6.4: Relative particle velocity versus PrPc concentration. The concentration of SPPs was 
kept constant at 2 x 109 mL-1 and DNA aptamer concentration as 100% relative to the SPP’s 
binding capacity. Events for each data point >500. Error bar represent 1 x SD from the mean; 
where n = 3 
 
Figure 6.4 shows the observed results from this concentration analysis. Here it has 
been established that the assay can detect the healthy form of the protein in PBS at 
the low nM scale, with a LoD estimated to be 0.1 nM since there is a statistical change 
(P<0.05) from the blank of 0 nM.  
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Figure 6.5: Blockade magnitude distributions for the incubation of DNA aptamer (concentration 
at 100% relative to their binding capacity – specified by the manufacturer) modified SPPs at a 
constant concentration of SPPs at 2 x 109 mL-1 and PrPC at Black: 0 nM; Blue: at 50 nM; and 
Red: 100 nM. Events for each data set >500 
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The fragment of the prion protein used in this study is from residues 23 to 230 of the 
protein’s amino acid sequence, which has a mass of 25 kDa. Using this estimate the 
minimum radius (Rmin) can be calculated assuming the protein has a simple shape 
and is a sphere. It is referred to as Rmin, because this is the minimal radius of a sphere 
that could contain the given mass of protein.23 The minimum radius of the protein 
has been calculated to be 1.90 nm, and assuming a sphere this would give a volume 
of ≈29 nm3. It was hypothesised that binding the protein to the DNA aptamer and 
SPPs could be detected by RPS using a change in SPP’s size, however using the 
blockade magnitude data collected from 0 nM, 50 nM and 100 nM sample sets it was 
observed this was not correct, Figure 6.5. 
Having taken the sequence of the aptamer from the literature, there is prior 
knowledge that it is highly selective and sensitive to PrPc.6 However, the assay 
proposed will use RPS and SPPs, and the interaction of these conjugates to other 
proteins likely to be found in the assay’s matrix needs to be understood, this has 
been studied in chapter 4. The ease of manufacture, greater temperature stability, 
and cost make aptamers a good choice for assay development. However, they must 
be at least as selective and sensitive as monoclonal antibodies are in biological assays 
and this will be explored next.  
 Control Protein Study 
Work already described in this thesis has detailed the effects of protein corona 
formation around nanoparticles but to further understand the effects of protein 
binding to SPP/DNA conjugates the three most abundant blood proteins were 
tested. These being γ-globulin, albumin and fibrinogen, all at twice the concentration 
of the highest PrPc used previously in the calibration curve, 200 nM, seen in Figure 
6.4. γ-globulin is a larger protein at 150 kDA (comprising of two heavy chains at 50 
kDa and two smaller chains at 25 kDa), compared to the smaller PrPc molecular mass 
at 25 kDa.  
After incubating the DNA aptamer modified SPPs at room temperature for 20 
minutes they were analysed to determine their relative velocity. A normalised 
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calibration was prepared since variations in DNA hybridisation and pore variations 
between batches could be taken into account; the data was normalised to blank DNA 
SPPs. Room temperature was selected as previous work showed that the degree of 
non-selective binding increased as a function of temperature.24  
After incubation in γ-globulin at 200 nM there was a relatively small decrease in 
relative velocity of the particle to 95% relative to the control particles. Since the pI 
of the protein is in the range of 5.8 – 7.3 meaning at pH 7.4 the protein will be slightly 
negatively charged; it must be noted fibrinogen has a molecular mass of 150 kDa. 
Albumin with a molecular mass of 66 kDa and a pI of 4.9, meaning at pH 7.4 it would 
be negative and an increase in relative velocity would be observed. However, the 
value observed relative to the control particles was 97%, indicating a small decrease 
in velocity, demonstrating a minor interaction. Fibrinogen, with a pI of 5.5, and the 
largest protein used in this study with a molecular mass of 340 kDa, had the smallest 
effect on the SPPs with a relative velocity decrease to 98%. This can be seen in Figure 
6.6a. 
Whilst the interaction between the aptamer and PrPc is selective, there is by nature 
a degree of non-selective binding observed. Another factor to consider it the fact 
that highly packed DNA on a surface can act as a densely packed brush, reducing any 
proteins or artefacts that are not selective to the aptamer. Here it can be seen there 
is very little binding of the three proteins to the aptamer or fouling of the particle’s 
surface. This can be seen as no increase in particle’s size given by an increase in 
blockade magnitude, nor any particle aggregation, Figure 6.7. It should also be noted 
the rate at which the particles translocated through the pore also remained 
unchanged, Figure 6.6b. 
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Figure 6.6: (A) Plot of normalised 1/T0.5 values for DNA aptamer modified SPPs incubated with 
three abundant blood proteins: IgG, albumin and fibrinogen at 200 nM. Data normalised to 
DNA aptamer SPPs with no protein present. n=3; error bars represent 1 x SD from the mean.  
(B) Rate plot of DNA aptamer modified SPPs incubated with γ-globulin - green, albumin – red, 
and fibrinogen - blue at 200 nM, black is the rate of DNA aptamer modified SPPs with no 
protein present. Events for each dataset >400 
A 
B 
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Figure 6.7: Blockade magnitude distributions for the incubation of DNA aptamer (concentration 
at 100% relative to their binding capacity) modified SBPs with three abundant blood proteins at 
200 nM with a constant concentration of SPPs at 2 x 109 mL-1 - red: albumin; blue: fibrinogen; 
green: γ-globulin. Black indicates DNA aptamer modified SPPs with no protein present. n=3; 
events for each dataset >500 
 141 
 
 PrPc Preconcentration   
At this point in the assay’s development it has been shown to have a detection limit 
of 0.1 nM in PBS, a level too high for a usable assay in the detection of vCJD. To 
overcome this challenge a strategy was formulated to pre-concentrate the prion in 
PBS using the same DNA aptamer modified SPPs used in previous experiments in this 
chapter. Here, the non-covalent interaction between the aptamer and protein was 
utilised prior to running a bioassay, it is not uncommon for samples to require pre-
concentration, purification or an extraction stage. SPPs offer a simple, cheap and 
rapid method for extracting target analytes from complex media. From a user's 
perspective it is a simple procedure of mixing the sample with a SPPs followed by the 
exposure of the tube to a magnet that precipitates the target-particle complex to the 
tube wall, thus removing the analyte from solution. It has been hypothesised an 
interaction between DNA and a protein can be disrupted by either altering the 
temperature of the reaction, typically heating, but this can denature the protein and 
therefore change its binding site, by varying the pH or by altering the ionic condition 
the interaction is under.25 Using elevated temperatures for extended periods 
subjects the streptavidin protein coating the particle to conditions where it is likely 
to denature the tetramer, destroying the biotin interaction.26 Since the integrity of 
the prion protein’s binding site needs to be maintained so it can be detected the 
method of changing the ionic strength was used. Altering the concentration of ions 
in solution acts to displace, or facilitate, DNA/protein binding by differential cation 
or anion binding, or changes to the macromolecular hydration.27  
After incubation, the DNA aptamer modified SPPs with PrPc were magnetically 
separated and re-suspended in 10x PBS, altering of the ionic conditions affects the 
protein/DNA interaction and therefore releases the protein from the conjugate back 
into the bulk PBS solution. To note a concentration of PrPc used in this study was kept 
constant at 50 nM, the reason for this level being selected was to elicit a change in 
SPP’s relative velocity that would be greater than a change in relative velocity due to 
pore fouling.  
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After the magnetic separation the ionic condition was return to 1x PBS with DIH2O 
and an aliquot of SPPs was added so that the concentration of SPPs remained at 2 x 
109 mL-1. The sample at this stage of analysis was placed in the upper and lower fluid 
cells to minimise any electrolyte imbalance between the stock PBS solution and the 
sample. The results for the isolation of the PrPc can be seen in Figure 6.8.  
 
 
Figure 6.8: (i) Relative velocities of SPPs modified with DNA aptamer; (ii) SPPs modified with 
DNA aptamer incubated with 50 nM PrPC; (iii) SPPs with DNA aptamer and PrPC removed via 
change in ionic conditions; and (iv) SPPs modified with DNA aptamer and incubated with PrPC 
previously removed from SPPs. n=3; events for each dataset >400. Error bars represents 1 x SD 
from the mean 
 
Having previously explored the use of a selective DNA aptamer to capture and detect 
PrPc using RPS, there was a degree of confidence that using the DNA aptamer 
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modified SPPs to isolate and pre-concentrate the protein would be plausible. What 
was unknown - would the protein remain intact so that further binding would be 
possible. The addition of DNA aptamer modified SPPs to a solution of 50 nM PrPc 
resulted in a decrease in velocity (as seen in section 6.5.3 previously) - here a 
decrease from 9.95 to 5.7 ms, a change of 42% was observed. After changing the 
ionic strength and removing the protein, the SPPs returned to a relative velocity of 
9.40 ms, a difference of 5.5%. This difference can be accounted for by the protein 
not being fully removed or by disruption of the biotin/streptavidin interaction 
resulting in some of the DNA aptamer detaching from the particle’s surface. After 
adding a fresh aliquot of DNA aptamer modified SPPs to the isolated protein and 
incubating for 10 minutes a decrease in relative velocity is observed. However, the 
magnitude of this decrease is not the same as stage (ii), but a decrease is observed 
from 9.40 to 6.67 ms, which is a decrease of 29%. This indicated some of the PrPc has 
been lost in the pre-concentration stages and/or has become denatured during the 
process. At this stage of the study it has been demonstrated that pre-concentrating 
was possible, although the change in relative velocity is not the same, but with 
further optimising this could be improved. This could be achieved by using larger 
magnetic particles to increase magnetic separation efficiency or studying the effects 
of alternative ionic conditions.  
 Conclusion  
Immobilising a DNA aptamer onto a particle’s surface alters the particle’s behaviour 
in an electrolyte solution that can be monitored using RPS. RPS has also shown it has 
the ability to detect the PrPc protein at a level of 100 pM without the additional steps 
of a pre-concentration strategy by using DNA aptamer modified SPPs to capture the 
protein. The data extracted from the particle-by-particle measurement of RPS shows 
by varying the temperature of the DNA aptamer prior to immobilisation onto the 
SPPs surface is non-dependent. Therefore, a room temperature assay is possible, 
which reduces the number of stages and steps involved in any future assay being 
developed using the methods demonstrated here.  
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It should also be noted the DNA aptamer has some non-specific binding when the 
three abundant blood proteins are present at 200 nM, which could also be attributed 
to the fouling of the particle’s surface. However, the change in relative velocity 
maybe statistically significant, it is also minimal. A future strategy could isolate the 
protein to a PBS solution so any non-specific protein binding would be negligible.  
By adding a pre-concentration step to the assay this could decrease the limit of 
detection further. Here it has been demonstrated by altering the ionic conditions the 
protein can be removed from the DNA aptamer and isolated into a smaller volume 
of buffer. To further lower the detection limit, a strategy of altering the protein per 
SPP ratio, changing the size of the particle to increase the number of DNA strand per 
particle, or isolating the protein to a smaller volume could be used. Another 
approach could be to modify the DNA aptamer, such as adding non-interacting bases 
to increase the distance of the binding region from the particle’s surface.  
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7 Conclusions and Future Work 
 
The work presented in this thesis provides the preliminary work for a reliable, robust 
and rapid assay that can be used to detect disease, in particular variant CJD (vCJD). 
The platform used to overcome this challenge was resistive pulse sensing (RPS). 
Towards this goal, a basis of knowledge needed to be outlined to understand the 
limitation and viability of the processes that are to be utilised. The first objective was 
to investigate how the elements of complex blood matrices affects the biological 
identity of nanoparticles i.e. the formation and characterisation of the protein 
corona. Here the zeta potential of carboxylated nanoparticles were studied after 
incubation in blood proteins, plasma and serum. Next was the detection of a new 
biomarker. Utilising the complimentary nature of DNA and the binding of the anti-5-
methylcytosine antibody to detect genomic DNA for hyper-methylation of the 
Rassf1a promoter region was outlined. The process involved the use of streptavidin 
modified nanoparticles and translocation velocities to detect methylation at a single 
or double point. Finally, the knowledge of nanoparticles in protein rich samples and 
DNA modified nanoparticles was implemented in the groundwork for an assay for 
the detection of the prion protein, which undergoes a conformational change to 
cause CJD.  
Chapter 4 is the first experimental chapter and presents the experimental work 
carried out to understand if the RPS platform can monitor the formation of the 
protein corona. As described elsewhere, blood is a complex matrix of proteins, which 
alters the biological identity of nanoparticles. The zeta potential and size of 
polystyrene carboxylated nanoparticles was measured as a function of temperature, 
protein composition and blood fraction matrix. Higher, physiological, temperatures 
showed the largest change in zeta potential when compared to nanoparticles 
incubated at the lower 25°C, and in PBS. The protein composition of the matrix also 
had an effect, in this instance serum had a greater effect, when comparing the result 
observed for plasma. The differing protein compositions of serum and plasma were 
used to study the changes in the soft and hard corona. Spiking of nanoparticles 
 150 
 
incubated in serum with plasma tested the corona structure as proteins with 
differing affinities were displaced and was observed as a change in zeta potential 
over 60 minutes. The data gained here validated the use of tunable pores when using 
serum and plasma samples, setting a protocol that can be used in later assays using 
such biological media. This will extend the use of pores, reducing costs and improving 
the validity of the signal gained in RPS experiments. The complex nature of the 
matrices, and the concentration of nanoparticles used in this chapter proved to be 
the biggest challenge. It became quickly apparent that analysing the samples would 
be difficult, either pore fouling would be observed, or the high concentration of 
nanoparticles would quickly block the pore. Reducing the concentration of 
nanoparticles would remedy this issue. Since the basis of the assay highlighted 
further in this thesis used streptavidin surface modified superparamagnetic particles 
(SPPs) therefore it would be useful to have data of the formation of the protein 
corona around these. Also, using particles of varying sizes would be advantageous. 
Going further, a surfactant spiking study would be interesting, understanding how 
stable the corona is as a function of surfactant concentration, or type of surfactant, 
would be extra knowledge that is likely to be beneficial for any future assay.  
Chapter 5 forms the foundations for the use of DNA modified particles as a carrier 
for protein detection using RPS. Biotinylated complimentary DNA acting as a capture 
probe was immobilised on to 125 nm streptavidin surface modified SPPs and 
incubated with the Rassf1a promotor DNA sequence that was either methylated at 
a single point, two points or simply without. When the anti-5-methylcytosine 
antibody was added, and the sample analysed, the translocation velocities could be 
observed using RPS, revealing the number and location of the epigenetic markers 
within the target. This strategy can distinguish between different methylation sites 
within a DNA promoter region as the binding of the antibody to the DNA disrupts the 
double layer structure around the particle and consequently affects the 
electrophoretic velocity. Crucially the approach was not dependant on accurate 
sequencing of the assayed DNA, with genomic regions targeted through 
complimentary probes. By varying the ratio of the number of proteins to the number 
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of particles (1000:1) optimised the RPS signal. To demonstrate a dose response of 
the strategy, the middle-methylated DNA was selected to quantify the number of 
DNA copies in solution, which contained these markers. As the number of target DNA 
increased the velocity of the particles decrease. To improve the sensitivity further, a 
lower number of capture probes were used - circa 50% of the binding capacity of the 
SPPs. By halving the capture probe concentration resulted in a sharp decrease in 
relative velocity of the SPPs. The concentration of target DNA was increased from 0 
nM to 119 nM and at concentrations above 47.6 nM there was no further decrease 
in velocity. It has been demonstrated that the characterisation of methylated DNA 
sequences using RPS is possible. The process allows for the rapid quantification of 
epigenetic markers with insight into the location of the marker within the target. 
At this stage the assay is at the early stages but shows promise in providing an 
alternative to the current detection method of bisulfide treatment. The proof of 
concept work could be further optimised in a few ways, firstly by altering the ionic 
strength of the buffers the experiments are carried out in. This would change the 
double layer formed around the particle and may have the effect of fine tuning the 
translocation velocities to differentiate the epigenetic markers further. By 
maintaining RPS as the detection platform, a different approach could be taken to 
identify the site of methylation. Here a capping strategy could be used to ‘cap’ off 
any methylation sites to block the binding of complimentary DNA; the length could 
be tuned to facilitate this. Also, the fact the work was carried out using DNA 
purchased ‘clean’ from a supplier means a real-world application of the technique 
should be performed. This would involve isolating DNA from biological samples using 
a restrictive enzyme digest, then using this DNA in the assay outlined. Furthermore, 
this would take a great amount of work and the knowledge of specialists to piece 
this together from start to finish. However, reducing the amount of time to 
determine DNA methylation, and removing the need for harsh bisulfite treatment, 
would be exceedingly beneficial to understanding the role of epigenetics in disease.  
The final experimental chapter (chapter 6) takes the detection of protein bound DNA 
further and instead of using capture DNA and its complimentary sequence, a DNA 
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aptamer is used to detect the human cellular prion protein. Similar to chapter 5, DNA 
was immobilised on to 125 nm streptavidin surface modified SPPs, however a DNA 
aptamer was used that is known to be selective to the cellular prion protein. The first 
stages varied the concentration of DNA aptamer relative to the binding capacity of 
the SPPs; the varying packing density was easily detected using translocation 
velocities. Other measures to observe protein binding - these being particle 
translocation rates, blockade magnitudes (which indicates size change) but 
translocation velocity proved to be the most robust. Using SPPs with 100% DNA 
coverage it was possible to detect the protein to 0.1 nM. To decrease the limit of 
detection a pre-concentration stage was explored, here a sample containing 50 nM 
of PrPc was used and the same DNA aptamer SPPs. It was possible to separate the 
bound protein by changing the ionic strength of the PBS solution. Extrapolating the 
data gained here, it was hypothesised it would be possible to reduce the limit of 
detection further. To test the selectivity of the aptamer, three abundant blood 
proteins at 200 nM were used, and from this data the aptamer proved to be highly 
selective with very little non-selective binding being observed. 
To further advance the work in this study, the next stages of the development 
process would be to understand how a protein-rich matrix would impact the DNA 
aptamer’s selectivity and sensitivity. This could be achieved by firstly taking the three 
most abundant blood proteins and creating a mix of them before moving on to the 
more complex matrices of serum, plasma and then whole blood. This would be a 
stepped process but based on a magnetic separation strategy since the protein 
would ideally be isolated from ‘blood’ and re-suspended into PBS, or another 
electrolyte solution, to reduce any matrix effects. To simplify the process only one 
particle size was used, however, the use of different sizes could be explored, such as 
using larger particles in the magnetic separation – here magnetic separation theory 
could be applied to optimise the assay. It might also be valuable to expand the 
knowledge of changing the pH to isolate the protein after magnetic separation since 
changing the pH of the sample would maintain the isolated volume at a similar level.  
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Still using RPS, a displacement method should also be considered, taking the 
knowledge gained in chapter 5 of complementary DNA binding and utilising a high 
affinity aptamer. This could be envisioned by immobilising the aptamer onto a 
surface and binding its complimentary DNA sequence to SPPs. The aptamer and/or 
the complimentary DNA sequence could be engineered to have a lower affinity than 
the target, so when the target is introduced the DNA bound SPPs are released into 
the bulk solution and these are detected. An increase in particle count as a function 
of target concentration would be observed. One thing that is likely to hinder the 
assay’s development is the lack of PrPsc as it is a highly controlled pathogen, and in 
very short supply. It must be noted, although the assay is still in the early stages, it is 
still more rapid than the current proposed amplification techniques, and with further 
work and optimisation it would prove to be a useful tool for clinicians, but this work 
is considerable.  
The experiments detailed in this thesis demonstrate RPS is a useful platform in the 
development of blood-based assays and would be a tool that could be deployed in 
many clinical settings – from hospitals, to clinics and more. RPS technology can 
detect, quantify and characterise various analytes in a range of solutions quickly 
using pore and particle-based assays. By optimising a generic assay, a range of 
targets could be detected, or maybe using multiplexing strategies.  
  
 154 
 
 
 
 
 
 
 
Chapter 8 
Research Output and 
Communication 
  
 155 
 
8 Research Output and Communication 
 
 Publications 
 
Rapid Quantification of Prion Proteins Using Resistive Pulse Sensing.  
Matthew J. Healey, Muttuswamy Sivakumaran, and Mark Platt.  
Analyst, 2020, 145, 2595-2601 
 
Rapid Assessment of Site Specific DNA Methylation Through Resistive Pulse 
Sensing 
Matthew J. Healey, William Rowe, Sofia Siati, Muttuswamy Sivakumaran, and Mark 
Platt 
ACS Sensors 2018, 3, 655 – 660  
 
Characterisation of the Protein Corona Using Tunable Resistive Pulse Sensing: 
Determining the Change and Distribution of a Particle’s Surface Charge  
Emma L. C. J. Blundell, Mathew J. Healey, Elizabeth Holton, Muttuswamy 
Sivakumaran, Sarabjit Mastana, and Mark Platt 
Analytical and Bioanalytical Chemistry 2016, 408 (21), 5757-5768 
 
 Attended Conferences 
• STEM for Britain, House of Commons (2018) 
• Biosensors 2018, Miami (2018) 
• Analytical Science Network Bright Sparks Symposium, University of Bath 
(2017) 
• Midlands Electrochemistry Group, University of Nottingham (2017) 
• Science Matters - School of Science Conference, Loughborough University 
(2017) 
• 22nd Congress of the European Hematology Association, Madrid (2017) 
• East Midlands University Association - Inspiring Futures, Loughborough 
University (2016) 
• Peterborough City Hospital - R&D Symposium: Celebrating Research in a 
District Hospital, Peterborough (2016) 
• Graduate School Summer Showcase, Loughborough University (2016) 
• Science Matters - School of Science Conference, Loughborough University 
(2016) 
• Graduate School Research Conference - Influence and Impact, 
Loughborough University (2016) 
• Izon Science Symposium, University of Oxford (2015) 
 
 156 
 
 Research Presentations 
 Presentations 
• Biosensors 2018, Miami (June 2018) – Rapid Assessment of Site Specific DNA 
Methylation Through Resistive Pulse Sensing 
• Café Academique, Loughborough University (July 2017) – Tainted Blood 
• Midlands Electrochemistry Group meeting, University of Nottingham (2017) 
- Using Nanopores to Exploit Particle Translocation Velocities for Assay 
Development 
• Peterborough City Hospital - R&D Symposium: Celebrating Research in a 
District Hospital (2016) - Detection of Prion Protein Using Aptamers and 
Tunable Resistive Pulse Sensing – Invited speaker 
• Department of Chemistry Research Talks, Loughborough University (2017) – 
Tainted Blood  
 
 Poster Presentations 
• STEM for Britain, House of Commons (2018) 
• Analytical Science Network Bright Sparks Symposium, University of Bath 
(2017) – Best poster 
• 22nd Congress of the European Hematology Association, Madrid (2017) 
• Graduate School Summer Showcase, Loughborough University (2017) 
• RSC Twitter Poster Conference (2017) - Best poster in the Analytical Category  
• Graduate School Summer Showcase, Loughborough University (2016) - Best 
overall poster 
• Graduate School Summer Showcase - Research Challenge, Loughborough 
University (2016) – Runner-up in the health and wellbeing category  
• Graduate School Summer Showcase, Loughborough University (2016) – 
Delegates’ choice award   
• Science Matters - School of Science Conference, Loughborough University 
(2016) 
• Graduate School Research Conference - Influence and Impact, 
Loughborough University (2016) 
  
 157 
 
 
 
 
 
 
Publications 
Analyst
PAPER
Cite this: Analyst, 2020, 145, 2595
Received 10th January 2020,
Accepted 11th February 2020
DOI: 10.1039/d0an00063a
rsc.li/analyst
Rapid quantification of prion proteins using
resistive pulse sensing†
Matthew J. Healey,a Muttuswamy Sivakumaranb and Mark Platt *a
Prion diseases are a group of fatal transmissible neurological conditions caused by the change in confor-
mation of intrinsic cellular prion protein (PrPC). We present a rapid assay using aptamers and resistive
pulse sensing, RPS, to extract and quantify PrPC from complex sample matrices. We functionalise the
surface of superparamagnetic beads, SPBs, with a DNA aptamer. First SPB’s termed P-beads, are used to
pre-concentrate the analyte from a large sample volume. The PrPC protein is then eluted from the
P-beads before aptamer modified sensing beads, S-beads, are added. The velocity of the S-beads
through the nanopore reveals the concentration of the PrPC protein. The process is done in under an
hour and allows the detection of picomol’s of protein.
Introduction
Prion diseases are a group of fatal transmissible neurological
conditions whose disease etiology is characterised by the
change in conformation of the normal intrinsic cellular prion
protein (PrPC) in to the highly ordered insoluble amyloid state
conformer (PrPSC). The significant event fundamental to the
progression of these diseases is the self-catalytic, and perpetu-
ating, nature of the conversion of PrPC in the presence of
PrPSC aggregates.1–3 The emergence of variant Creutzfeldt–
Jakob disease (vCJD), the most predominant prion disease in
humans in the United Kingdom (UK) during the 1990s, is
thought to be an effect of dietary exposure to the bovine spon-
giform encephalopathy (BSE) agent through contaminated
meat products. The link between BSE and vCJD was uncovered
after lengthy surveillance, epidemiologic studies and experi-
mental investigation.3 Unlike the sporadic form for of the
disease (sCJD), the infectious prion protein associated with
vCJD is found outside the central nervous system, accumulat-
ing in peripheral lymphatic tissue, which increases the public
health concern. To date, the widely accepted estimate for the
prevalence of vCJD in the UK puts the number of potential car-
riers at 1 in 2000.4 Although most of the occurrences of vCJD
have occurred in the UK there has been a number of individ-
uals that have developed the disease overseas.
Since the disease is known to be infectious and transmissi-
ble, the iatrogenic ability of this disease is a significant risk to
public health through blood transfusion products and surgical
procedures. There have been efforts to develop an assay that
can detect the low levels of the infectious protein in the peri-
pheral blood of pre-symptomatic patients that has the selecti-
vity and sensitivity the assay will need.1,5,6 There are a number
of reasons why developing an assay has been challenging.
What has puzzled researchers is the fact that PrPSC fragments
isolated from organisms are identical but cause different
strains of diseases with differing clinical manifestations.7 vCJD
is not encoded by RNA and DNA, in contrast to other patho-
genic agents but still have the ability to transmit information.8
This lack of genetic material has negated the use of polymer-
ase chain reaction (PCR) for nucleic acid detection methods.
As the amino acid sequence is identical in both PrPSC and
PrPC developing an antibody capable of differentiating
between the isoforms has proven difficult. Lastly, the notion
that a person could be asymptomatic and act as a carrier for
vCJD may mean the levels of PrPSC are too low for traditional
assays.
Two widely adopted sensing strategies utilise an amplifica-
tion step to increase the level of the infectious protein to aid
detection using the in vitro conversion of PrPC into PrPSC.
The two strategies, termed protein misfolding cyclic amplifi-
cation and quaking-induced conversion assay, work in
similar way.1,9 Briefly, they use cycles of either shaking or
sonication interspersed with incubation periods. If PrPSC is
present in the sample the addition of a large excess of PrPC
results in its conversation to PrPSC amplifying the signal into
the detectable range. In 2011 a major breakthrough in the
diagnosis of vCJD in symptomatic patients and preclinical
asymptomatic individuals was made.10 Edgeworth et al. at the
†Electronic supplementary information (ESI) available: Blockade magnitudes for
the particles, during the assays stages. See DOI: 10.1039/d0an00063a
aDepartment of Chemistry, Loughborough University, LoughboroughLeicestershire,
LE11 3TU, UK. E-mail: m.platt@lboro.ac.uk; Tel: +44 (0)1509222573
bPeterborough City Hospital, Edith Cavell Campus, Bretton Gate, Peterborough, PE3
9GZ, UK
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Medical Research Council’s (MRC) prion unit in London
reported their findings on a prototype blood test. Notably
this protocol exploited previous research that found PrPSC
had an extremely high affinity to stainless steel.11 In this
assay, PrPSC in the blood sample is isolated on 45 µm stain-
less steel balls, and then detected by ELISA using ISCM18
antibodies, before visualising using commercial chemilumi-
nescence. Although the assay currently falls short of the
European Commission’s Health and Consumer Directive, it
does not rely on a lengthy amplification step (only requiring
overnight incubation).
Here we develop a simple workflow using superpara-
magnetic beads, SPB’s to extract, concentrate and quantify
PrPC direct from solution. The SPB’s are functionalised with
a DNA aptamer that has been previously identified to bind to
the PrPC protein.12 DNA aptamers are sequence specific
single strand nucleic acids, that bind to target analytes via
the formation of a specific tertiary structure.13–15
Researchers have demonstrated how aptamers and modified
SPB’s can be incorporated into resistive pulse sensors (RPS).
Resistive pulse sensing strategies have the capacity to quan-
tify DNA protein interactions facilitating epigenetic, proteo-
mic and metal ion detection.16–30 In the assay DNA aptamer
was conjugated to superparamagnetic beads, SPBs, creating
a negatively charged surface. Protein binding to this DNA
aptamer/strand changes the charge density around the par-
ticle as the phosphate groups on the DNA backbone adopt
the new shape.16,18,31 This is measured as a change in par-
ticle velocity, and the magnitude of the velocity is used to
quantify the analyte.16,18,32 Fig. 1. The use of SPBs to concen-
trate the target analyte improves the limit of detection by an
order of magnitude and the entire work flow from extraction
to quantification is less than an hour. The aim is to produce
a rapid, reliable assay for the detection of prions. We find
the assay is highly sensitive in discriminating between the
target protein of other high abundant proteins found in
serum.
Experimental
Chemicals and reagents
Phosphate buffered saline (PBS. 0.01 M phosphate buffer,
0.0027 M potassium chloride, 0.137 M sodium chloride) was
used for analysis. PBS tablets (P4417) were purchased from
Sigma-Aldrich, UK. The control study proteins used were
γ-globulin from human blood (G4386), albumin from human
serum (A9511) and fibrinogen from human plasma (F3879), all
sourced from Sigma Aldrich, UK. Streptavidin surface modified
SPBs were purchased from Ademtech, France (03121), with a
known mean diameter of 125 nm and a measured concen-
tration of 1 × 1012 mL−1 and used in all experiments.
Invitrogen dynabeads were used, mean size of 1.05 μm.
DNA oligonucleotides
A custom oligonucleotide used in the study was purchased
from Sigma Aldrich, UK in lyophilized form (0.2 µM). The
oligonucleotide was purified using reverse-phase cartridge
purification (RP1) by the manufacturer. The details and its
modifications: 5′ CTTACGGTGGGGCAATT[BtnTg] 3′. Here
[BtnTg] is biotin TEG modification with five additional T
bases. This was made up into a stock solution of 100 µM with
deionized water. This aptamer was previously reported by
another study.12
Human cellular PrP
Recombinant N-terminal His-tagged full-length prion protein
(residues 23–231, PR-902) was purchased from Jena
Bioscience, Germany in lyophilized form. The protein was
reconstituted in 1× PBS containing 0.5% Triton X-100 (Sigma-
Aldrich, UK). Aliquots were prepared and stored at −80 °C
until required.
Aptamer immobilisation
Streptavidin modified SPBs were diluted to a concentration of
1 × 1010 mL−1, vortexed for 30 seconds and sonicated for
Fig. 1 Work flow of the extraction, and quantification of the PrPC. (a) To the sample P-beads are added, (b) the P-beads and bound PrPC are
extracted and suspended into buffer (c). (d) The target protein is eluted and the P-beads removed from the sample. S-beads are mixed to the solu-
tion and the binding of the PrPC to the S-beads is measured using the resistive pulse sensor (‘P-beads’ – preconcentration beads, ‘S-beads’ –
aptamer functionalised sensor beads). (e) Schematic of the RPS process and generated data. Each particles creates a pulse magnitude Δip, and full
width half maximum, FWHM.
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2 minutes to ensure monodispersity. The aptamer was added
at concentrations equal to 33% and 100% binding coverage;
having determined this from the binding capacity given by the
manufacturer (4122 pg mg−1). The samples were placed on a
rotary wheel for 1 hour at room temperature. Any unbound oli-
gonucleotides in solution were removed by placing the
samples on a MagRack (GE, UK) for 15 minutes until a cluster
was visible adjacent to the magnet before removing and repla-
cing the buffer. The resulting capture probe was stored at 4 °C
or used for further study the same day. For the full work flow,
the same aptamer and particles were used, but depending
upon the stage, they are termed preconcentration beads,
P-beads, or sensing beads, S-beads.
PrPC binding
DNA modified SPBs were vortexed for 30 seconds before being
placed on a rotary wheel prior to use. At varying concentration
between 0–100 nm, PrPC was added to the particles, which
were at 2 × 109 mL−1, vortexed for 30 seconds before incu-
bation at room temperature on a rotary wheel for 10 minutes
before analysis.
Varying temperature DNA aptamer binding
Prior to DNA aptamer immobilisation the concentration equi-
valent to 100% binding capacity (determined from the manu-
facturer’s information) of the streptavidin modified SPBs, in
PBS, were vortexed for 15 seconds before heating to either
21 °C or 90 °C in a mini dry bath (Benchmark Scientific, USA)
for 5 minutes. The mixture was allowed to cool to room temp-
erature for 30 minutes on a rotary wheel before the addition of
particles. The mixture was placed on a MagRack (GE, UK) for
10 minutes until a cluster of particles was visible. The solution
was carefully removed and replaced with an equal volume of
PBS. The concentration of particles was kept constant through-
out all experiments at 2 × 109 mL−1.
Control protein binding
After modifying streptavidin SPBs with DNA aptamer,
albumin, fibrinogen or γ-globulin was added at a concen-
tration of 200 nM and incubated for 20 minutes on a rotary
wheel. 200 nM was selected as this concentration is 2× higher
than the highest concentration used in the calibration curve.
PrPC work flow
DNA aptamer modified SPBs were first prepared as described
above. The full work flow is shown in Fig. 1. Preconcentration:
to P-beads, PrPC was added to give a final concentration of 50
nM, the total volume here was 1 mL. The sample was then vor-
texed for 30 seconds and incubated for 10 minutes on a rotary
wheel. The SPBs were then magnetically separated by placing
the samples on a magnetic rack (GE, UK) for 5 minutes until a
cluster was visible adjacent to the magnet before removing
and replacing the buffer with 100 µL 10× PBS solution. The
sample was sonicated for 30 seconds and vortexed for 30
seconds before being placed on a rotary wheel for 20 minutes.
After, the SPBs were magnetically separated for 5 minutes and
the supernatant removed, the P-beads were discarded.
Sensing: to the supernatant 900 μL DI water was added to
dilute give a 1× PBS solution, and an aliquot of S-beads were
added to give a concentration of 2 × 109 mL−1; these were then
incubated for 10 minutes on a rotary wheel and then the
S-beads were analysed.
Resistive pulse sensing (RPS)
A qNano (Izon Science Ltd, NZ) was used to complete all
measurements in this study. Briefly, in all experiments the
lower fluid cell contained 80 µL of PBS buffer, ensuring no
bubbles were present. When a sample measurement was being
taken, the upper fluid cell contained 40 µL of the sample (sus-
pended in PBS buffer). After each measurement was taken the
nanopore was rinsed several times by removing and replacing
40 µL of buffer, each time applying varied pressures until no
particles were observed. This was performed several times to
remove any residual particles in the system and thus ensure no
cross contamination between samples. The nanopores used
throughout all experiments were capable of detecting particles
within the size range of 110–630 nm (as stated by the manufac-
turer, Izon Science Ltd), and denoted as an NP200. To account
for the variation in the manufacturing of the nanopores, an
appropriate stretch (44–49 mm), voltage and pressure were
applied in all experiments; the conditions were matched to the
blockade magnitudes of CPC200s in PBS.
Zeta potential measurements using RPS
When carrying out zeta potential measurements, the nanopore
stretch was kept the constant for calibration and sample
measurements, detailed explanations can be found
elsewhere.33,34 When running samples, the blockade magni-
tudes were ensured to be at least 100× larger than the respect-
ive background noise of ca. 10 pA. Calibration measurements
were completed when a new nanopore (NP200) was introduced
or the start of a day. Where zeta potentials are not reported,
the method used the resistive pulse to calculate the relative vel-
ocity and identifies the point of greatest resistance in the
signal trace (the resistive blockade peak). For each blockade,
the time at which the peak occurs is defined as T1.0 (time at
100% of peak magnitude) and the maximum magnitude of the
pulse (relative to the local baseline resistance) is recorded as
ΔRmax. Here the value at T0.5 (width of the pulse at 50% of the
peak magnitude is used).20,23 To keep the method simple and
applicable in further applications the actual zeta potential of
the particle is not calculated and for further simplicity in the
subsequent figures we use only one measurement to represent
the particle speed which is 1/T0.50.
Results and discussion
Within RPS experiments each translocation of the SPB through
the nanopore produces a pulse, Fig. 1e. The magnitude of the
pulse, known as the pulse magnitude (Δip) is related to the
volume of the carrier, and the width or full width half
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maximum (FWHM) of the pulse relates to its velocity.22 In the
absence of convection, the velocity of the carrier can be pro-
portional to the surface charge or zeta potential of the carrier,
assuming electro osmosis remains constant.35 As the density
of the DNA aptamer and/or its length increases the velocity of
the SPB through the pore also increases.21,22 Here the aptamer
length remains constant, and as the concentration of the
aptamer of the SPB’s surface increases so does the velocity.
This is recorded as a decrease in zeta potential. Example
pulses recorded are shown in Fig. 2.
Fig. 3a shows the decrease in zeta potential from the blank
value of −1.16 ± 1.31 mV to −4.43 ± 0.78 mV and −7.75 ±
0.94 mV for 33 and 100 percentage coverage of the beads
surface with DNA. In the current setup the RPS is not sensitive
enough to measure a change in SPB size as the DNA aptamer
is placed on in surface, and the blockade magnitude does not
change as the more aptamer is added to the SPB, Fig. s2.†
Before carrying out the extraction and detection of the PrPC
target, we first incubated aptamer modified beads (S-beads)
with varying concentrations of the target. Their velocity was
then measured through the RPS, Fig. 3b. The velocity of the
SPB’s through the pore can be converted to a zeta potential as
illustrated in Fig. 3a. However from this point we simply report
the velocity of the SPB’s measured at the 1/T0.5 values,
20 which
we have previously shown capable of monitoring the length
and packing density of DNA around SPB’s. The simplification
make the analysis quicker as the velocities do not need to be
converted to the final zeta potential value. In addition, it is the
authors’ view that the reporting of zeta potential values for
DNA and DNA–protein covered nanomaterials can be mislead-
ing, as there is no consistent location of the plan of shear and
no assumption is made about the structure. The binding of
the PrPC protein to the aptamer results in a change in its ter-
tiary structure resulting in a decrease in translocation velocity,
Fig. 3b.16,21 The magnitude of the velocity change has been
shown to be dependent upon the shape of the DNA as well as
the relative location of the binding event with respect to the
carriers surface.32 As shown in Fig. 3b the velocity was shown
to decrease over two orders of magnitude, and no change in
their size was observed, Fig. s3,† indicating the particles did
not aggregate.
Having taken the sequence of the aptamer from the litera-
ture, there is prior knowledge that it is highly selective and
sensitive to PrPC.36 However to illustrate the signal observed in
Fig. 3 was specific to the target, other proteins were also added
to S-beads. These proteins were chosen based on their relative
abundances found in human blood.37 Albumin and γ-globulin
are present in both plasma and serum samples at approxi-
Fig. 2 Example data sets for DNA blank S-beads (green), S-beads incubated with 50 nM PrPC (olive) and 100 nM PrPC (red). Magnified section of
this are also shown in Fig. s1.† N.B. the blank beads have been run prior to dilution.
Fig. 3 (a) Plot of zeta potential versus frequency for SPB modified with no DNA curve (i) (blank); DNA aptamer equal to 33% of the particles binding
capacity curve (ii); and SPBs with 100% binding capacity (iii). (b) Relative particle velocity as a function of PrPC concentration. The concentration of
SPBs was kept constant at 2 × 109 mL−1 and DNA aptamer concentration as 100% relative to the SPB’s binding capacity. Events for each data point
>500. Error bar represent 1× SD, where n = 3.
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mately 4 and 2%, whereas fibrinogen (as well as other clotting
factors) is only found in plasma at approximately 0.4%. This
translates to concentrations of 40 g L−1 for albumin, in com-
parison to the fibrinogen and γ-globulin samples only having
protein concentrations of 4 and 20 g L−1 respectively.
Fig. 4 shows that following incubation of the S-beads with
the different proteins no change in velocity was observed. Here
the data is plotted normalised to calibration particles as vari-
ation from pore to pore or batches of beads can sometimes
results in different absolute velocity values.22 After incubation
with each control there was a relatively small decrease in rela-
tive velocity. There appears to be very little binding of the three
proteins to the aptamer, or fouling of the particle’s surface.
This can be seen in no increase in particle’s size given by an
increase in blockade magnitude, Fig. s4,† nor any particle
aggregation. It should also be noted the rate at which the par-
ticles translocated through the pore also remained unchanged,
Fig. 4b, indicating that neither the pore or the S-beads are
affected by nonspecific interactions.
To be adopted within a clinical environmental, assays for
PrPSC/C must have a limit of detection lower then demon-
strated in Fig. 3. To avoid the use of protein misfolding cyclic
amplification or other methods to amplify the target which
may increase the analysis times the direct extraction and pre-
concentration of the protein is proposed using SPB’s. Prior to
running a bioassay, it is not uncommon for samples to require
pre-concentration, purification or extraction stage. SPB’s offer
a simple, cheap and rapid method for extracting target ana-
lytes from complex media. From a user’s perspective it is
nothing more than a simple procedure of mixing the sample
with a SPB’s followed by the exposure of the tube to a magnet
that precipitates the target-particle complex to the tube wall,
thus removing the analyte from solution. However, there is a
need to balance and consider the size of the SPB, their concen-
tration and the time the magnetic field is applied. The size of
the SPB, or the loading of iron oxide nanomaterial within the
polymer affects the speed in which they move across the mag-
netic gradient. The force acting on each SPB is proportional to
their size, put simply larger particles are extracted quicker.
However larger particles have a smaller surface area to volume
ratio, and as the total amount of analytes that can be extracted
is proportional to the surface area, sufficient numbers of SPBs
must be added increasing the cost of the reagents. In addition
the concentration of the SPBs also affects the recovery and
speed of extraction from the solution as SPBs tend to form
chains as they move via magnetophoresis through the solu-
tion. Again showing the benefit of higher particle concen-
trations i.e. the increased surface area and the faster recovery.
Fig. 5 shows the speed of recovery for two particle sizes at two
different concentrations.
To fully extract any analyte from solution sufficient time
and number of SPB’s are needed. However, the requirements
for an efficient extraction and pre-concentration step contra-
dict the requirements for RPS analysis. The dynamic range,
and sensitivity of assay strategies that use SPB’s and aptamers
in RPS has been shown to be dependent upon the number of
Fig. 5 Separation efficiencies for 300 nm and 1000 nm particles are
different concentrations, error bars shows the st. dev of triplicate experi-
ments. Plotted are bars for the 1 μm particles but the variation in
measurements was low and is not visible on the graph.
Fig. 4 (A) Plot of normalised 1/T0.5 values for DNA aptamer modified SPBs incubated with three abundant blood proteins: IgG, albumin and fibrino-
gen at 200 nM. Data normalised to DNA aptamer SPBs with no protein present. n = 3; error bars represent 1× SD. (B) Rate plot of DNA aptamer
modified SPBs incubated with IgG – green, albumin – red, and fibrinogen – blue at 200 nM, black is the rate of DNA aptamer modified SPBs with no
protein present events for each dataset >400.
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SPBs present as well as the loading of aptamers on their
surface.16,23 Briefly RPS is improved by smaller particles, with
lower numbers of aptamers on their surface. To get around
this and to use the full work flow to show the concept as
shown in Fig. 1 we used a higher concentration of SPBs to pre-
concentrate the protein, P-beads, before eluting the targets
from their surface and adding fewer S-beads into a smaller
volume of buffer. Fig. 6 shows the velocity of the SPBs at
different stages of the workflow. To aid the reader we have
taken a section of Fig. 1 and overlaid the points at which the
SPB’s were characterised.
Due to the nature of the RPS device, particles with dia-
meters equal to and larger than 1 μm do not have a velocity
proportional to their surface charge. To demonstrate the feasi-
bility of our approach the P-beads here are the same size as
the S-beads to allow the binding and elution of the prion from
the P-beads. Fig. 6i shows the velocity of the P-beads prior to
incubation with the sample, Fig. 6ii shows a decrease in vel-
ocity due to the binding of the PrPC to the P-bead. Fig. 6iii is
the velocity of the P-beads after the PrPC has been eluted. The
velocity almost returns back to its original value indicating
that the recovery rate of the PrPC is high. Fig. 6iv shows the vel-
ocity of the S-beads after incubation with the solution contain-
ing the extracted PrPC. The velocity decreases showing the
elution process confirming that the use of high ionic strengths
has not effects the protein and it retains its binding to the
aptamer. Using this concept, we were able to detect 50 pmol of
PrPC from 1 mL of sample comparable to other detection
techniques.12
Conclusion
Here we present a rapid assay using aptamers and resistive
pulse sensing, RPS, to extract, pre-concentrate and quantify
proteins from complex sample matrices. The binding of PrPC
to aptamer modified SPB’s results in a change in translocation
velocity through the RPS device. The signal is specific to the
target protein. Aptamer modified SPBs, were then used to
extract and pre-concentrate PrPC from a larger sample volume.
The elution of PrPC from the P-beads before the addition of
S-beads results in an improved limit of detection. The process
is done in under an hour and allows the detection of pico-
moles of target protein. The technique could be easily adopted
to the mutated version of the protein (PrPSC) and integrated
into clinical workflows for the screening of blood donations
and transfusions.
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Rapid Assessment of Site Specific DNA Methylation through
Resistive Pulse Sensing
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ABSTRACT: Many diseases are defined by patterns of DNA methylation which result in
aberrant gene expression. We present a rapid assay based upon resistive pulse sensing, RPS,
to characterize sequence specific DNA methylation sites in genomic DNA. We modify the
surface of superparamagnetic beads, SPBs, with DNA (capture probe). The particles are
added to solution where they bind to and extract sequence specific DNA (target DNA). The
target loaded SPBs are then incubated with antibodies which bind to the methylation sites,
and the velocity of the SPBs through the nanopore reveals the number and location of the
epigenetic markers within the target. The approach is capable of distinguishing between
different methylation sites within a DNA promoter region. Crucially the approach is not
dependent on accurate sequencing of assayed DNA, with genomic regions targeted through
complementary probes. As such the number of stages and reagents costs are low and the
assay is complete in under 60 min which includes the incubation and run times. The format
also allows simultaneous quantification of number of copies of methylated DNA, and we
illustrate this with a dose response curve.
KEYWORDS: nanopore, resistive pulse sensor, epigenetics, methylation, bioassay
One of the most challenging goals in modern bioscienceremains: how can we understand disease through analysis
of biological variation? In the post genomic era, quantitative
bioscience has been dominated by seeking the answer through
analysis of genomic and transcriptomic variation. This arises
not from an ad hoc understanding of the pre-eminence of these
components, but rather the relative ease, scope and reliability of
the underlying measurements. As our repertoire of quantitative
tools expands and improves, so does our understanding of the
role of metabolomic,1 proteomic,2 and epigenetic3 dysregula-
tion in disease.
The role of DNA methylation has been shown to be
fundamental to many processes including aging,4 exercise and
cancer.3 In fact, cancer specific DNA methylation patterns have
been observed across many tumors.5 Despite the potential
utility of methylation assays their adoption in the clinic and the
lab has been far from absolute due to inherent challenges.
Methods for measuring DNA methylation often rely on
chemical modification through bisulfite treatment.6 Treatment
of cytosine with bisulfite leads to conversion to uracil, a
reaction that is prevented in 5-methylcytosine. The modified
base (or lack thereof) can be identified through sequencing or
hybridization of sequence specific primers and subsequent PCR
amplification. Many problems arise with bisulfite conversion
and subsequent assay, including DNA degradation, reaction
byproducts leading to alternative modifications, a requisite for
large sample quantities, PCR bias, etc.7
Recent studies have demonstrated the potential of solid state
nanopores in identifying DNA methylation sites.8−10 By
binding MBD (methyl binding domain) proteins to 5-
methylcytosine sites, they were able to observe a 3-fold
increase in ionic blockage current relative to unmethylated
DNA. The technique avoids the need for bisulfite conversion
and its inherent problems, yet requires detailed sequence
analysis on the nanopore platform.
Tunable resistive pulse sensing (TRPS) is a solid state
nanopore technique based upon the Coulter principle.11,12
Such technologies have been applied to the characterization of
biological and nanomaterials.11,13−17 We have previously
demonstrated the capacity of the technique to quantify DNA
protein interactions, in the form of a bound protein biomarker
to a DNA aptamer.18−21 In the assay DNA was conjugated to
superparamagnetic beads, SPBs, creating a negatively charged
surface. Protein binding to this DNA changes the charge
density around the particle and consequently reduces its
velocity as it traverses the nanopore. The decrease is
proportional to the concentration of protein in solution.
Rassf1a is a tumor suppressor gene, repression of which has
been associated with a range of cancers.22 Hypermethylation of
CpG islands in the promoter of Rassf1a is prognostic of its
dysregulation, with degree of methylation inversely correlated
with gene expression.23 We assess the ability of TRPS to
determine the level of methylation in a proportion (54 bases)
of the promoter region of Rassf1a. Anti-5-methylcytosine
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antibody (an antibody that specifically binds methylation sites
in single stranded DNA) is bound to the promoter (target),
which is anchored to a nanoparticle through a complementary
(capture) probe. Measuring the degree to which the DNA
charge is shielded by the antibody will determine the level of
methylation. Crucially the assay negates the requirement of the
pore to sequence the DNA, with specific genomic regions
targeted through hybridizaton to complementary probes.
The aim is to produce a rapid, reliable assay for methylation,
with applications ranging from the clinic to the farming
industry.24 We find the assay is highly sensitive in
discriminating between methylated and unmethylated sequen-
ces. In addition methylation sites at different points in the
sequence could be distinguished in the ion blockage profiles of
the nanoparticles as they traversed the pore. The assay also
correlates particle velocity with number of methylations sites in
the promoter region, where by the presence of single or double
epigenetic markers can be identified. The number of
methylated target DNAs in solution allows a dose response
curve for the quantification of methylated DNA in solution over
2 orders of magnitude.
■ EXPERIMENTAL SECTION
Chemicals and Reagents. A 54 base region from the Rasf1a
promoter sequence from chromosome III of the human genome was
selected (5′-GG[met1-C]CCGCCCTGTGGCCCCG[met2-C]CCG-
GCCCGCGCTTGCTAGCGCCCAAAGCCAGCGA-3′); this is to
simulate the product of a restriction enzyme digest. A 30 base capture
probe complementary to the Rassf1 promotor sequence was purchased
from Sigma-Aldrich Chemicals with a 5′ biotin tag and 5T linker
(biotin-TTTTTTCGCTGGCTTTGGGCGCTAGCAAGC). In addi-
tion four variations of the Rassf1a promoter, unmethylated
ControlDNA, 5′ single methylation (at site met1-C above EndDNA),
3′ single methylation (site met2-C MiddleDNA), and double
methylation (sites met1-C and met2-C DoubleDNA), were also
purchased in lyophilized powders with RP1 purification from Sigma-
Aldrich Chemicals (UK). Anti-5-methylcytosine antibody at 1 mg/mL
(ab73938) was purchased from Abcam, UK. The concentration of the
antibody was verified using UV−vis spectroscopy (Nanodrop 2000,
ThermoFisher Scientific). Using the average MW of the antibody
(970 000 g/Mol) the number of antibodies per unit volume could be
established and used for ratio calculations. Water purified to a
resistivity of 18.2 MΩ cm (Maxima) was used to make all solutions.
Phosphate buffered saline (PBS, P4417 (1× PBS tablet (0.01 M
phosphate buffer, 0.0027 M potassium chloride, 0.137 M sodium
chloride) in 200 mL of deionized water (18.2MΩ cm)) was purchased
from Sigma-Aldrich (UK) and used unmodified through the
experiment. Carboxylated polystyrene beads, denoted as CPC200,
with a mean nominal diameter of 210 nm and stock concentration of
1 × 1012 particles/mL, were purchased from Bangs Laboratories, USA
and used as a concentration calibrant at 2 × 109/mL. Prior to use the
beads were vortexed for 30 s and sonicated for 1 min to ensure
monodispersity.
Preparation of SPB. Streptavidin coated beads (120 nm,
Ademtech 03211) were used and functionalized with the biotin
labeled capture probe with the Rassf1a promoter sequence as follows:
Equal volumes of oligonucleotides, corresponding to 100% of the
beads binding capacity (calculated using the manufacturer’s specifica-
tion) of the streptavidin modified beads, were vortexed for 30 s prior
to heating to 95 °C for 5 min in a mini drybath (Benchmark
Scientific). The reaction mixture was vortexed again for 30 s and
allowed to cool to RT for 30 min on a rotary wheel before the addition
of beads. The mixture was placed on a MagRack (Life Science) for 10
min until a cluster of beads was visible. The solution was carefully
removed and replaced with an equal volume of PBS. The
concentration of beads was kept constant throughout all experiments
at 2 × 109/mL.
Concentration Analysis. Anti-5-methylcytosine antibody (a
pentameric IgM) was added to the DNA hybridized beads. The
ratio of antibodies to beads varied from 0 up to 3 orders of magnitude
of antibodies per bead. After the addition of the antibody the mixtures
were vortexed for 30 s and placed on a rotary wheel for 8 min and
prior to TRPS analysis the mixture was vortexed for 15 s and sonicated
for 5 s.
Dose Response. Full-Binding Capacity Experiment. The
concentration of Rassf1 was maintained at 100% relative to the
binding capacity of the beads, to which varied amounts of
complementary DNA equivalent to 0, 10, 20, 40, 60, 80, and 100%
of the bead’s binding capacity were added. The bound DNA sequences
were then hybridized to the beads as previously described. The
concentration of anti-5-methylcytosine antibody was maintained at 3
orders of magnitude relative to the bead concentration.
Half-Binding Capacity Experiment. Throughout this set of
experiments the Rassf1 concentration was kept constant: 50% of the
beads binding capacity. The bead binding capacity is calculated to be
half using the manufacturer’s specifications and assumed from previous
studies.21,25 The amount of complementary DNA varied from 0, 10,
20, 30, and 40% of the beads binding capacity. As previously described
the bound DNA was hybridized to the beads with the concentration of
anti-5-methylcytosine antibody maintained at 3 orders of magnitude
relative to the bead concentration.
TRPS Analysis. TRPS was performed using the qNano system
purchased from IZON Science (New Zealand). The technique uses
elastomeric tunable nanopores with Izon’s own data capturing software
Izon Control Suite (V3.1.2.53). NP200 pores were used, suitable for
analyzing beads between 85 and 500 nm (stated by the manufacturer).
An appropriate stretch and voltage were applied throughout so that
the blockades of CPC200s in PBS were at least 0.5 nA above the
background noise; a measure to account for the variations in pore
manufacturing. The operation of the qNano is described else-
Figure 1. Schematic of the assay. (A) Biotinyated capture probe is incubated with the target DNA. (B) Streptavidin coated SPBs capture the DNA.
(C) Antibody is added to the solution. (D) Depending upon the target DNA present the SPBs have (i) Capture DNA, (ii) unmethylated Target
DNA, (iii) single methylated site (MidDNA), (iv) single methylation (EndDNA), or (v) two methylation sites (DoubleDNA). (E) The velocity of
the particles through the RPS reveals which target is present.
ACS Sensors Article
DOI: 10.1021/acssensors.7b00935
ACS Sens. 2018, 3, 655−660
656
where12,18,26 but briefly: the lower fluid cell was filled with 75 μL of
PBS, ensuring no air bubbles are present and the upper fluid cell
contained 40 μL of the sample. After each measurement, the sample
was removed from the upper fluid cell and replaced with PBS. This
was repeated several times, applying varying amounts of pressure and
vacuum, until visible blockades were no longer observed. Samples were
replicated in triplicate, unless stated with H15 estimates of the mean
reported and used for normalization.
Calculating the Particle Velocities. The method used the
resistive pulse to calculate the relative velocity, and identifies the point
of greatest resistance in the signal trace (the resistive blockade peak).
For each blockade, the time at which the peak occurs is defined as T1.0
(time at 100% of peak magnitude) and the maximum magnitude of the
pulse (relative to the local baseline resistance) is recorded as dRmax.
Here the value at T0.5 (width of the pulse at 50% of the peak
magnitude is used).25,27 To keep the method simple and applicable in
further applications, the actual zeta potential of the particle is not
calculated, and for further simplicity in the subsequent figures we use
only one measurement to represent the particle speed which is 1/T0.50.
■ RESULTS AND DISCUSSION
The outline for the assay is shown in Figure 1. Here a
synthesized target is used, however it should be noted the
concept can be adapted to any working assay where the
genomic DNA is first extracted and digested prior to analysis. A
biotinylated capture probe is added to the DNA sample (Figure
1A). The capture probe was designed to be a perfect
complement to a flanking region of the Rassf1a gene where
the methylation is known to occur. The mixture was heated to
95 °C for 5 min to denature the target DNA. The mixture was
then allowed to cool to RT for 30 min allowing the biotinylated
probe to hybridize to its target. Streptavidin coated super-
paramagetic beads, SPBs, were then added to the solution,
mixed for 5 min (Figure 1B), and extracted using a magnetic
rack before being finally placed into PBS buffer. During this
extraction, the aim was to allow the SPBs to bind the
biotinytated capture DNA along with the hybridized target
DNA (Figure 1D).
The concentration of SPBs added to the solution was
adjusted such that their total binding capacity was equal to the
concentration of biotinylated DNA. This results in the
extracted SPBs always having a coating of DNA even in the
absence of target DNA (Figure 1Di). We have recently shown
how the length and concentration of single and double
stranded DNA on SPBs can be monitored using TRPS.26 We
utilize the same concept and signal transduction mechanism
here. In summary the binding of DNA to the SPBs results in
the zeta potential of the particles becoming more negative. The
change in zeta potential is measured by monitoring the
translocation velocity of the particles through the pore, and
measured via the full width half-maximum, fwhm, (Figure 1E).
Increasing the number of DNA molecules or the length of the
sequence around each SPB results in an increase in zeta
potential, inferred by an increase in 1/T0.5, i.e., more negatively
Figure 2. Left: Plot of 1/T0.5 versus frequency for SPB modified with no DNA, curve A (blank). Capture probed modified DNA (ssDNA), curve B,
and SPBs with target DNA, curve C (dsDNA). Right: Same data visualized as box-whisker plots. Events for DNA type and blank beads > 500.
Figure 3. (A) Normalized 1/T0.5 values as a function of antibody per SPB. The ratio of SPBs/antibody was varied for all four types DNA used to
determine methylation site. Magenta shows data for ControlDNA, in which no methylation is present; green represents EndDNA; red MiddleDNA;
and blue the doubly methylated DoubleDNA. (B) Translocation velocities distributions taken from 1/T0.5 of the four DNA types. The ratio of SPBs/
antibody is constant at 3 orders of magnitude more antibodies per SPBs, with the concentration of capture DNA and target equivalent to 100% of
the SPBs binding capacity. Black distributions represent when no antibody is present. Events for each data point > 400.
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charged particles move through the pore quicker. An example
of this is shown in Figure 2. The relative velocity of the particles
is then plotted as the reciprocal of T0.5 and shown for
streptavidin SPBs (blank), capture probe modified SPBs
(ssDNA), and target probe modified SPBs (dsDNA). The
relative order of the velocity of the three particles shows that
the target DNA is faster than capture probe only, and the
slowest particles are the blank SPBs.
Here we do not convert the translocation velocities into zeta
potential values, as it is not required and adds an extra stage
within the calibration. Monitoring the relative change in
velocities of the particles is sufficient to determine the presence
of the DNA.
Having captured the target DNA, the next stage was to assess
if the methylated bases within the target DNA could be
identified. Two samples were prepared: the first was a target
DNA with no methylation makers, and the second with a single
methylation point approximately halfway within the sequence
(MidDNA) Figure 1Dii and iii, respectively. The anti-methyl
antibody was incubated with the SPBs, and if epigenetic
markers are present, they should bind to the DNA. We have
recently demonstrated how the TRPS system can monitor
protein−DNA interactions and is the basis for many aptamer
based sensors. The binding of the antibody to the DNA
changes the charge density around the particles and results in a
change in particle velocities.18,20,21,28 A decrease in velocity
(with respect to a positive bias below the pore) is thought to be
due to several parameters. Changes to the DNA structure as it
binds the protein may require an increased number of
counterions to stabilize any tertiary structure; second, the
protein’s pI is between 6 and 7.4 and therefore has a net (and
slight) positive charge for the pH used in the experiment, which
can counter the charge on the DNA backbone. In addition, the
binding of the protein (even if in a net neutral charge state) to
the DNA will disrupt the double layer structure and affect the
electrophoretic velocity.
To test this hypothesis and to optimize the amount of
antibody required, we titrated differing bead/antibody ratios
shown in Figure 3A (and Figure S1). For the methylated
sample, as the number of antibodies per bead increases from 0
up to 3 orders of magnitude (∼1:1000), the particle velocity
decreases as they bind to the DNA. While there is a selective
interaction between the antibody and methylation site, there
will be some nonspecific interactions between the antibody and
DNA. Thus, at the larger concentrations of antibody, we
attribute the change in velocity for the nonmethylated DNA to
nonspecific interactions between the IgM and the DNA/beads
surface. It should also be noted that while the binding of the
antibody changes the relative velocity of the particle, we do not
observe within the current setup a change in particle volume.
We repeated this experiment using target DNA which
contained a single methylation site at a different location
further from the bead surface (EndDNA), Figure 1Div, and a
target DNA which contained two methylation sites (Double-
DNA), Figure 1Dv. Similar trends were observed; i.e., as the
antibody number increased, the particle velocity decreased at a
rate much higher than the control. It should be noted that in no
case did we see particle aggregation, and the particle size
distribution plots are given in Figure S2. In the presence of
nonspecific interactions taking place at higher antibody
numbers, it was concluded that a ratio of 3 orders of magnitude
more antibodies to bead was a suitable ratio to proceed with
further experiments.
We hypothesized that the location at which the antibody
bound to the DNA, i.e., if the methylation site was in the Mid,
End, or Double, may result in different magnitudes of velocity
change helping identify the location of the methylation site.
However, as can be seen in Figure 3B, the mean velocity change
and distribution of velocities for hundreds of particles are
similar in this design of the experiment.
From the above experimental design, the presence of the
epigenetic marker could be easily identified. To quantify the
number of DNA copies in solution which contained these
markers, we prepared a dose−response curve. To demonstrate
this, we chose the MidDNA. In this experiment, the number of
SPBs, the concentration of capture DNA, and the antibody
ratio were kept constant. The concentration of target DNA was
varied, and the results shown in Figure 4A. The dose response
curve shows a change over 2 orders of magnitude. As the
number of target DNA increases the velocity of the particles
decrease. At lower concentrations of target DNA, most of the
SPBs surface is covered with biotinylated capture probe, and as
it does not bind to the antibody its negative charge dominates
the particles velocity. To improve the sensitivity of the dose−
response curve at lower concentrations of target DNA, we
lowered the number of capture probes to be ca. 50% of the
binding capacity of the beads, i.e., keeping every other
parameter the same as Figure 4A but the concentration of
the capture probe was halved. The ratio of the bead
concentration, binding capacity, capture probe capacity, and
numbers of antibodies are given in Table 1.
As can be seen in Figure 4B, halving the capture probe
concentration resulted in a sharp decrease in velocity of the
SPBs and the concentration of target DNA was increased from
0 to 119 nM. The dynamic range of this assay is lower than that
in Figure 4A as the beads can only capture half the
concentration of target DNA, and at concentrations above
47.6 nM there was no further decrease in velocity. Owing to the
rapid change in velocity for the lower concentrations of capture
probe, we again measured the 1/T0.5 for the Mid, End, and
DoubleDNA targets to see if their relative velocities differ-
entiated. Table 2 shows the change in velocity for the same
concentrations of SPB, antibody, and target DNA for the
different variations of epigenetic target DNA.
Figure 4. Concentration of beads was kept constant at 2 × 109/mL.
(a) Concentration of capture probe is 100% relative to the binding
capacity of the bead. The concentration of target EndDNA was varied
from 0% to 100%, relative to the binding capacity of the bead. (b)
Concentration of capture probe is 50%, relative to the binding capacity
of bead. Again the concentration of target EndDNA was varied from
0% to 40% of the beads binding capacity. Events for each data point >
500.
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Table 2 shows that the largest change in velocity was
observed for the double methyl target, followed by the end and
middle. At the lower concentrations of capture probe, the
relative velocity of the beads allows differentiation of the
location of the epigenetic marker. At these lower concen-
trations of capture probe, the average distance between
neighboring DNA on the SPB’s surface increases, and this
may allow the antibody−DNA to adopt a different structure/
bind easier than in the fully packed SPB experiment. Although
it should be noted that the middle methylation target still
shows a change in velocity and thus binding to the antibody
must still take place.
■ CONCLUSION
We demonstrate the characterization of methylated DNA
sequences through TRPS. The process allows for the rapid
quantification of epigenetic markers with insight into the
location of the marker within the target. The capacity of the
technique to quickly and reliably quantify nucleic acid−protein
interactions presents a platform for the potential analysis of
polysome gradients (translation rate), RNA methylation (anti-
5-methylcytosine also binds methylated RNA), protein
phosphorylation, and histone acetylation. This is in addition
to previous studies that have demonstrated the ability of TRPS
to quantify SNPS, microvesicles, protein biomarkers, and so
forth. TRPS is a burgeoning technology that lends itself to
multiomic analysis, and we highlight its application in the
characterization of methylation sites within DNA. Further
optimization of the approach may yield a multipurpose tool for
the clinic capable of analyzing biological variation beyond the
scope of current technologies.
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Abstract The zeta potential of the protein corona around car-
boxyl particles has been measured using tunable resistive
pulse sensing (TRPS). A simple and rapid assay for character-
ising zeta potentials within buffer, serum and plasma is pre-
sented monitoring the change, magnitude and distribution of
proteins on the particle surface. First, we measure the change
in zeta potential of carboxyl-functionalised nanoparticles in
solutions that contain biologically relevant concentrations of
individual proteins, typically constituted in plasma and serum,
and observe a significant difference in distributions and zeta
values between room temperature and 37 °C assays. The effect
is protein dependent, and the largest difference between the
two temperatures is recorded for the γ-globulin protein where
the mean zeta potential changes from −16.7 to −9.0 mV for 25
and 37 °C, respectively. This method is further applied to
monitor particles placed into serum and/or plasma. A
temperature-dependent change is again observed with serum
showing a 4.9 mV difference in zeta potential between sam-
ples incubated at 25 and 37 °C; this shift was larger than that
observed for samples in plasma (0.4 mV). Finally, we monitor
the kinetics of the corona reorientation for particles initially
placed into serum and then adding 5 % (V/V) plasma. The
technology presented offers an interesting insight into protein
corona structure and kinetics of formation measured in bio-
logically relevant solutions, i.e. high protein, high salt levels,
and its particle-by-particle analysis gives a measure of the
distribution of particle zeta potential that may offer a better
understanding of the behaviour of nanoparticles in solution.
Keywords Biosensor . TRPS . Zeta potential . Protein
corona . Tunable pores
Introduction
In recent years, synthesis methods for nanoparticles have
evolved to the extent that particle size, shape and composition
can be easily modified [1–4] and this had led in turn to great
advances in the field of diagnostics [5, 6], drug delivery [7–9]
and technology platforms [10, 11]. With the desire to under-
stand and improve nanomaterials comes a need for character-
isation platforms to offer rapid analysis of size, charge and
shape. Ensemble techniques that take measurements on sev-
eral particles simultaneously and provide an average measure-
ment can underestimate subpopulations within multimodal
samples [12, 13], and a raft of technologies have appeared to
help tackle this [14, 15]. Such technologies now offer an abil-
ity to quantify the population of particles with single particle
resolution building an understanding that not all particles are
created equal and there exists distributions such as particle
size or ligand density.
One such technology is based on the Coulter Counter
principle, referred to as resistive pulse sensing (RPS)
[16–18]. The technique allows the characterisation of proteins,
inorganic ions, colloids and nanoparticles within their natural
environment. Two categories of resistive pulse sensors exist
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that utilise either biological [19, 20] or inorganic nanopores
[21–23]. Here, we describe a recent adaptation to inorganic
pores that uses a tunable elastomeric pore termed tunable re-
sistive pulse sensing (TRPS) [14, 24–36]; the pore can be
stretched in real time to suit the sample. The brief setup and
theory for TRPS technologies is as follows: A stable ionic
current is established by two electrodes, separated by a pore;
as particles/analytes translocate the pore, they temporarily oc-
clude ions, leading to a transient decrease in current known as a
‘blockade event’, examples of which can be seen in Fig. 1. In
the TRPS arrangement used here, the pore is mounted laterally
so that particles typically move from the upper fluid cell into
the lower fluid cell, aided by an inherent pressure head due to
40 μl of liquid in the upper fluid cell of approximately 50 Pa
[35]. By monitoring changes in blockade width, blockade
magnitude (Δip) and blockade frequency (events/min), it is
possible to elucidate the zeta potential, size and concentration
of colloidal dispersions in situ [14, 37, 38]. By controlling the
aspect ratio of the pore, resistive pulse sensors have been used
to measure analytes that range from single molecules, DNA,
proteins, cellular vesicles to cell bacteria and viruses; detailed
reviews on the types of analytes and applications can be found
elsewhere [24, 36, 39, 40]. TRPS is becoming an increasingly
common variation of RPS for the characterisation of biological
and inorganic nanomaterials [24, 36] and since its conception
has been tested against alternative technologies such as DLS/
PALS [14, 15, 41–44], TEM [33], and ultracentrifugation [44]
for the characterisation of nanomaterials [15, 45].
The how and where of measuring the properties of particles
are important to consider as changing pH, ionic strength or
temperature, or purifying particles can give a misrepresenta-
tion of their behaviour in their natural environment. In the case
of nanomaterials that are intended to be used in vivo, it is not
properties within synthesis processes that determine their bio-
logical activity, but how they interact with proteins upon en-
tering the body. Upon the addition of nanoparticles to biolog-
ical fluids, there is an almost immediate fouling of their sur-
faces with proteins, peptides and other cellular apparatus
forming a layer known as the protein corona [46–48]. The
composition of the corona has been shown to determine the
eventual properties of the particles [49–51] and has been re-
ported as critically affecting pathophysiological effects of
nanoparticles [52]. The structure of the protein corona can
be dynamic and complex and is different for particles of the
same composition but with different surface chemistries and
size in the same solution [46, 53]. Detailed studies of the
corona have been performed using an array of technologies
including mass spectroscopy [54, 55]. Various techniques
have been used to look at a range of specificities of protein
coronas, for example, protein corona thickness has been in-
vestigated using ensemble techniques such as dynamic light
scattering (DLS) and differential centrifugal sedimentation
Fig. 1 Particles in the presence of
human plasma and serum
showing the formation of both a
‘hard’ and ‘soft’ protein corona.
I1.0, I0.8, I0.6, I0.4, I0.2 represent the
position of the particle as it
translocates the pore (where I1.0 is
the narrow pore entrance) and are
relative to T1.0, T0.8, T0.6, T0.4,
T0.2, which represent the time
taken (ms) for the particle to reach
that position. T1.0, is equivalent to
dRmax when the blockade event is
at 100 % magnitude; T0.8, T0.6,
T0.4, T0.2, correspond to when the
blockade is 80, 60, 40, and 20 %
of its dRmax and indicates the
particle traversing the pore
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(DCS) [49, 56]. Protein corona conformation has been studied
using circular dichroism (CD) and fluorescence quenching [57,
58]; the affinity has also been a popular characterisation pro-
perty of protein coronas and has previously been measured
using size exclusion chromatography (SEC), surface plasmon
resonance (SPR) and isothermal calorimetry (ITC) [49, 56,
59]. A frequent and easy value used to characterise the corona
is zeta potential [46, 48, 50, 54, 60]. The zeta potential repre-
sents the value of the electrostatic potential at the plane of
shear, and typically for nanoparticle systems, zeta potential
values of ±30 mVare representative of stabilised particles [61].
When nanoparticles are introduced to biological fluids, the
protein corona is formed in a series of layers, otherwise known
as the ‘hard’ and ‘soft’ corona. Proteins forming the hard
corona are those with a higher affinity that interact directly
with the nanoparticle surfaces, whereas proteins forming the
soft corona are those engaging in weaker protein–protein in-
teractions with the hard corona [56, 62]. It has previously been
found that a vast range of particles bind successfully to apoli-
poproteins in physiological fluids [55]. Formation of a protein
corona alters the size, aggregation properties and surface
properties of nanoparticles [63], thus creating a new biological
distinctiveness for further application. There are 5 main com-
ponents that define the composition of a protein corona: thick-
ness and density, identity and quantity, orientation, conforma-
tion and affinities [63].
Protein adsorption kinetics play a prominent role in this
study and are key to understanding the binding mechanisms
that will occur in a natural environment. Although this process
is time-dependent, the kinetics rely on kon and koff parameters,
indicating the rate constants for adsorption and desorption of
proteins. kon is largely dependent on how often the protein
contacts the nanoparticle surface, as well as the probability
of successful binding between the two materials [64]. The
strength of the protein–nanoparticle interaction defines koff
[64], and a strong, high-energy interaction will exert a low koff
value. Understanding the kinetics of formation and protein
corona composition is important to understand processes
nanoparticles may undertake when introduced into the body
and into physiological conditions.
Here, we present a protocol for the rapid analysis of the
corona zeta potential and demonstrate its versatility bymaking
the measurement in solutions that mimic the natural environ-
ment, i.e. high ionic strength and high protein composition.
By making comparable measurements of carboxyl polysty-
rene nanoparticles in a range of incubation temperatures and
with different proteins, a clear difference in magnitude and
variation of zeta potential within the particle population was
observed; the three proteins chosen to demonstrate this are the
most predominant (in terms of quantity) proteins in normal
human plasma and we perform the experiment concentrations
that would reflect normal plasma. The ability to have individ-
ual particle resolution provides an opportunity to see the full
variation of zeta potential in a single sample. The findings
highlight the need to monitor the protein corona and its for-
mation at biologically relevant temperatures and suggest that
the kinetics of protein adsorption and spread in zeta potential
values varies for each of the proteins and biological mediums
studied. Finally, we show the scope of the technology by
monitoring the change in the hard and soft corona elements
interacting with the particles through incubation in serum,
followed by the addition of a small amount (5 % (V/V)) of
plasma. It is known that protein components of a higher con-
centration or affinity to the particle can remove and restructure
the soft corona that is formed in biological fluid [55], and we
monitor the rate of this change and the kinetic effects that
eventually settle on a new zeta potential value.
Materials and methods
Chemicals and reagents
The initial buffer used for particle analysis was phosphate
buffered saline (1× PBS tablet (0.01 M phosphate buffer,
0.0027 M potassium chloride, 0.137 M sodium chloride) in
200 mL deionised water (18.2 MΩ cm)). PBS tablets (P4417)
were purchased from Sigma-Aldrich, UK.
Carboxyl polystyrene standards
Carboxylated polystyrene particles, denoted as CPC200, with a
mean nominal diameter of 210 nm and stock concentration of
1 × 1012 particles/mL, were purchased fromBangs Laboratories,
USA and used as a calibrant for zeta potential analysis, as well
as the sample particles. CPC200s were vortexed for 30 s follow-
ed by a 2 min sonication to ensure monodispersity prior to any
TRPS analysis or sample incubation.
Isolated proteins
All isolated proteins studied were purchased from Sigma-
Aldrich, UK, without modification or purification unless stat-
ed otherwise: fibrinogen from human plasma (F3879), albu-
min from human serum (A9511) and γ-globulin from human
blood (G4386).
Human plasma and serum samples
Blood samples were collected and prepared at Peterborough
City Hospital Pathology Laboratory, UK. Plasma collection
was completed using blood from a healthy volunteer donor
that was collected in citrate medium (Sarstedt, UK.) and cen-
trifuged at 3000 rpm for 8 min. Serum was gathered using
blood from a healthy volunteer donor that was collected into
a Sarstedt monovette/collection tube, and was centrifuged at
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3000 rpm for 6 min. The supernatants from each sample were
transferred into separate sample vials and stored at room tem-
perature prior to use.
Isolated protein studies
Using PBS buffer, isolated albumin, fibrinogen and γ-
globulin samples were prepared to give the following concen-
trations: 43, 3.2 and 20 g/L, respectively, as to mimic protein
concentrations found in human blood. The concentrations of
proteins were measured from human plasma and serum sam-
ples. The samples used in this study were analysed by an
Instrument Laboratory ACL TOP CTS500 coagulation
analyser (Werfen, Spain) to obtain the fibrinogen concentra-
tion. Albumin and immunoglobulin levels were taken from
test serum samples that were analysed by a Roche Cobas
Biochemistry Analyser (Roche Diagnostics, Switzerland).
CPC200s were added resulting in a final concentration of
1 × 1010 particles/mL. Each sample was vortexed for 30 s
and sonicated for 1 min before incubation. Samples were then
incubated at 25 and 37 °C in a mini dry bath (Benchmark
Scientific, USA) for 10 min prior to TRPS analysis.
Serum and plasma studies
Human plasma and serum were prepared immediately before
the experiments to minimise ex vivo artefactual changes. The
prepared plasma and serum were separately diluted 10-fold
with PBS before CPC200s were added to both samples
resulting in a final particle concentration of 1 × 1010 parti-
cles/mL, herein these solutions are referred to as serum and
plasma. Samples were vortexed for 30 s and sonicated for
1 min, followed by incubation in a mini dry bath
(Benchmark Scientific, USA) at 25 and 37 °C for 10 min
before being removed for TRPS analysis. It should be noted
that it is possible for some proteins in human plasma and
serum to interact and adsorb onto the pore walls; therefore, a
control measurement of CPC200s in PBS (of known zeta po-
tential, -20 mV) was completed before and after each protein/
plasma/serum sample to establish if any changes had occurred
to the pore itself.
Plasma spiking assay
Human serum was 10× diluted in PBS before CPC200s were
added to a final concentration of 1 × 1010 particles/mL.
Samples were vortexed for 30 s and sonicated for 1 min before
being incubated for 10 min at 25 and 37 °C in a mini dry bath
(Benchmark Scientific, USA). At 10 min, 5 % (V/V) human
plasma was added to the serum samples and the samples were
vortexed for 30 s. TRPS measurements were completed once
the plasma had incubated with the serum sample for 5, 10, 15,
20, 30 and 60 min.
Tunable resistive pulse sensing
All measurements were completed using the qNano (Izon
Science Ltd, NZ). The system utilises tunable nanopores with
propriety data capturing software (Izon Control Suite
v3.1.2.53). In all experiments, the lower fluid cell contained
80μL of PBS buffer, ensuring no bubbles were present.When
a sample measurement was being taken, the upper fluid cell
contained 40 μL of the sample (suspended in PBS buffer).
After each measurement was taken, the nanopore was washed
several times by removing and replacing 40 μL of buffer, each
time applying varied pressures until no particles were ob-
served. This was performed several times to remove any re-
sidual particles in the system and thus ensure no cross-
contamination between samples. The nanopores used
throughout all experiments were capable of detecting particles
within the size range of 100–300 nm (as stated by the manu-
facturer, Izon Science Ltd) and denoted as an NP200. To ac-
count for the variation in the manufacturing of the nanopores,
appropriate stretch (44–46 mm), voltage and pressure were
applied in all experiments; the conditions were matched as
to the blockade magnitudes of CPC200s in PBS being of a
similar size throughout all experiments. All samples were
vortexed for 30 s and sonicated for 2 min prior to analysis.
Zeta potential measurements using TRPS
When carrying out zeta potential measurements, the nanopore
stretch was kept the same for a particular dataset and nanopore
between calibration and sample measurements. To calibrate a
nanopore for zeta potential analysis, the calibration particles,
of known size and zeta potential, were measured in PBS at 3
applied voltages; the particles measured at the highest voltage
were measured at 2 external pressures (in addition to the in-
herent 47 Pa pressure head on the system). When running the
samples, the blockade magnitudes were ensured to be at least
100× larger than the respective background noise of ca. 10 pA.
In accordance with the calibration runs, the samples were run
at the highest calibration voltage. Calibration measurements
were completed when a new nanopore (NP200) was intro-
duced to ensure conditions were matched so the blockade
magnitudes of CPC200s in PBS were of a similar size to other
NP200s used for this study. A CPC200 sample in PBSwas run
after each protein/plasma/serum sample to ensure the zeta po-
tential of the pore remained unchanged and as such did not
affect the measured zeta potential of further samples.
Results and discussion
Zeta potential values were determined from the particle veloc-
ities as they traversed the nanopore; a full description of the
protocol and theory can be found elsewhere [21, 38]. Briefly,
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the duration of particle translocation is measured as a function
of applied voltage, taking an average electric field and average
particle velocities over the entire sensing zone that is a regular
conical pore. Each particle’s electrophoretic mobility is de-
rived from 1/T, where T is the blockade duration and voltage,
multiplied by the square of the sensing zone length, L, as part
of a calibration constant. Figure 1 shows the conical sensing
zone and an example of the blockade duration times, T, as a
result of a blockade event at various positions, I, in the
nanopore. T1.0 for example is equivalent to when the blockade
is 100 % in magnitude and is indicative of I1.0, the position to
which the particle is approaching the pore entrance. T0.6 re-
lates to position I0.6 where the blockade is 60 % in magnitude
and the particle has traversed 40 % of the pore. It is important
to note each blockade depicted in the signal trace is indicative
of a single particle as it passes through the pore, highlighting
the advantages of using particle-by-particle technologies such
as TRPS.
Average velocities determined across multiple reference
points within the nanopore vastly reduce any errors in this zeta
potential calculation process [38]. The calibration of the pore
itself is based on a linear relationship between 1/Tand voltage,
V, at each blockade reference point. Equation 1 shows the
direct relationship between particle velocities and their zeta
potentials, vxð Þel Cal and vix
 
el Sample are the particle velocities
of calibration and sample particles, respectively, and ξnet Cal
and ξix net Sample represent their zeta potential values [38].
vix
 
el Sample
vxð Þel Cal
¼ ξ
i
x net Sample
ξnet Cal
ð1Þ
Equation 2 shows the zeta potentials measured at each of
the blockade reference points can then be used to determine
the zeta potential of each individual particle, i, as it passes
through the pore, ξiSample.
ξiSample ¼
∑xξ
i
x Sample
∑x
¼
∑x vix Sample−vPx Cal  P
 .
vVx Cal  V
 
∑x
 ξnet Cal þ ξm ð2Þ
Where vVx Cal,v
P
xCal, P and V are electrokinetic velocity per
unit voltage, convective velocity per unit pressure, applied
pressure and voltage, respectively. Ix is the position of the
particle in the nanopore after time t = Tx, vx Sample
i is the sum
of the particle velocities at relative positions, lx [38].
The proteins used in this study were chosen based on their
relative abundances in both blood plasma and serum samples.
Albumin and γ-globulin are present in both plasma and serum
samples at approximately 4 and 2 %, whereas fibrinogen (as
well as other clotting factors) is only found in plasma at ap-
proximately 0.4 %. Zeta potential values measured for parti-
cles incubated with each of the isolated proteins are shown in
Fig. 2 (for reference the starting zeta potential of a CPC200 in
PBS is −20 mV).
When the particles were incubatedwith each of the proteins
separately at 25 °C, both fibrinogen and γ-globulin showed a
relatively small change inmean zeta potential from particles in
PBS buffer, differences of 3.2 and 3.6 mV, respectively. The
size and zeta potential distributions of CPC200 carboxyl par-
ticles in PBS are shown in Fig. 3. Albumin was seen to have a
much larger effect on the particle zeta potentials at 25 °C as the
zeta values were reduced by 9.2 mV from the PBS control.
Albumin was at the highest concentration at 40 g/L in com-
parison to the fibrinogen and γ-globulin samples only having
protein concentrations of 4 and 20 g/L respectively. The pro-
tein concentrations were chosen to replicate the typical com-
position usually found in the human body, although it should
be noted that the concentration of proteins to that of the par-
ticles in each experiment was always in a large excess as to
coat each surface of every particle. The proteins were also
investigated at a constant concentration (5 g/L) at a 25 °C
incubation temperature for 10 min to determine whether pro-
tein concentration had an effect on the protein corona on the
particles, results of which are shown in the Electronic
Supplementary Material (ESM), Fig. S1. From this, it was
found that the relative change in zeta potential (from a control
of the particles just in PBS) was smallest for fibrinogen and γ-
globulin with values of 4.3 and 4.9 mV, respectively. The
largest change in zeta potential was again observed for the
albumin protein with a difference of 8.9 mV. These compara-
ble changes show the results are protein specific and not re-
lated to the concentration at these levels. It was therefore ex-
pected that the proteins would adsorb onto the particle surface,
forming the protein corona. Any such protein corona would
change the surface charge density on the particles and be mea-
sured by a change in particle velocity, which in turn is plotted
as the zeta potential. At 25 °C, the small zeta potential changes
for fibrinogen and γ-globulin samples are more than likely
because of the protein isoelectric points and their behaviour
at physiological pH. Albumin has an isoelectric point of 4.7
whereas fibrinogen and γ-globulin have isolectric points of
5.8 and 6.6, respectively [65]. Previous reports have found
that as the adsorption pH moves away from the protein
isolectric points, the adsorbed molecules will occupy a larger
area of the surface. This is due to internal electrostatic repul-
sions and thus a lower structural stability [66]. Our samples
were all suspended in PBS buffer at pH 7.4, and therefore, the
albumin is expected to occupy the largest area of the nanopar-
ticle surface as the adsorption is occurring at a pH furthest
from its isoelectric point. This may be the reason the albumin
shows the largest change in zeta potential after a 25 °C
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incubation in comparison to the smaller changes observed for
fibrinogen and γ-globulin (isoelectric points closer to 7.4).
Particles were also incubated with each of the proteins at a
higher temperature of 37 °C; it was hypothesised that as the
proteins are present in such a large excess that the incubation
time of 10 min would be enough to coat the particles with a
monolayer of protein, and that the temperature would have
little effect on the result. In contrast, at 37 °C, there were
significant differences from values at 25 °C and each protein
produced varying shifts in zeta potential values. At the elevat-
ed temperature, γ-globulin was seen to have the largest reduc-
tion in zeta potential from a value of −20.3 mV (particles in
PBS) to −9.0 mV. This is of particular interest as these results
indicate each protein interacts with the particle surface unique-
ly, having direct implications on the particle zeta potential. γ-
Globulin also showed the largest change in zeta potential as a
function of incubation temperature between 25 and 37 °C
(5.0 mV), whereas albumin showed the smallest change
(1.3 mV). The distribution of zeta potentials for each isolated
protein at 25 and at 37 °C are shown in the ESM, Fig. S2.
The particle-by-particle nature of TRPS allows for individ-
ual particles to be analysed, as well providing a measure of the
spread in values across the sample population. Figure 3 de-
picts the zeta potential versus particle size plots for the given
sample populations summarised in Fig. 2. Note here that each
data point in Fig. 3 is representative of a single particle.
Whilst the distribution of the values does not change as the
incubation temperature increases, the shift in mean zeta poten-
tial as the incubation temperature was significant. This shift
may be due to the affinities of the proteins for the particle
surface being affected by the incubation temperature.
Previous studies have found that negative particles have
Fig. 2 Mean zeta potential (mV) versus the protein the particles were
incubated with. The blue bars show results for a 10-min particle incuba-
tion at 25 °C and the red bars show the mean zeta potential values for
particles incubated with the proteins for 10 min at 37 °C. The green lines
represent the measured mean zeta potential for calibration particles of
known zeta potential (−20 mV) in PBS that were run after each protein
sample to show the protein samples were not having a direct effect on the
pore walls themselves that may influence the recorded zeta potentials of
future samples run on the same pore. Error bars are representative of the
st.dev where n = 3
Fig. 3 Zeta potential (mV) versus particle size (nm). The red, blue and
green datasets are zeta potential distributions for CPC200s incubated for
10min with fibrinogen, γ-globulin and albumin, respectively at (a) 25 °C
and (b) 37 °C. The black data points represent CPC200s in PBS for both
figure parts a and b
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maximum protein adsorption at 15, 35 and 37 °C [67] and
explain why the CPC200s incubated at 37 °C in each protein
medium shifted to a smaller zeta potential value more so than
those incubated at 25 °C. When proteins have a higher affinity
to the particle surface, there is either the formation of a robust
hard corona, or slower release of the proteins from the surface
once absorbed. The hard corona layer will alter the particle
surface chemistry and will result in a slower particle transloca-
tion velocity through the pore due to shielding of the negative
particle surface, which consequently results in a smaller zeta
potential value. Interestingly, at the 25 °C incubation (Fig. 3a),
the γ-globulin and particularly the fibrinogen sample showed a
wider spread of data than those samples incubated at 37 °C
(Fig. 3b). Figure 3b also shows that at elevated temperatures, a
thicker protein corona layer is formed resulting in an increase
in particle size. These results suggest the protein binding kinet-
ics may differ as a function of temperature. The population
spread may be wider at lower temperatures as the proteins
may not have reached maximum levels of adsorption to the
particle surface at 25 °C [67], also supporting the small chang-
es in mean zeta potential at 25 °C demonstrated in Fig. 2.
Monitoring individual protein–nanoparticle interactions is
interesting but becomes more complex in a medium containing
a protein mixture, such as plasma or serum. Both plasma and
serum are extracted from blood samples but contain a different
composition of proteins. Relevant to this study, serum contains
albumin, γ-globulin and apolipoproteins. Plasma has a similar
protein composition to serum, but also contains clotting factors
such as fibrinogen. Figure 4 shows the measured zeta poten-
tials of CPC200s in PBS and of CPC200s incubated in plasma
and serum for 10 min at both 25 and 37 °C.
As seen in the isolated fibrinogen and γ-globulin samples
above, only small changes in zeta values were observed for
both plasma and serum at 25 °C. Interestingly, at the elevated
incubation temperature of 37 °C, the plasma still did not ap-
pear to show a significant difference in zeta potential, whereas
the sample in serum showed a reduction in zeta potential of
5.9 mV. The most prominent difference between plasma and
serum is the presence of clotting factors in plasma; this will
have an inherent effect on the protein corona structure and
resulting interactions with the particle surface [63]. Protein
corona formation is complex in physiological environments
Fig. 4 (a) Mean zeta potential
(mV) versus incubation medium.
Comparison of CPC200 particles
incubated in PBS (green), plasma
and serum for 10 min at 25 °C
(blue) and 37 °C (red). Error bars
are representative of the st.dev
where n = 3. (b) Frequency (%)
versus zeta potential (mV). Zeta
potential distributions for
CPC200s incubated for 10 min at
37 °C in plasma (purple) and
serum (pink). Repeat datasets for
CPC200s incubated in both
plasma and serum at 37 °C for
10 min are illustrated in ESM
Fig. S3 and are compared to a zeta
potential distribution of CPC200s
in PBS only
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as it consists of the simultaneous binding of numerous pro-
teins to the particle surface creating both protein-nanoparticle
interactions as well as protein–protein interactions [63].
Proteins within plasma and serum are undergoing a com-
petitive binding assay to the particle’s surface, and proteins of
higher concentration and/or affinity will bind to the particle
surface more rapidly at the first instance. Protein–protein in-
teractions are also common in plasma and serum samples, and
some proteins will have a higher affinity to a subsequent pro-
tein over the particle surface. Zeta potential distribution as a
function of temperature for the particles incubated with plas-
ma and serum samples are shown in Fig. 5.
When the incubation temperature was increased, the zeta
potential for both particles in plasma and serum were smaller.
The advantage of distribution studies of a sample population is
the discrete differences that can be identified, that cannot be
determined immediately from mean values. For example, in
Fig. 5a, the distribution shape of the particles incubated with
plasma at 25 °C (red) is almost twice as wide as the distribution
for 37 °C (purple), yet themean values only changed by 0.4mV
between temperatures, a negligible difference. The difference in
distribution shape can be reflected using median skewness
values. The median skewness values for a given sample popu-
lation of particles incubated in plasma were 0.111 and −0.065
for incubation temperatures of 25 and 37 °C, respectively.
Particles in serum showed the same effect and as the incubation
temperature was increased, the median skewness values de-
creased from −0.105 (25 °C) to −0.343 (37 °C).
The protein–nanoparticle interactions in plasma and serum
were evidently varied, and to investigate this further, we com-
pleted a plasma spiking experiment. This aimed to ascertain if
the soft corona formed in the plasma would reorganise in the
presence of serum proteins. Figure 6 shows the effect on zeta
potential as plasma (5 % V/V) was used to spike samples con-
taining nanoparticles in serum at various time intervals.
Plasma protein adsorption onto a particle surface is due to
the Vroman effect and is defined as the constant change in
protein composition based on continuous adsorption and de-
sorption at an interface [68]. There can be both faster and
slower stages in this effect dependent on the protein. For ex-
ample, albumin, γ-globulin and fibrinogen are all proteins that
will adsorb rapidly onto a surface based on their high
Fig. 5 (a) Zeta potential
distributions for CPC200s
incubated in plasma for 10 min at
25 °C (red) and 37 °C (purple).
(b) Zeta potential distributions for
CPC200s incubated in serum for
10min at 25 °C (green) and 37 °C
(blue)
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abundances, but are generally replaced by apolipoproteins in a
matter of seconds [69] due to their fast dissociation properties.
Apolipoproteins, however, although of low abundance, have a
much slower dissociation constant and will therefore remain
on the potential surface for longer [70]. As with a lot of
nanoparticle-based assays, there may be an element of com-
petition between proteins in binding to the nanoparticle sur-
face that will affect the protein corona structure as displace-
ment and exchange reactions may then take place over time.
As the hard corona involves the higher affinitive proteins, this
should remain adsorbed onto the nanoparticle surface over
time and during any biophysical event that may occur [63].
The soft corona involves much weaker protein interactions in
the system and will therefore dissociate more rapidly and pro-
tein exchange will occur much more readily. This effect is
dependent on the relative protein concentrations of all proteins
present in the plasma and serum samples. It is well known that
protein concentration has a significant effect on the formation
of a protein corona when incubated with nanoparticles [55,
71]; when a protein is of high concentration in a given sample,
that protein will initially occupy the nanoparticle surface and
form a protein corona [55] at a potentially faster rate than
those of lower concentrations that may be later exchanged
for those at a lower concentration but higher affinity. This
effect also depends on the nanomaterial and there have been
cases where proteins that have adsorbed first have had the
longest residence time [72].
The first measurement was taken after the plasma had been
introduced to the serum sample for 5 min. Between 5 and
10 min of the plasma being present (Fig. 6(i-ii)), the zeta
potential of the particles was reduced. This is due to the addi-
tion of proteins into the sample, a higher concentration of
proteins interacting with the particles will result in a slower
pore translocation velocity, hence the reduced zeta potential.
Figure 6(iii) shows that after 15 min, the zeta potential was
reduced to its lowest measured value in this experiment. This
is due to some of the plasma proteins displacing those from
serum that may have reversibly bound to the particle surface
as part of a hard corona layer. The plasma proteins may have
been of a higher affinity to those present in the serum sample
and therefore form the new hard corona layer [56, 62]. After
20min and gradually onto 60min (Fig. 6(iv)), the particle zeta
potentials became more negative, indicating an increase in
particle translocation velocity through the pore. We attribute
Fig. 6 The effect of spiking a sample of CPC200s incubated in serum
with plasma. (a) Visual representation of the effect of protein
displacement and exchange within a protein corona system. (i) Protein
corona formed by particle incubation in serum, (ii) introduction of plasma
proteins to sample, (iii) displacement of hard corona proteins due to
proteins of higher affinities and exchange of soft corona proteins, (iv)
Depletion of soft corona layer as proteins dissociate from loose protein-
protein interaction. (b) Particles were incubated in serum for 10 min and
then spiked with 5% (v/v) plasma. Zeta potentials were measured at 5, 10,
15, 20, 30 and 60min. (i)–(iv) indicate the shift in zeta potential as a result
of the effects described in (a)
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this result to the weak interactions of the soft corona layers.
For example, once the plasma proteins have potentially
displaced those in the original hard corona, the displaced pro-
teins will form part of the soft corona and be part of weaker
protein–protein interactions. Over time, the soft corona pro-
teins will dissociate more readily away from the particle due to
their loose interactions [73], reducing the protein coverage
around the particle and thus resulting in a larger zeta potential.
The zeta potential becomes larger after this process as there are
less bound proteins surrounding the particle to reduce the par-
ticle’s translocation velocity. The faster the particle can traverse
the pore, the larger the zeta potential value. This is of particular
interest as it gathers valuable information on how the different
compositions of plasma and serum proteins in a blood sample
would affect a nanoparticle and how they behave differently
when isolated and in a mixture.
Conclusions
We have demonstrated the effects of more prominent pro-
teins found in protein coronas individually (isolated in
PBS) and within their natural environment (within plasma
and serum samples) on carboxylated polystyrene nanopar-
ticle surfaces. Protein–nanoparticle interactions involved
in the formation of a protein corona have been found to
be protein dependent at 25 °C, as well as temperature de-
pendent for each studied protein. Significant changes in
particle zeta potentials were observed when all of the pro-
teins interacted with the nanoparticles at 37 °C. TRPS tech-
nology has enabled the provision of single particle analy-
sis, as well as information on the zeta potential distribu-
tions amongst a given sample population in all experiments
carried out, a more detailed insight than some other previ-
ously used ensemble techniques. We have found that al-
though a stable hard and soft corona can be formed around
particles in serum, we can also track various protein dis-
placement and exchange processes occurring when plasma
proteins are introduced to these samples. This has provided
more detailed information on the affinities and reaction
kinetics of protein coronas dependent on their biological
medium and incubation conditions. A further understand-
ing of protein–nanoparticle interactions in complex matri-
ces and in physiological conditions is proving useful for
advances in biotechnological assays and therapeutics.
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